

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 1/15, 15/54, 15/80</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/12661</b> <b>(43) International Publication Date:</b> 11 May 1995 (11.05.95)
<b>(21) International Application Number:</b> PCT/US94/12423 <b>(22) International Filing Date:</b> 28 October 1994 (28.10.94) <b>(30) Priority Data:</b> 148,132 2 November 1993 (02.11.93) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 148,132 (CON) Filed on 2 November 1993 (02.11.93) <b>(71) Applicant (for all designated States except US):</b> MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> VINCI, Victor, A. [US/US]; 2041 Locke Lane, Charlottesville, VA 22901 (US). CONDER, Michael, J. [GB/US]; 767 Northfield Court, Harrisonburg, VA 22801 (US). McADA, Phyllis, C. [US/US]; 15611 173rd Avenue, N.E., Woodenville, WA 98072 (US). REEVES, Christopher, D. [US/US]; 19403 NE 203rd Place, Woodenville, WA 98072 (US). RAMBOSEK, John [US/US]; 7701 17th Avenue, N.E., Seattle, WA 98115		<b>(US).</b> DAVIS, Charles, Ray [US/US]; 17727 66th Place W., Lynnwood, WA 98037 (US). HENDRICKSON, Lee, E. [US/US]; 35915 NE 112th Street, Carnation, WA 98014 (US). <b>(74) Common Representative:</b> MERCK & CO., INC.; Patent Dept., 126 East Lincoln Avenue, Rahway, NJ 07065 (US). <b>(81) Designated States:</b> AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).  <b>Published</b> <i>With international search report.</i>

**(54) Title:** DNA ENCODING TRIOL POLYKETIDE SYNTHASE**(57) Abstract**

DNA encoding triol polyketide synthase (TPKS) has been isolated, purified and sequenced. Expression vectors comprising TPKS, cells transformed with the expression vectors, and processes employing the transformed cells are provided.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

**TITLE OF THE INVENTION****DNA ENCODING TRIOL POLYKETIDE SYNTHASE****CROSS-RELATED TO OTHER APPLICATIONS**

5                   This is a continuation of U.S.S.N. 08/148,132 filed  
November 2, 1993, now pending.

**BACKGROUND OF THE INVENTION**

10                   Hypercholesterolemia is known to be one of the prime risk  
factors for ischemic cardiovascular diseases such as arteriosclerosis.  
Cholesterol and other lipids are transported in body fluids by  
lipoproteins of varying density. The two lipoproteins carrying the  
majority of cholesterol in the blood are low-density lipoproteins (LDL)  
15                   and high-density lipoproteins (HDL). The role of LDL is to transport  
cholesterol to peripheral cells outside the liver. LDL-receptors on a  
cell plasma membrane bind LDL and allow entry of cholesterol into the  
cell. HDL may scavenge cholesterol in the tissues for transport to the  
liver and eventual catabolism. LDL levels are positively correlated with  
20                   the risk of coronary artery disease while HDL levels are negatively  
related, and the ratio of LDL-cholesterol to HDL-cholesterol has been  
reported to be the best predictor of coronary artery disease. Thus  
substances which effectuate mechanisms for lowering LDL-cholesterol  
may serve as effective antihypercholesterolemic agents.

25                   Mevacor® (lovastatin; mevinolin) and ZOCOR®  
(simvastatin), now commercially available, are two of a group of very  
active antihypercholesterolemic agents that function by inhibiting the  
enzyme HMG-CoA reductase. Lovastatin and related compounds inhibit  
cholesterol synthesis by inhibiting the rate-limiting step in cellular  
cholesterol biosynthesis, namely the conversion of hydroxymethyl-  
30                   glutarylcoenzyme A (HMG-CoA) into mevalonate by HMG-CoA  
reductase [3.7-9.12]. HMG-CoA reductase inhibitors act through  
cellular homeostatic mechanisms to increase LDL receptors with a  
consequent reduction in LDL-cholesterol and a resultant therapeutic  
antihypercholesterolemic effect. The HMG-CoA reductase inhibitors

- 2 -

within this invention include, but are not limited to compactin (ML-236B), lovastatin, simvastatin, pravastatin, fluvastatin and mevastatin.

Many HMG-CoA reductase inhibitors are synthesized by microorganisms. The general biosynthetic pathway of the HMG-CoA reductase inhibitors of the present invention has been outlined by Moore *et al.*, who showed that the biosynthesis of mevinolin (lovastatin) by Aspergillus terreus ATCC 20542 proceeds from acetate via a polyketide pathway (R. N. Moore *et al.*, Biosynthesis of the hypocholesterolemic agent mevinolin by Aspergillus terreus. Determination of the origin of carbon, hydrogen, and oxygen atoms by  $^{13}\text{C}$  NMR and mass spectrometry. J. Amer. Chem. Soc., 1985, 107: 3694-3701). Endo and his coworkers demonstrated that similar biosynthetic pathways existed in Penicillium citrinum NRRL 8082 and Monascus ruber M-4681 (A. Y. Endo *et al.*, Biosynthesis of ML-236B (compactin) and monacolin K., 1985, J. Antibiot., 38:444-448).

The recent commercial introduction of HMG-CoA reductase inhibitors has provided a need for high yielding processes for their production. Methods of improving process yield include, but are not limited to scaling up the process, improving the culture medium or, simplifying the isolation train. The present invention focuses on a method of increasing process yield wherein the increase in productivity is due to the use of a microorganism that produces increased levels of HMG-CoA reductase inhibitor.

It may be desirable to increase the biosynthesis of HMG-CoA reductase inhibitors at the level of gene expression. Such increases could be achieved by increasing the concentration in an HMG-CoA reductase inhibitor-producing microorganism of one or more of the enzymes or enzymatic activities in the biosynthetic pathway of the HMG-CoA reductase inhibitor. It may be particularly desirable to increase the concentration of a rate-limiting biosynthetic activity.

Triol polyketide synthase (TPKS) is a multifunctional protein with at least four activities as evidenced by the product of the enzymatic activity (Moore, *supra*). TPKS is believed to be the rate-

- 3 -

limiting enzymatic activity(ies) in the biosynthesis of the HMG-CoA reductase inhibitor compounds.

The present invention identifies a DNA encoding triol polyketide synthase (TPKS) from Aspergillus terreus. The DNA encoding the TPKS of the present invention has been isolated, purified and sequenced. Complementary DNA (cDNA) and genomic DNA sequences corresponding to TPKS have been prepared. The TPKS cDNA of the present invention may be used to increase the production of HMG-CoA reductase inhibitors by HMG-CoA reductase inhibitor-producing microorganisms. The TPKS cDNA of the present invention may also be used to produce purified TPKS.

#### SUMMARY OF THE INVENTION

DNA encoding the full-length form of triol polyketide synthase (TPKS) is identified. The DNA is sequenced and cloned into expression vectors. Cells transformed with the expression vectors produce increased levels of TPKS and increased levels of HMG-CoA reductase inhibitors. The DNA is useful to produce recombinant full-length TPKS. The DNA may be used to isolate and identify homologues of TPKS present in organisms that are capable of producing polyketides, particularly microorganisms that are capable of producing HMG-CoA reductase inhibitors.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is the nucleotide sequence of triol polyketide synthase.

Figure 2 is the predicted amino acid sequence of triol polyketide synthase.

Figure 3 shows pTPKS100.

Figure 4 is a graphic view of the open reading frame of the TPKS protein and the overall placement of the TPKS peptides and PKS activities established by alignments generated by the Intelligenetics GeneWorks program.

- 4 -

Figure 5 shows the alignments of keto acyl synthase, acetyl/malonyl transferase and dehydratase carried out on regions of TPKS, rat fatty acid synthase (FAS) and P. patulum 6MSAS.

5 Figure 6 shows the alignments of enoyl reductase, keto reductase and acyl carrier protein carried out on regions of TPKS.

Figure 7 is a Chou-Fasman secondary structure prediction of pyridine nucleotide binding regions of TPKS and related proteins.

Figure 8 shows the S-adenosylmethionine binding regions of a variety of prokaryotic and eukaryotic methyl transferases.

10 Figure 9 is a Southern blot showing the homology of ketoacylsynthase of the TPKS of A. terreus to M. ruber and P. citrinum.

#### 15 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a DNA molecule encoding triol polyketide synthase (TPKS) which is isolated from TPKS-producing cells. Cells capable of producing TPKS include, but are not limited to, strains of Aspergillus terreus, Monascus ruber, Penicillium citrinum, Penicillium brevicompactum, Hypomyces chrysospermus,  
20 Paecilomyces sp M2016, Eupenicillium sp. MM603, Trichoderma longibrachiatum M6735 and Trichoderma pseudokoningii M6828.

TPKS, as used herein, refers to enzymatic activities that convert acetate precursors and S-adenosyl methionine to an intermediate in the triol biosynthetic pathway. This intermediate is further modified to produce a triol nonaketide. Polyketide synthases from bacteria and fungi employ common enzymatic functions to synthesize polyketides from two carbon units (for a review, see D.A. Hopwood and D.H. Sherman, 1990, "Comparison to fatty acid biosynthesis", Ann. Rev. Genet., 24: 37-66).

30 Polyketides are an important class of natural products because of their structural diversity and because many have antibiotic or other pharmaceutical activities. Most of the economically important polyketides are produced by fungi or actinomycetes.

- 5 -

Polyketide biosynthesis is similar to that of fatty acid biosynthesis in that it involves the sequential condensation of carboxylate units. Unlike fatty acids, which are built from acetate units, polyketides may be built from acetate, propionate, or butyrate units. Additionally, some or all of the  $\beta$ -keto groups added at each cycle of condensation during polyketide biosynthesis are left unreduced, or are reduced only to hydroxyl or enoyl functionalities. This variation in building units and the variation in modification of the beta-keto groups results in a tremendous variety of products as well as difficulty in comparing biosynthetic genes from different pathways.

Aspergillus terreus is a filamentous soil fungus; different strains of A. terreus produce a variety of polyketides (Springer, J. et al., 1979, terretonin, a toxic compound from Aspergillus terreus, J. Org. Chem., Vol. 44, No. 26, 4852-4854). Lovastatin is a polyketide produced by certain strains of A. terreus (Moore, *supra*). In addition to lovastatin and related metabolites such as triol or monacolin J, other polyketides found in A. terreus include sulochrin and related structures (Curtis, R. G. et al., 1964, "The biosynthesis of phenols", J. Biochem., 20:43-51) derived from emodin (Fujii, I., et al., 1982, "Partial purification and some properties of emodin-o-methyltransferase from (+)-geodin producing strain of Aspergillus terreus". Chem. Pharm. Bull., 30(6):2283-2286); terreic acid (Sheehan, J. C. et al., 1958, J. Am. Chem. Soc., 80:5536); patulin (D. M. Wilson, 1976, "Adv. Chem. Ser. No. 149") and citrinin (Sankawa, U. et al., 1983, "Biosynthesis of citrinin in Aspergillus terreus", Tetrahedron, 39(21):3583-3591). Presumably each of these products is made by a specific PKS encoded by a specific and distinct PKS gene(s), thus increasing the difficulty in cloning the triol PKS.

The structure and activity of lovastatin was reported by A. Alberts et al., (Proc. Natl. Acad. Sci. U.S.A., 1980, 77:3957-3961). Lovastatin is a reduced molecule consisting of a methylbutyryl group joined by an ester linkage to a nonaketide having a conjugated decene ring system.

- 6 -

Moore et al., (supra) described lovastatin biosynthesis. Proton and  $^{13}\text{C}$  NMR studies of in vivo labeled lovastatin showed that all the carbons are derived from acetate except in the methyl groups at positions 6 and 2', which were derived from methionine. The triol molecule is composed of nine acetate units. The side-chain is composed of two acetate units. Esterification of triol and the butyrate side chain occurs enzymatically (Kimura, supra). The methyl butyrate side chain is presumably synthesized by a separate PKS. Lovastatin is first synthesized as a highly reduced precursor longer than 9 acetate units which undergoes reoxidation, including oxidative cleavage of a carbon-carbon bond.

Limited information is available for compactin biosynthesis. The most likely pathway would be nearly identical to that of lovastatin biosynthesis in M. ruber and A. terreus, except that methylation does not occur at the 6 position on the diene ring system.

Polyketide synthases (PKS) and fatty acid synthases (FAS) are classified by functional types. Type II enzymes, typical of bacteria and plants, have a separate polypeptide for each enzymatic activity. Type I enzymes, found in animals, bacteria and fungi, consist of large polypeptides with multiple activities or functional domains. Regions of amino acid sequence similarity have been identified in these genes: domains for ketoacyl synthase, acetyl/malonyl transferase,  $\beta$ -keto reductase, enoyl reductase, dehydratase and acyl carrier protein. The identification of these domains is considered evidence of the resulting enzymatic activity in light of the difficulty in obtaining functional Type I PKS in vitro (Sherman, supra).

Any of a variety of procedures may be used to molecularly clone the TPKS genomic DNA or complementary DNA (cDNA). These methods include but are not limited to, direct functional expression of the TPKS gene in an appropriate host following the construction of a TPKS-containing genomic DNA or cDNA library in an appropriate expression vector system. The preferred method consists of screening a TPKS-containing cDNA expression library constructed in a bacteriophage or vector with an antibody directed against the purified



- 7 -

TPKS protein. The antibody is obtained by standard methods (Deutscher, M. (ed), 1990, Methods in Enzymology, Vol. 182) by isolating purified TPKS protein from HMG-CoA reductase inhibitor-producing cells, inoculating an appropriate host, such as a rabbit, with the purified protein and, after several boosts, collecting immune sera. Antibody collected from the animal is used to screen the cDNA expression library and cDNA clones expressing TPKS epitopes recognized by the antisera are selected. The positive clones are further purified, labeled and used to probe TPKS-containing genomic or cDNA libraries to identify related TPKS containing DNA. Standard restriction analysis of the related clones can be used to create a restriction map of the region and sequence analysis of the genomic and cDNA clones can be used to define a structural map and the open reading frame of the gene, respectively.

Another method of cloning TPKS involves screening a TPKS-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labelled oligonucleotide probe designed from the amino acid sequence of TPKS. The method may consist of screening an TPKS-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the TPKS subunits. This partial cDNA is obtained by the specific PCR amplification of TPKS DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence of the purified TPKS subunits.

It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cells or cell types, may be useful for isolating TPKS-encoding DNA. Other types of libraries include, but are not limited to, cDNA libraries derived from other cells or cell lines and genomic DNA libraries.

It is readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have TPKS activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate TPKS cDNA may be done by first measuring cell associated TPKS activity using incorporation of radiolabelled

- 8 -

acetate and separation of products by high performance liquid chromatography (HPLC).

Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well-known cDNA library construction techniques can be found for example, in Maniatis, T., Fritsch, E.F., Sambrook, J., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1982).

It is also readily apparent to those skilled in the art that DNA encoding TPKS may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well-known in the art. Well-known genomic DNA library construction techniques can be found in Maniatis *et al.*, (*supra*).

In order to clone the TPKS gene, knowledge of the amino acid sequence of TPKS may be necessary. To accomplish this, TPKS protein may be purified and partial amino acid sequence determined by conventional methods. Determination of the complete amino acid sequence is not necessary. Once suitable amino acid sequences have been identified, the DNA sequences capable of encoding them are synthesized.

Because the genetic code is degenerate, more than one codon may be used to encode a particular amino acid, and therefore, the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides. Only one member of the set will be identical to the TPKS sequence but will be capable of hybridizing to TPKS DNA even in the presence of DNA oligonucleotides with mismatches. The mismatched DNA oligonucleotides may still hybridize to the TPKS DNA to permit identification and isolation of TPKS encoding DNA.

It is readily apparent to those skilled in the art that DNA encoding TPKS from a particular organism may be used to isolate and purify homologues of TPKS from other organisms. To accomplish this, the first TPKS DNA may be mixed with a sample containing DNA encoding homologues of TPKS under appropriate hybridization

- 9 -

conditions. The hybridized DNA complex may be isolated and the DNA encoding the homologous DNA may be purified therefrom.

5 cDNA clones encoding TPKS may be isolated in a two-stage approach employing polymerase chain reaction (PCR) based technology and cDNA library screening.

Amino acid sequence information may be obtained by automated amino acid sequencing using Edman chemistry of both the intact protein and the peptide fragments generated by specific proteolytic cleavage. Following incubation for the prescribed periods,  
10 digestion is terminated and resulting peptide fragments are fractionated and detected.

TPKS in substantially pure form derived from natural sources according to the purification processes described herein, is found to be encoded by a single mRNA.  
15

The cloned TPKS cDNA obtained through the methods described above may be expressed by cloning it into an expression vector containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant TPKS. Techniques for  
20 such manipulations are well-known in the art.

In order to simplify the following Examples and the Detailed Description, certain terms will be defined.

Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned copies of genes and the translation of their mRNAs in an appropriate host. Such vectors can be  
25 used to express eukaryotic genes in a variety of hosts such as bacteria, bluegreen algae, plant cells, insect cells and animal cells. Expression vectors include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses. Specifically  
30 designed vectors allow the shuttling of DNA between hosts, such as bacteria-yeast or bacteria-animal cells. An appropriately constructed expression vector should contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited

- 10 -

number of useful restriction enzyme sites, a potential for high copy number, and active promoters.

5 An expression vector is a replicable DNA construct in which a DNA sequence encoding a TPKS is operably linked to suitable control sequences capable of effecting the expression TPKS in a suitable host. Control sequences include a transcriptional promoter, an optional operator sequence to control transcription and sequences which control the termination of transcription and translation.

10 Certain vectors, such as amplification vectors, do not need expression control domains but rather need the ability to replicate in a host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of transformants.

15 A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one which causes mRNAs to be initiated at high frequency.

DNA encoding TPKS may also be cloned into an expression vector for expression in a host cell. Host cells may be prokaryotic or eukaryotic, including but not limited to bacteria, yeast, mammalian and insect cells and cell lines.

20 The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation. The expression vector-containing cells are clonally propagated and individually analyzed to determine whether they contain the TPKS gene or produce TPKS protein. Identification of TPKS expressing host cell clones may be done by several means, including but not limited to immunological reactivity with anti-TPKS antibodies, and the presence of host cell-associated TPKS activity.

25 Expression of TPKS DNA may also be performed using in vitro produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to

- 11 -

microinjection into frog oocytes, with micro-injection into frog oocytes being preferred.

5 PCR is the polymerase chain reaction, which is a technique for copying the complementary strands of a target DNA molecule simultaneously for a series of cycles until the desired amount is obtained.

10 Plasmids are generally designated by a low case p preceded or followed by capital letters and/or numbers. The starting plasmids used in this invention are commercially available, are publicly available on an unrestricted basis, or can be constructed from such available plasmids by conventional procedures. In addition other equivalent plasmids or constructs will be readily apparent to one skilled in the art.

15 Transformed host cells are cells which have been transformed or transfected with TPKS vectors constructed using recombinant DNA techniques. Expressed TPKS may be deposited in the cell membrane of the host cell or may be intracellular or may be secreted.

20 It is also well known, that there is a substantial amount of redundancy in the various codons which code for specific amino acids. Therefore, this invention is also directed to those DNA sequences which contain alternative codons which code for the eventual translation of the identical amino acid. For purposes of this specification, a sequence bearing one or more replaced codons will be defined as a degenerate variation. Also included within the scope of this invention are  
25 mutations either in the DNA sequence or the translated protein which do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in functionality of the polypeptide.

30 It is also well known that DNA sequences coding for a peptide may be altered so as to code for a peptide having properties that are different than those of the naturally-occurring peptide. Methods of altering the DNA sequences include, but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited

- 12 -

to changes in the affinity of an enzyme for a substrate. Alteration of the amino acid sequence may lead to altered properties that in turn result in the production of modified structures; for example, the elimination of one of the reductase activities may result in the biosynthesis of a less-reduced compound.

The full-length TPKS-encoding DNA in plasmid pLOA was designated pTPKS100. A sample of pTPKS-100 in *E. coli* strain JM109, was deposited under the terms of the Budapest Treaty, on September 15, 1993 in the permanent culture collection of the American Type Culture Collection, at 12301 Parklawn Drive, Rockville, MD., 20852, and has been assigned the Accession number ATCC 69416.

The following examples illustrate the present invention without, however, limiting the same thereto.

### EXAMPLE 1

#### Culture Conditions

Three strains of *Aspergillus terreus* were used. The two lovastatin-producing strains included *A. terreus* ATCC 20542. A lovastatin nonproducing strain was also used. A lovastatin-nonproducing strain or a lovastatin-overproducing strain of *A. terreus* may be derived from lovastatin-producing strains of *A. terreus* that are publicly available; an example of a publicly-available strain is *A. terreus* MF-4833, which is deposited with the American Type Culture Collection under Accession No. 20542. One skilled in the art would appreciate that a variety of techniques such as mutagenesis techniques, including but not limited to ultraviolet irradiation, treatment with ethylmethanesulfonate (EMS), exposure to nitrous acid, nitrosoguanidine and psoralen-crosslinking, could be used to generate a strain that does not produce or which overproduces lovastatin. The extent of the mutagenesis may be determined in a variety of ways including auxotrophy, i.e., the requirement of the mutated strain for a specific growth substance beyond the minimum required for normal metabolism and reproduction of the parent strain as well as

- 13 -

measurement of production of lovastatin by individual cultures. An alternative monitoring system involves the use of an intercalating dye such as acriflavine, which prevents any growth of the parent (lovastatin-producing) strain when plated at 10,000 spores per plate but, following  
5 mutagenesis, allows growth of about 3-5 colonies per plate.

Alternatively, the extent of mutagenesis may be monitored by visual observation of colonies having morphologies or colors that differ from the unmutagenized parent strain. Mutant strains are reisolated and  
10 pooled and subjected to further mutagenesis so that, by repetition of these procedures, mutated strains of A. terreus that do not produce or which overproduce lovastatin may be obtained.

Monascus ruber ATCC 20657 and Penicillium citrinum ATCC 20606 were used in hybridization studies.

The strains were maintained on YME + TE medium. The  
15 recipe for YME + TE medium is as follows:

0.4% Yeast Extract (w/v);  
1.0% Malt Extract (w/v);  
0.4% Glucose (w/v);  
0.5% Trace Element (TE; v/v); and  
20 2.0% agar (w/v) in 1 liter of water, pH 7.2.

The recipe for Trace Elements (TE) is as follows:

0.1% FeSO<sub>4</sub>·7H<sub>2</sub>O (w/v);  
0.1% MnSO<sub>4</sub>·H<sub>2</sub>O (w/v);  
0.0025% CuCl<sub>2</sub>·2H<sub>2</sub>O (w/v);  
25 0.0132% CaCl<sub>2</sub>·2H<sub>2</sub>O (w/v);  
0.0056% H<sub>3</sub>BO<sub>3</sub> (w/v);  
0.0019% (NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub>·4H<sub>2</sub>O (w/v); and  
0.02% ZnSO<sub>4</sub>·7H<sub>2</sub>O (w/v) in 1 liter of water.

## 30 EXAMPLE 2

### Fermentation Conditions

For the generation of spore stocks, single colonies were generated by growing on YME + TE plates for 8 days at 28°C and 65%

- 14 -

relative humidity. Single colonies were removed, and streaked on YME + TE slants. The slants were incubated for 8 days at 28°C in 65% humidity. Spores were harvested by addition of 2 ml of Spore Suspension Solution (SSS). SSS contains 10% Glycerol (v/v) and 5% Lactose (w/v) in water. Spores were scraped into the SSS with a sterile inoculation loop and counted. The suspension was stored at -20°C.

A two-stage fermentation from spore suspensions was used for the production of lovastatin. A seed culture was started by inoculating  $1 \times 10^8$  spores into 2 ml/15 ml culture tube of HLC medium.

The recipe for HLC medium is as follows:

1.5%  $\text{KH}_2\text{PO}_4$  (w/v);  
2.0% Cerelese (w/v);  
0.1% Ardamine pH (Champlain Industries) (w/v);  
1.5% Pharmamedia (Traders Protein) (w/v);  
0.2% Lactic acid (v/v); and  
0.4% ammonium citrate (w/v) in 1 liter of water.

The pH of HLC medium was adjusted to pH 7.2 before sterilization.

Cultures were shaken at a 30 degree angle at 28°C for approximately 28 hours on a rotary shaker with a 70 mm diameter amplitude at 220 rpm. Two ml of seed culture was used to inoculate 25 ml of GP-9 medium in a 250 ml flask.

The recipe for GP-9 medium is as follows:

0.9% Ammonium Citrate (w/v);  
0.12% Ardamine pH (w/v);  
1.2% Cerelese (w/v);  
4.0% Pharmamedia (w/v);  
24.5% Lactose (w/v); and  
0.2% P 2000 (v/v) in water at pH 7.2.

Incubation was continued as described for seed cultures without the 30 degree angle. Lovastatin production was monitored after 12 days of fermentation.

A one stage fermentation of A. terreus cultures in CM media was used to generate vegetative mycelia for transformations or



- 15 -

DNA preparations. Fermentations were started by inoculating  $1 \times 10^8$  conidiospores into 50 ml of CM medium in a 250 ml flask and incubated as described.

The recipe for Complete Medium (CM) is as follows:

50 ml of Clutterbuck's salts;  
2.0 ml Vogel's Trace elements;  
0.5% Tryptone (w/v);  
0.5% Yeast extract (w/v); and  
1.0% Glucose (w/v) in one liter of water.

The recipe for Clutterbuck's salts is as follows:

12.0%  $\text{Na}_2\text{NO}_3$  (w/v);  
1.02% KCl (w/v);  
1.04%  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  (w/v); and  
3.04%  $\text{KH}_2\text{PO}_4$  (w/v).

The recipe for Vogel's trace elements is as follows:

0.004%  $\text{ZnCl}_2$  (w/v);  
0.02%  $\text{FeCl}_3$  (w/v);  
0.001%  $\text{CuCl}_2$  (w/v);  
0.001%  $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$ ;  
0.001%  $\text{NaB}_4\text{O}_7 \cdot 10\text{H}_2\text{O}$  (w/v); and  
0.001%  $(\text{NH}_4)_6\text{MO}_7\text{O}_{24} \cdot 7\text{H}_2\text{O}$  (w/v).

### EXAMPLE 3

#### Construction of Vector, pLO9

pLO9 is a 5.6 kb vector constructed with features useful for both cosmid library construction and fungal transformations. For dominant selection in Aspergillus terreus, pLO9 contains a Streptoalloteichus hindustanus phleomycin resistance gene driven by an A. niger  $\beta$ -tubulin promoter and terminated by a Saccharomyces cerevisiae terminator sequence. For selection in Escherichia coli, the vector contains the ampicillin resistance gene and for lambda packaging, the vector contains a lambda cos site. The construction of pLO9 is described below.

- 16 -

The phleomycin resistance marker originated from S. hindustanus and the termination sequence is from the CYC1 gene in S. cerevisiae. Both sequences were isolated on one DNA fragment from pUT713 (CAYLA, Toulouse Cedex, France) by digesting pUT713 with the restriction enzymes BamH1 and BgIII. The isolated fragment was cloned into BamH1-digested pUC18 to produce vector pLO1. The genomic copy of the  $\beta$ -tubulin gene from A. niger ATCC 1015, was cloned as a 4.3 kb EcoRI fragment in pUC8 to create p35-C-14. Several modifications were made to the genomic sequence. An EcoRI site was introduced at the initiator ATG by in vitro mutagenesis. The HindIII site in the promoter was removed by digestion with exonuclease, filling in with Klenow, and religation. Finally, an upstream EcoRI site was changed to a PstI site by digestion with EcoRI, filling in with Klenow and addition of a PstI linker by religation with ligase. The  $\beta$ -tubulin promoter was then subcloned as a PstI to EcoRI fragment in pUC8 to create pC15-1. An XbaI site was introduced at the initiator ATG by digestion with EcoRI, filling in with Klenow, addition of a XbaI linker and religation. The resulting vector was named pTL-113.

The  $\beta$ -tubulin promoter was cloned upstream of the phleomycin gene by cutting pTL113 with PstI and XbaI and cloning the isolated promoter fragment into the PstI and XbaI sites of pLO1 to produce pLO3. The BgIII site was removed with a fill in reaction followed by blunt-end ligation to produce vector pCS12. The PstI to Hind III fragment containing the beta tubulin promoter, phleomycin resistance gene, and the terminator sequence were cloned into a pUC8 vector to generate pLO6. The XbaI site at the ATG was removed by a fill-in reaction and ligation to give pLO7. The PstI to HindIII was moved as a fragment into a pUC18 backbone in which the XmaI site had been filled and replaced with a BgIII linker. The resulting vector was named pLO8. A PstI fragment containing the lambda cos site from pJL21 was inserted into the vector to generate pLO9.

- 17 -

#### EXAMPLE 4

##### Isolation of Genomic DNA

5 Vegetative mycelia were generated in CM media for 48 hr at 220 rpm at 28°C. Mycelia were collected by filtration through cheesecloth and frozen in liquid nitrogen for lyophilization overnight. Lyophilized mycelia were ground with sand using a mortar and pestle and suspended in 5 ml of Breaking Buffer (100 mM NaCl; 50 mM  
10 EDTA; 10 mM Tris, pH 8.0; 1% SDS; 50 ug/ml pancreatic RNase; 50 ug/ml Proteinase K). The mix was transferred to a 125 ml flask and an equal volume of Tris-saturated phenol/chloroform (50:50) was added. The flask was shaken for 1 hour at 37°C and 200 rpm. The aqueous layer was removed after centrifugation at 10,000 rpm for 10 minutes. The aqueous layer was extracted twice more with phenol/chloroform  
15 and was then extracted once with chloroform. DNA was precipitated from the aqueous layer by addition of 0.1 volume 3 M NaCl and 2.5 volumes of ethanol and then freezing at -70°C for 10 minutes. The precipitated DNA was collected by centrifugation at 10,000 rpm for 15 minutes. The pelleted DNA was dried and resuspended in a solution of  
20 10 mM Tris-HCl, 1 mM EDTA, pH 7.5. DNA concentrations were determined by measuring absorbance at wavelength 260 nM.

#### EXAMPLE 5

##### 25 Construction of *A. terreus* Libraries

###### A. Preparation of Genomic Fragments

30 *A. terreus* genomic DNA was isolated as described. Large random DNA fragments for insertion into the vectors were isolated by partially digesting 10 µg of DNA with the restriction enzyme Sau3A. The digested DNA was electrophoresed on a 1.0% Agarose gel. For the genomic library, an area containing 9-23 kb sized fragments was cut from the gel. For the cosmid library, another segment of the gel containing 30-60 kb sized fragments was excised. The large

- 18 -

chromosomal DNA fragments contained in the gel slices were isolated by electroelution. The DNA was concentrated by addition of 0.1 volumes of 3 M sodium acetate and 2.5 volumes of ethanol, freezing at -70°C for 15 minutes, and centrifugation at 10,000 rpm for 10 minutes to precipitate the DNA.

**B. Construction of the *A. terreus* Cosmid Library**

The pLO9 cosmid DNA was used to supply the two arms and cos sites required for lambda packaging. Two fragments were isolated from pLO9 for the packaging reaction.

Fragment one was isolated by digesting pLO9 with XbaI, phosphatasing with HK phosphatase (Epicenter Technologies), digesting with BgII, electroeluting on a 1% Agarose gel, concentrating by the addition of 0.1 volumes of 3 M sodium acetate and 2.5 volumes of ethanol, freezing at -70°C for 15 minutes and centrifuging at 10,000 rpm for 10 minutes to precipitate the DNA.

Fragment two was isolated by digesting pLO9 with SmaI, phosphatasing with HK phosphatase and then digesting with BgIII. Fragment two was isolated with the procedure described for fragment one. Fragment one, fragment two and isolated *A. terreus* insert DNA were ligated in a 1:1:2 ratio at a concentration of 0.5 µg of each DNA.

**C. Packaging into Lambda Phage and Plating**

Packaging into lambda phage was accomplished by mixing the ligation mixture with 10 µl of extract A from *E. coli* strain BHB2688 (Amersham) and 15 µl of extract B from *E. coli* strain BHB2690 (Amersham). The packaging mix was incubated at 22°C for 120 minutes. A volume of 500 µl of SM (0.58% NaCl(w/v); 0.20% MgSO<sub>4</sub>(w/v); 0.05 M Tris pH 7.5; 0.01% Gelatin(w/v)) and 10 µl of chloroform was then added to the packaging mix.

*E. coli* strain DH5 was prepared for transfection by growing cells to an optical density of 1.0 at wavelength 600 nm in LB + maltose medium. LB + maltose medium consists of 1.0% Bacto-tryptone (w/v); 0.5% Bacto-yeast extract (w/v); 1.0% NaCl (w/v); pH 7.5; 0.2% Maltose (v/v) is added after autoclaving.

- 19 -

The cells were centrifuged at 4,000 rpm for 10 minutes and resuspended in 10 mM MgSO<sub>4</sub>. Fifty microliters of the packaging mix was added to 200 µl of the resuspended DH5 cells and incubated for 30 minutes at 37°C. A 500 µl of aliquot of LB medium was added and the mix was incubated for 30 minutes at 37°C. The cell mix was spread on LB agar plates containing 100 µg/ml ampicillin (Sigma) and incubated at 37°C. A total of 10,000 colonies were generated with this library.

**D. Construction of the *A. terreus* Genomic Library**

The lambda replacement vector, EMBL3 (Promega), was used for the construction of the genomic library. The vector was purchased as predigested arms ready for ligation with the genomic inserts. The two arms were ligated to the 9-23 kb genomic inserts at a ratio of 1:1:2, packaged into lambda phage, and plated for hybridization with selected probes as described above.

**EXAMPLE 6**

**A. Isolation of Cosmid DNA from *E. coli***

The *A. terreus* cosmid library in *E. coli* was grown on 25 cm x 25 cm plates containing 200 ml LB agar supplemented with 100 µg/ml ampicillin added. Nearly confluent colonies were scraped from plates in 10 ml of cold TS solution (50 mM Tris, pH 8.0 and 10% Sucrose(w/v)). A 2.0 ml aliquot of 10 mg/ml lysozyme made in 0.25 M Tris, pH 8.0 was added; then 8 ml of 0.25 M ethylenediamine tetraacetic acid (EDTA) was added. The mix was inverted several times and incubated on ice for 10 minutes. A 4 ml aliquot of a 10% SDS solution was added slowly while mixing gently with a glass rod. Next, 6.0 ml of 5 M NaCl was added slowly while mixing with a glass rod. The cell lysate was incubated on ice for 1 hour and then centrifuged. The supernatant was saved and then extracted twice with an equal volume of Tris-saturated Phenol/Chloroform (50:50). DNA was precipitated by adding 2 volumes of ethanol, freezing at -70°C for 15 minutes and then

- 20 -

centrifuging at 3,000 rpm for 15 minutes. The precipitated cosmid DNA was dried and resuspended in 9 ml of Tris-EDTA.

5 Cosmid DNA was prepared for cesium chloride density gradient purification by dissolving 10 gm of CsCl<sub>2</sub> in the DNA suspension and then adding 250 µl of 10 mg/ml ethidium bromide. Cosmid DNA was banded with a 20 hour centrifugation in a Ti865.1 Sorvall rotor at 55,000 rpm. The DNA bands representing cosmid DNA were recovered from the gradient, and ethidium bromide was removed by extraction with water-saturated butanol. Cosmid DNA was  
10 precipitated by adding 3 volumes of water and 10 volumes of ethanol, incubating on ice for 30 minutes and then centrifuging. The DNA was resuspended in Tris-EDTA and reprecipitated by the addition of 0.1 volume of 3 M sodium acetate and 2.5 volumes of ethanol. DNA was  
15 frozen at -70°C for 10 minutes, centrifuged, and resuspended in Tris-EDTA.

The DNA preparation was electrophoresed through a 0.5% Low Melting Temperature Agarose (BioRad) gel to eliminate contamination by pLO9 DNA. The band containing cosmid DNA with  
20 inserts was cut from the gel and heated to 65°C with 2 volumes of Tris-EDTA. The melted agarose was extracted 3 times with Tris-saturated phenol and then once with chloroform. Cosmid library DNA was precipitated by addition of 0.1 volumes of 3 M sodium acetate and 2.5 volumes of ethanol, freezing at -70°C for 15 minutes, and centrifuging  
25 at 10,000 rpm for 15 minutes. The DNA was dried and resuspended in Tris-EDTA. The concentration of DNA was determined by measuring the optical density at 260 nm.

### EXAMPLE 7

30 Transformation of *A. terreus*

Cultures were grown by inoculating  $1 \times 10^8$  conidiospores into 50 ml of CM media in a 250 ml Erlenmeyer flask. Cultures were grown for between 24 and 30 hr at 200 rpm and 28°C. Mycelia were harvested by gravity filtration through Miracloth. Mycelia (4 g) were

- 21 -

transferred to a 500 ml Erlenmeyer flask containing 100 ml KMP. KMP consists of 700 mM KCl, 800 mM Mannitol, and 20 mM  $\text{KH}_2\text{PO}_4$  pH 6.3. Lysing Enzymes from Trichoderma harzianum (100 mg; Sigma) was added. Flasks were shaken at 100 rpm for 18 hours at 28°C.

Spheroplasts were harvested by gravity filtration through Miracloth. The filtrate was collected in 50 ml conical centrifuge tubes, concentrated by centrifugation and washed by resuspending the spheroplasted cells in 15 ml of KCM solution. KCM consists of 700 mM KCl; 10 mM MOPS adjusted to pH 5.8. The washing was repeated twice. Washed spheroplasts were resuspended at a concentration of  $5 \times 10^7/\text{ml}$  in KCMC. KCMC consists of 5% 1 M  $\text{CaCl}_2$  and 95% KCM.

For each transformation, a sample of 5  $\mu\text{g}$  of DNA was brought to a volume of 20  $\mu\text{l}$  in Tris-EDTA; then 5 units of heparin in 6.5  $\mu\text{l}$  of KCMC was added. Next, 200  $\mu\text{l}$  aliquot of the spheroplast suspension was added to the DNA-containing solution. Finally, 50  $\mu\text{l}$  of aliquot of a solution containing 5% 1 M  $\text{CaCl}_2$  and 95% PCMC (40% PEG 8,000; 10 mM MOPS, pH 5.8; 0.05 M  $\text{CaCl}_2$ ) was added. The mixture was incubated on ice for 30 minutes.

An aliquot (600  $\mu\text{l}$ ) of the KCMC solution was added to a 45°C equilibrated solution of MA. MA consists of 5% Clutterbuck's salts(v/v); 0.5% Tryptone (w/v); 0.5% Yeast Extract (w/v); 1.0% Glucose(w/v); 23.4% Mannitol(w/v) and 3% Agar. This suspension was divided among 5 preweighed petri dishes and incubated at 28°C for 4 hours. The weight of agar in each plate was determined by a second weight and an equal amount of Overlay (OL) consisting of: 1% Peptone (w/v); 1% Agar (w/v); with between 100  $\mu\text{g}/\text{ml}$  and 150  $\mu\text{g}/\text{ml}$  (strain ATCC 20542) of phleomycin was added to each petri dish. Petri dishes were incubated at 28°C and 65% humidity for 7-10 days before transformed colonies were picked.

- 22 -

### EXAMPLE 8

#### Rescue of Cosmid DNA from *A. terreus*

5       The transforming cosmid DNA was rescued from an *A. terreus* transformants by isolating chromosomal DNA and packaging into lambda phage particles. Isolation of genomic DNA and packaging into lambda phage were performed as described above.

### EXAMPLE 9

10

#### Detection of Lovastatin

15       Fermentation extracts were prepared by adding two volumes of reagent alcohol to the fermentation flasks and shaking the flasks were shaken for 15 minutes at 220 rpm and 28°C. The contents were allowed to settle for 15 minutes and 1 ml of the liquid was removed. The sample was diluted 1/20 in methanol, filtered and then analyzed by HPLC. Lovastatin was detected by a Waters HPLC using a 8 mm x 10 cm C18 4 um Waters Novapak column. Mobile phases were  
20       A: Acetonitrile with 0.02% Trifluoroacetic acid and B: Distilled water with 0.02% Trifluoroacetic acid. Gradients were run at a flow rate of 1.5 ml/min. Initial conditions were 35% A and 65% B and were held for 1 minute after sample injection. A gradient was formed to 65% A and 35% B over 3 minutes and held for 3.6 minutes. Lovastatin ammonium salt was detected at 239 nm.  
25

### EXAMPLE 10

#### Southern Analysis of DNA

30       Southern analysis was performed by electrophoresing 5 µg of digested DNA on a 1.0% agarose gel in TAE buffer (0.04 M Tris and 0.002 M EDTA). DNA in the gel was denatured by soaking the gel in Solution A (1.5 M NaCl and 0.5 M NaOH) for 30 minutes. The gel was then neutralized in Solution B (1.0 M Tris and 1.5 M NaCl) for 30 minutes. DNA was transferred to nitrocellulose or nylon membranes



- 23 -

by blotting overnight with a 10 X SSC solution. SSC consists of 8.75% NaCl (w/v) and 4.4% sodium citrate (w/v), pH 7.0. DNA was baked onto the nitrocellulose at 80°C under vacuum for 30 minutes.

5 Standard hybridization conditions were as described in Sambrook, J. et al., (Molecular Cloning, 1989 (ed. Chris Nolan) Cold Spring Harbor Press). Membranes were prepared for hybridization by incubating at 42°C in hybridization buffer consisting of: 6x SSC, 5x Denhardt's reagent, 0.5% SDS, 100 µg/ml denatured and fragmented salmon sperm DNA, and 40% formamide. After incubating for two  
10 hours, the denatured labeled probe was added and further incubated overnight at 42°C. Unless otherwise stated, the filters were washed twice in 6x SSC and 0.1% SDS at room temperature for 15 minutes followed by two 30 minute washes at 42°C in 0.1X SSC and 0.5% SDS. Filters were exposed to X-ray film for visualization of the signal.  
15

### EXAMPLE 11

#### A. Isolation of Triol Polyketide Synthase from *A. terreus*

20 Mycelia of *A. terreus* were grown in GP-9 medium. After 48 hours the mycelia were collected by vacuum filtration, washed with cold water, frozen in liquid nitrogen and lyophilized. All subsequent steps of the purification were performed on ice or at 3°C unless otherwise noted.

25 Lyophilized mycelia (6 g) were homogenized by grinding with 20 gm glass beads (0.2 mm) in a mortar with pestle in 135 ml homogenization buffer consisting of: 20 mM Tris, pH 8; 10% glycerol; 5 mM EDTA; 50 mM NaCl; 5 mM ascorbic acid; 3.8 µg/ml leupeptin; 17.7 µg/ml chymostatin; 2.0 µg/ml pepstatin, 42 µg/ml turkey trypsin inhibitor; 0.2 mM PMSF; and 2.2% (dry wt/v) hydrated polyvinyl  
30 polypyrrolidone. The homogenate was centrifuged at 7,650 x g for 10 minutes; and the supernatant applied to an SH-affinity column (Affi-gel 501 organomercurial agarose; Bio-Rad; 1.5 x 8.0 cm) equilibrated in Buffer A. Buffer A consists of 20 mM Tris, pH 8; 50 mM NaCl; 5 mM EDTA; 5 mM ascorbic acid; at 30 ml/hr. The column was washed with

- 24 -

25 ml Buffer A followed by 75 ml Buffer A containing 0.5 M NaCl. After reequilibrating the column with 50 ml Buffer A, bound proteins were eluted with 40 ml Buffer A supplemented with 100 mM dithiothreitol (DTT). The eluted protein fraction was made 4.2 µg/ml leupeptin; 2 µg/ml pepstatin; 18 µg/ml chymostatin; 0.2 mM PMSF and then was pelleted by ultracentrifugation at 180,000 x g for 16 hr. The supernatant was discarded, and the pellet was rinsed with a buffer consisting of 20 mM Tris, pH 8; 5 mM ascorbic acid; 1 mM DTT; 1 mM EDTA. The washed pellet was resuspended in 2 ml of buffer consisting of 40 mM Tris, pH 6.8; 20 mM DTT; 2% SDS, then heated to 90°C for 10 minutes and put on ice.

A 250 µl aliquot of the resuspended pellet was combined with an equal volume of sample buffer (125 mM Tris, pH 6.8; 20% glycerol; 0.005%(w/v) bromphenol blue; 4%(w/v) SDS; 1.5 M beta mercaptoethanol) and heated to 95°C for 10 minutes. The sample was electrophoresed on a preparative 1.5 mm, 4% acrylamide SDS precast gel (Novex) at 145V for 2 hr using Laemmli electrode buffer system (25 mM Tris; 192 mM glycine; 0.1% SDS). When a prestained 200 kD reference standard was 1.4 cm from the bottom of the gel, the electrophoresis was terminated.

Proteins were visualized as follow. The gel was rinsed for 5 seconds in distilled H<sub>2</sub>O, then rinsed for 10 minutes in 0.2 M imidazole with shaking and was then transferred to a solution of 0.3 M zinc acetate for 5 minutes with shaking. The gel was then rinsed in water. The TPKS, which ran with an apparent molecular weight of 235 kD, was localized to a relative mobility position of 0.53 (relative to the bottom of the gel). The TPKS protein was the protein of greatest abundance on the gel; no significant protein banding was seen with lower R<sub>f</sub>. The apparent 235 kD protein band was excised from the gel and was then destained in 0.25 M Tris and 0.25 M EDTA pH 9.5 for approximately 5 minutes.

The destained gel slice was crushed between two glass plates and placed in a 50 ml tube containing 5 ml of 20 mM Tris, 5 mM EDTA, 0.1% SDS, pH 8.0. The tube was shaken on a rotary shaker for

- 25 -

48 hours at 37°C. Gel fragments were removed by centrifugation, and the supernatant containing the eluted protein was concentrated to 100 µl with a Centricon 30 microconcentrator (Amicon).

5     **B.           Molecular Weight Determination**

          The gel-purified protein was resuspended in Laemmli load buffer, heated to 95°C for 5 min. and then electrophoresed on a 4-15% gradient SDS polyacrylamide gel (BioRad Ready-Gel) in Laemmli electrode buffer. After staining, the molecular weight of the protein  
10     was determined by comparison to molecular weight standard proteins.

**C.           Antibody Production**

          The TPKS protein was prepared via preparative SDS-PAGE as described, except the protein was not electroeluted from the  
15     acrylamide gel matrix. Following destaining, the gel slice was crushed between two glass plates, and first forced through a 18 gauge syringe needle and then through a 25 gauge syringe needle. A 0.5 ml aliquot of the 25 gauge needle eluate was mixed with an equal volume of Freund's complete adjuvant and injected intradermally at five sites of a New  
20     Zealand white male rabbit. Boosts were done at 21 and 42 days using protein prepared as described, but mixed with 0.5 ml of Freund's incomplete adjuvant. Ten days after the final boost the rabbit was exsanguinated and the antiserum collected.

25     **D.           Affinity Purification of Antibody**

          Affinity purified antibody was prepared by immobilizing the TPKS protein to PVDF membrane by transfer from a preparative SDS polyacrylamide gel. The TPKS was visualized and that area of the membrane cut out. After blocking in 5%(w/v) non-fat dry milk in  
30     TTBS for 1 hour, the membrane was washed 3 x 5 minutes in TTBS. A 2 ml aliquot of antisera was diluted 1:1 with TTBS supplemented with 1%(w/v) non-fat dry milk and incubated with the immobilized antigen for 5 hours. The membrane was then washed 4x (10 minutes per wash) with TTBS, and the bound antibody was eluted with 2 ml of 0.1 M

- 26 -

glycine, pH 2.8. The eluted antibody was neutralized with 50  $\mu$ l of 1.0 M Tris, pH 9.5 and concentrated twenty-fold.

**E. Western Blot Analysis**

Purified TPKS protein and partially purified protein preparations of organomercurial eluates were resolved by 4% acrylamide SDS-PAGE (NOVEX, precast 1.0 mm thick gels) and then transferred to nitrocellulose in Towbin transfer buffer (25 mM Tris; 192 mM glycine, pH 8.3; 20% methanol; 0.05% SDS) at 240 mA for 2 hr. All subsequent steps were done at room temperature with shaking.

The nitrocellulose blot was rinsed for 1 minute in TBS (50 mM Tris, pH 7.5; 0.5 M NaCl) and then blocked for 2 hours in TBS supplemented with 0.05% Tween 20 (TTBS) and 5%(w/v) non-fat dry milk. The blot was incubated with the primary antibody (a 1:1000 dilution of rabbit antisera in TTBS containing 1%(w/v) non-fat dry milk) for 16 hr. The blot was washed in TTBS 3 times for 5 min. The blot was incubated with the second antibody (goat anti-rabbit alkaline phosphatase conjugate diluted 1:1000) for 2 hr in TTBS supplemented 1%(w/v) non-fat dry milk. After washing 4 times (10 minutes per wash) in TTBS, color development was achieved with 5-bromo-4-chloro-3-indolyl phosphate (115  $\mu$ g/ml) and nitroblue tetrazolium (330  $\mu$ g/ml) in 66 mM Tris, pH 9.5; 0.1 M NaCl; 5 mM  $MgCl_2$ .

**EXAMPLE 12**

**Isolation of Aspergillus RNA**

**A. Isolation of Total RNA**

A. terreus was grown for 48 hours in 25 ml of GP-9 fermentation medium at 28°C and 220 rpm on a rotary shaker. Mycelia were collected by vacuum filtration through Miracloth and cheesecloth and washed with approximately 100 ml distilled water. The mycelia were scraped from the filter into a plastic beaker and frozen with liquid nitrogen. Frozen mycelia were stored at -80 C until needed.

- 27 -

Frozen mycelia were weighed and placed in a mortar chilled with liquid nitrogen. Approximately 2 g of 0.2 mm glass beads were added, and the mix was ground to a fine powder with a pestle. Liquid nitrogen was added as needed to keep the mycelia frozen at all times. Ground mycelia were added to a flask containing approximately 2.5 ml/g Breaking Buffer (50 mM Tris pH 7.4; 150 mM NaCl; 5 mM EDTA; 5% SDS(w/v)) and an equal volume of Tris-saturated phenol:chloroform:isoamyl alcohol (50:50:1), and vanadyl ribonucleoside complex (BRL) to a final concentration of approximately 2 mM. The mixture incubated on a rotary shaker at 37°C for 20 minutes and was then centrifuged at 12000 x g for 10 min at 4°C. The aqueous layer was removed and extracted with an equal volume of Tris-saturated phenol:chloroform:isoamyl alcohol (50:50:1). Second and third extractions were done with 1 M Tris-saturated phenol:chloroform (50:50) and chloroform, respectively. The final aqueous layer was mixed with an equal volume of 6 M LiCl and left at -20°C for at least 4 hours. The precipitate was pelleted at 12,000 x g for 20 minutes at 4°C and resuspended in 0.6 ml water treated with 0.1% diethyl pyrocarbonate (DEPC). The total RNA was reprecipitated with 0.1 volume of sodium acetate and 2.5 volumes ethanol. The final pellet was dissolved in 0.3 ml water treated with 0.1% DEPC.

**B. Isolation of Polyadenylated RNA**

Polyadenylated RNA was isolated by heating approximately 500 µg of total RNA in 0.2 to 1.0 ml water to 65°C for 5 minutes, cooling on ice, and adding 10X sample buffer consisting of: 10 mM Tris pH 7.5; 1 mM EDTA; 5 M NaCl in 0.1% DEPC-treated water to a final concentration of 1X. The treated sample was applied to a column of oligod(T) cellulose prepared according to the manufacturer's instructions (Poly(A)Quik™ mRNA purification kit - Stratagene). The column was washed twice with High Salt Buffer (10 mM Tris pH 7.5; 1 mM EDTA; 0.5 M NaCl) and three times with Low Salt Buffer (10 mM Tris pH 7.5; 1 mM EDTA and 0.1 M NaCl). PolyA mRNA was then eluted from the column with four 200 µl aliquots of Elution Buffer (10

- 28 -

mM Tris pH 7.5 and 1 mM EDTA) which had been heated to 65°C. RNA concentration was determined spectrophotometrically using absorbance at 260 nm.

5

### EXAMPLE 13

#### Construction of Lambda gt-11 cDNA Library

A cDNA library was constructed using 4 to 5 µg of polyadenylated RNA that had been purified twice over an oligo(dT) column. The reagents for construction of cDNA, addition of adapters and ligation of lambda gt-11 arms except [<sup>32</sup>P]dCTP were provided in the Superscript™ Choice System (BRL) and were used according to the manufacturer's instructions.

First strand synthesis was primed using either 0.05 µg random hexamers plus 0.5 µg oligo(dT)<sub>12-18</sub> or 1 µg oligo(dT)<sub>12-18</sub> alone. The reaction was carried out in a final volume of 20 µl (final composition: 50 mM Tris, pH 8.3; 75 mM KCl; 3 mM MgCl<sub>2</sub>; 10 mM DTT; 500 µM each dATP, dCTP, dGTP, dTTP; primers; mRNA; 10 µCi [<sup>32</sup>P]dCTP; 200 U Superscript™ reverse transcriptase/µg mRNA). The reaction mixture was incubated for 1 hr at 37°C and then placed on ice.

Second strand synthesis was carried out in a final volume of 150 µl using 18 µl of the first strand reaction. The final composition of the reaction was: 25 mM Tris pH 7.5; 100 mM KCl; 5 mM MgCl<sub>2</sub>; 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>; 0.15 mM B-NAD<sup>+</sup>; 250 µM each dATP, dCTP, dGTP, dTTP; 1.2 mM DTT; 65 U/ml DNA Ligase; 250 U/ml DNA polymerase I; and 13 U/ml RNase H. This reaction mixture was incubated at 16°C for 2 hr; then 10 U of T4 DNA polymerase was added, and the incubation was continued at 16°C for an additional 5 minutes. The reaction was put on ice and stopped by adding 10 µl of 0.5 M EDTA. The mix was extracted with 150 µl of Tris-saturated phenol:chloroform:isoamyl alcohol (25:24:1). The aqueous layer was removed, and cDNA was precipitated with 0.5 volume 7.5 M ammonium acetate and 3.5 volumes ethanol. The cDNA pellet was

- 29 -

washed with 70% ethanol. EcoRI (Not1) adapters were ligated to the cDNA in a reaction mix comprised of 66 mM Tris, pH 7.6; 10 mM MgCl<sub>2</sub>; 1 mM ATP; 14 mM DTT; 200 µg/ml EcoRI (Not1) adapters; 100 U/ml T4 DNA ligase. The reaction mixture was incubated for 16 hours at 16°C, then heated to 70°C and placed on ice. The adapted cDNA was phosphorylated by adding 30 U of T4 polynucleotide kinase to the reaction mix and incubating for 30 minutes at 37°C. The kinase was inactivated by heating to 70°C for 10 minutes. The completed reaction was diluted with 97 µl of TEN buffer (10 mM Tris, pH 7.5; 0.1 mM EDTA; 25 mM NaCl) and placed over a Sephacryl® DNA sizing column prepared according to the manufacturer's directions (BRL). The DNA was eluted with TEN buffer and fractions were collected. Cerenkov counts were obtained for each fraction and the amount of cDNA/fraction was calculated. The column fractions were pooled in order of elution until 50 ng cDNA was collected. The pool was then precipitated with 5 µl yeast tRNA, 0.5 volumes 7.5 M ammonium acetate and 2 volumes ethanol (-20°C). The resultant pellet was washed with 70% ethanol, dried and ligated to lambda gt-11 arms. The final composition of the ligation reaction was 50 mM Tris pH 7.6; 10 mM MgCl<sub>2</sub>; 1 mM ATP; 5% PEG 8000(w/v); 1 mM DTT; 100 µg/ml lambda vector EcoRI arms; 10 µg/ml cDNA; and 200 U/ml T4 DNA ligase. This mixture was incubated for 3 hours at room temperature. The cDNA/lambda gt-11 ligation was packaged into infectious lambda phage particles as described above.

#### EXAMPLE 14

##### A. Antibody Screening of Lambda gt-11 Library

E. coli strain Y1090 was used as the host for lambda phage infections and was maintained on LB/ampicillin plates consisting of: 1% tryptone (w/v); 0.5% yeast extract (w/v); 0.5% NaCl (w/v); 1.5% agar (w/v); the pH was adjusted to 7.5 before autoclaving, and 100 µg/ml ampicillin added after autoclaving. Cultures were grown for phage infection by incubating a single colony overnight on a rotary shaker at

- 30 -

37°C in 3 ml LB/maltose broth consisting of: 1% tryptone(w/v); 0.5% yeast extract(w/v); 0.5% NaCl(w/v) and 0.2% maltose(w/v).

**B. Pretreatment of Antisera**

5 Antisera were treated with an E. coli lysate prior to screening so as to decrease cross-reaction to E. coli protein. E. coli lysate was prepared from Y1090 cells grown overnight in LB broth at 37°C on a rotary shaker at 220 rpm. Cells were pelleted by  
10 centrifugation at 10,000xg at 4°C and resuspended in 3 ml Lysate Buffer (50 mM Tris pH 8.0 and 10 mM EDTA). Cells were frozen in a dry ice/ethanol bath and thawed at room temperature; the freeze/thaw process was repeated. The suspension was sonicated 5 x 10 seconds at output control 4 on a constant duty cycle using a Branson Sonifier 450.  
15 Cells were placed on ice for 10 seconds after each pulse. Protein concentration in the lysate was estimated using the Bradford Assay (Bio-Rad) according to the manufacturer's suggestion. Sonicated lysate was stored at -20°C until needed. The antisera was diluted 10-fold with TBST plus 1% dried milk(w/v) and mixed with 1/20 volume E. coli lysate. This solution was incubated at room temperature on a rotary  
20 shaker for two hours.

**C. Screening of Lambda Gt-11 Phage Plaques**

Recombinant phage diluted to  $6 \times 10^3$  pfu in 100 µl of SM  
25 was added to 600 µl of an overnight culture of E. coli Y1090 and absorbed at 37°C for 30 minutes. The cells were then added to 7.5 ml of a 47°C solution of LB Top Agarose/MgSO<sub>4</sub> (0.1% tryptone(w/v); 0.5% yeast extract(w/v); 0.5% NaCl(w/v); 10 mM MgSO<sub>4</sub>) and plated on a 140 mm LB agar plate. The plate was incubated at 42°C for  
30 approximately 5 hours until tiny plaques were visible. The plate was then overlaid with a 137 mm nitrocellulose filter which had been saturated with a 10 mM solution of IPTG (isopropyl-B-D-thiogalactopyranoside) and air-dried. Incubation of the plate was continued overnight at 37°C. The filter was removed and washed 3 times for 15 minutes each. All washes were carried out at room



- 31 -

temperature on a rotary shaker in TBST. The filters were blocked in TBST plus 5% w/v dried milk (Carnation instant non-fat dried milk) for 30 minutes at room temperature on a rotary shaker. Filters were washed 3 x 15 minutes and then incubated with a 1:1000 dilution of goat anti-rabbit IgG alkaline phosphatase conjugate (Bio-Rad) in TBST plus 1% dried milk(w/v) for 2 hours. The filters were washed 3 x 15 minutes and then developed in AP buffer (100 mM Tris pH 9.5; 100 mM NaCl; 5 mM MgCl<sub>2</sub>) to which was added NBT (nitroblue tetrazolium) to a final concentration of 0.33 mg/ml and BCIP (5-bromo-4-chloro-3-indoyl phosphate) to a final concentration of 0.165 mg/ml for 2-5 minutes. The color reaction was stopped by washing the filters with water. Positive plaques were picked to 1 ml SM plus 10 µl chloroform and stored at 4°C until needed.

Positive plaques were further purified until all the plaques on a filter were positive. Purification rounds were done on 100 mm LB/agar plates with phage titer adjusted to approximately 100 pfu/plate. Positive plaques were confirmed by screening with an affinity-purified antibody at a dilution of 1:100.

### EXAMPLE 15

#### Preparation of Lambda DNA

Phage were adsorbed to 1.5 ml of an overnight culture of *E. coli* Y1090 at a multiplicity of infection of 0.01 for 30 minutes at 37°C and then added to 300 ml LB media. The cells were incubated at 37°C on a rotary shaker about 6 hours (until the cells lysed). One ml chloroform was added to complete the lysis. Cell debris was pelleted by centrifugation at 10,000 x g for 10 minutes at 4°C. Lysate was stored at 4°C until needed.

Lysate was treated with DNase I (final concentration 1 µg/ml) and RNase H (final concentration 5 µg/ml) at 37°C for one hour. Phage were pelleted by centrifugation for 90 minutes at 27,000 rpm in a Sorvall AH-629 rotor; and the tubes were inverted to drain. Phage pellets were resuspended in 200 µl 0.05 M Tris, pH 8 and were

- 32 -

5 extracted with 200 µl Tris-saturated phenol by vigorous shaking for 20 minutes. The mixture was spun in a microcentrifuge, and the aqueous layer saved. The aqueous layer was extracted with phenol and then extracted twice with 200 µl chloroform. DNA was precipitated with 0.1 volume 3 M sodium acetate and 6 volumes ethanol at room temperature. DNA was pelleted in a microcentrifuge, washed with 70% ethanol, dried and resuspended in 100 µl TE pH 8.0 (10 mM Tris; 1 mM EDTA).

### 10 EXAMPLE 16

#### Screening of EMBL3 Genomic Library

15 The EMBL3 genomic library was plated for screening with <sup>32</sup>P-labeled DNA probes. Approximately 10,000 plaques were plated and transferred to nitrocellulose for hybridizations. Filters were prehybridized for 2 hours and hybridized overnight in hybridization buffer in the presence of a DNA probe labeled with <sup>32</sup>P-dCTP (Oligolabeling Kit, Pharmacia). For the selection of EMBL-1, the DNA probe consisted of the EcoRI cDNA insert of lambda gt-11 2-9 which 20 was identified using the antibody to the 235 kD protein. Filters were washed using the protocol employed for Southern hybridizations, and positive plaques were identified after an overnight exposure to film. DNA from positive EMBL-3 phage was prepared as described.

### 25 EXAMPLE 17

#### Sequencing Strategy and Analysis

30 A series of overlapping subclones from the genomic EMBL1 clone, which contained the triol PKS gene, were constructed in M13mp18 and M13mp19. Nested deletions of some of the clones were obtained using the Cyclone I Biosystem (International Biotechnologies, Inc., New Haven, CT). Single stranded DNA was purified by precipitation with 20% polyethylene glycol-2.5 M NaCl followed by phenol extraction and ethanol precipitation. The nucleotide sequence of

- 33 -

both strands of the DNA was determined using the USB Sequenase Version 2.0 DNA Sequencing Kit (United States Biochemicals, Cleveland, OH). The -40 sequencing primer from the kit or custom synthesized oligonucleotides were used to prime the reactions. Regions containing GC compressions were resequenced using dITP in place of dGTP. The sequencing reactions were separated on 6% polyacrylamide denaturing gels. The genomic M13 clones were resequenced using a 373A DNA Sequencer (Applied Biosystems, Inc.) for verification. Introns were identified by sequence analysis of cDNA. The RNA was prepared from a 16 hr culture grown in GP9 medium, and cDNA was synthesized using AMV reverse transcriptase. Custom synthesized oligonucleotides were used to amplify short overlapping stretches of the cDNA by PCR. The PCR conditions, reagents, and product purification were performed as described for PCR with genomic DNA in the PCR/Sequencing Kit PCR Amplification Module manual (Applied Biosystems, Inc., Foster City, CA). The PCR were performed using a Perkin Elmer GeneAmp PCR system 9600. The PCR products were sequenced as described in the Taq DyeDeoxy Terminator Cycle Sequencing Kit manual (Applied Biosystems, Inc.), and sequencing reactions were analyzed using the 373A DNA Sequencer. All sequence analyses and manipulations were performed using GeneWorks (IntelliGenetics, Inc., Mt. View, CA) on a Macintosh computer (Apple Computer, Inc., Cupertino, CA).

### EXAMPLE 18

#### A. Construction of pTPKS100

The transformation vector pTPKS100 contains the polyketide synthase gene responsible for the synthesis of the nonaketide backbone of the triol structure, the phleomycin resistance gene for selection in A. terreus and the ampicillin resistance gene for selection in E. coli.

The vector was constructed from the pUT715 vector (Cayla, Toulouse Cedex, France) which contains the phleomycin

- 34 -

resistance marker from S. hindustanus and the termination sequence from the Cyc1 gene in S. cerevisiae. The pUT715 vector was digested with BamHI and EcoRV. The  $\beta$ -tubulin gene promoter was inserted in front of the phleomycin marker gene as follows. The  $\beta$ -tubulin promoter was removed from pTL113 by digestion with EcoRI, filling with Klenow fragment, and releasing the fragment from the vector with a BgIII digest. The  $\beta$ -promoter was ligated into the pUT715 vector to form pCLS7. The  $\beta$ -tubulin promoter, phleomycin marker and Cyc1 terminator were removed from PCLS7 by digestion with NdeI and BgIII followed by filling in the sites, and ligating into the SmaI site of the Bluescript vector (Stratagene). This vector was named pLOA.

The polyketide synthase gene was inserted into pLOA in a two step process. The promoter and 5'-end of the PKS gene was obtained from EMBL-1 as a KpnI to EcoRI fragment and ligated into pLOA which had been digested with KpnI and EcoRI. This vector was named TPKS A. The 3' end of the PKS gene was then added to the construction by digesting TPKS A with EcoRI and ligating in the 3' EcoRI gene fragment isolated from EMBL-1. The resulting vector was named pTPKS100.

Transformation of a lovastatin-nonproducing strain with pTPKS100 restored lovastatin production. Transformation of ATCC 20542 (a lovastatin-producing strain) increased lovastatin production relative to untransformed cells.

## EXAMPLE 19

### Transformation of *A. terreus* ATCC 20542

To determine whether increasing the copy number of the PKS gene in a lovastatin-producing strain would result in an increase in the amount of lovastatin produced, a set of experiments were designed and carried out using the *A. terreus* ATCC 20542. ATCC 20542 was transformed with pTPKS-100. Transformants were checked by PCR to confirm that they contained the phleomycin marker and were true transformants. Following single spore isolation, the confirmed

- 35 -

transformants were fermented and lovastatin production was measured by HPLC. The highest producer of single isolates, strain 3-17-7#7, was 32% greater for the transformant than for the parent.

5

## EXAMPLE 20

### Characterization of the TPKS Protein Sequence

Splicing of the introns from the DNA sequence and translation of the 9114 nucleotide open reading frame results in a protein of 3038 amino acids with a molecular weight of 269,090 daltons. The final amino acid sequence of the TPKS protein is shown in Figure 2. The features discussed below are presented with their amino acid position noted in the following table.

15

### TPKS PROTEIN FEATURES

	<u>Description</u>	<u>Motif</u>	<u>Amino Acid</u>
20	Keto-acyl synthase	Cysteine	181
	Acetyl/Malonyl Transferase	GXSXG	654-658
	Dehydratase	HXXXGXXXXP	985-994
	Methyl Transferase	GXGXG	1446-1450
	Enoyl Reductase	SXGXXS	1932-1937
	Keto Reductase	LXGXXG	2164-2169
25	Acyl Carrier Protein	Serine	2498

Inspection of the TPKS amino acid sequence for active site residues and motifs known to be associated with polyketide synthases and fatty acid synthase (FAS) activities resulted in the identification of candidates for expected functional sites. These sites were identified by carrying out searches for amino acid sequences and amino acid homologies using the Intelligenetics Gene Works program. A graphic view of the open reading frame of the protein and the overall placement of the TPKS peptide sequences obtained by partial sequence analysis of

30

- 36 -

TPKS peptides and PKS activities established by alignments and is shown in the figures. Except for the presence of a methyl transferase, not present in FAS, the succession of activities on the TPKS protein is the same as that observed for the rat FAS protein. The alignments carried out on regions of the TPKS, the rat FAS, and the 6-methylsalicylic acid synthase (6-MSAS) of Penicillium patulin in order to identify the best candidate for each of the activities are also presented in the figures.

### EXAMPLE 21

#### Identification of the Keto Acyl Synthase Region

The most 5' site is the  $\beta$ -keto acyl synthase (KAS), also known as the condensing enzyme. This activity is centered around the active site cysteine to which the acyl chain is attached prior to the entry and condensation of the incoming acyl unit. The region shown in the Keto Acyl Synthase Alignment figure contains 30% homology when compared to both the rat FAS and 6-MSAS sequences. However, the TPKS KAS region is most closely related to the rat FAS sequence, exhibiting 49% homology over this region compared to 41% to 6-MSAS.

### EXAMPLE 22

#### Identification of the Acetyl Malonyl Transferase

Proceeding towards the COOH terminus, the next functional site identified is the acetyl/malonyl transferase, which is responsible for accepting the incoming substrate for transfer to either the active thiol of the beta-keto synthase (if a priming acetyl unit) or to the active site thiol of the ACP-pantetheine-SH if a malonyl building block. The identification of the acetyl/malonyl transferase site was found by searching for the GX SXG motif found in many proteins with an active site serine (Wakil, S. J., 1989, Biochemistry, 28: 4523-4530).

- 37 -

The conservation of this motif in the TPKS protein was observed beginning at amino acid 654, as shown in the figures.

### EXAMPLE 23

#### Identification of the Dehydratase

The next site in common with the FAS protein is the dehydrates. The dehydratase motif consistently found not only in the rat FAS, but the 6-MSAS and the erythromycin SU4 as well consist of a "HXXXGXXXXP" sequence (Donadio, S. and Katz, L., 1992, Gene, 111, 51-60.). The homology outside of this signature sequence is very weak.

### EXAMPLE 24

#### Identification of the Enoyl and Keto Reductase

The next two activities identified on the rat FAS protein are the enoyl reductase (ER) and keto reductase (KR). In general, the ER and KR are identified by searching for the GXGXXG/A motif which is proposed to represent the pyridine nucleotide binding site in many proteins (Wierenga, R. K. and Hol, W. G. J., 1983, Nature, 302, 842-844). An identical match to this motif has been identified in the rat FAS for both the KR and ER (Witkowski, V., et al., 1991, Eur. J. Biochem., 198, 571-579). Inspection of the TPKS protein identified three matches to the motif. The first begins at position 321 between the  $\beta$ -keto synthase and acetyl/malonyl transferase functions. However, this is not considered to be a good candidate for either of the reductase activities due to its 5' position in the protein and because it lies in a region which is highly homologous to rat FAS. The GXGXXG motif is seen again at position 1446-1451, however, this is considered to be part of the methyl transferase domain. The third time the motif occurs is at position 2438 which lies 60 amino acids 5' of the ACP active site serine. A similar GXGXXG motif is seen in the rat FAS at 125 amino acids prior to the ACP and in 6-MSAS 129 amino acids 5' of the ACP. Since candidates

- 38 -

for the NAD(P) binding sites of the KR and ER were not observed in the TPKS protein, homology searches were performed between the regions of the rat FAS which contain these sites and similar regions of the TPKS protein.

5           As shown in the Enoyl Reductase Alignment, the region of the TPKS protein which lies between the dehydratase and the keto reductase and shows the best alignment to the rat FAS enoyl reductase does not bear a strong homology to the GXGXXG motif or to the  
10           region in general. A much stronger homology is evident between the ER domain of SU4 of Erythromycin AII and the rat FAS sequence. The Keto Reductase Alignment of the rat FAS and 6-MSAS keto reductase regions with the TPKS shows slightly higher homology, with  
15           6 out of 30 amino acids surrounding the glycine-rich region conserved between all genes and 13 of 30 conserved between TPKS and either FAS or 6-MSAS.

          The glycine-rich segment is part of an overall structural motif for pyridine-nucleotide binding domains in many proteins (Wierenga, *ibid.*; Scrutton, N. S., *et al.*, 1990, Nature, 343, 38-43; Ma, Q., *et al.*, 1992, 267, 22298-22304; Hanukoglu, I., and Gutfinger, T.,  
20           1989, Eur J. Biochem., 180, 479-484). This structural motif consists of a beta sheet-turn-alpha helix where the glycine rich region codes for the strong turn signal in the middle. In addition, downstream acidic or basic amino acids are positioned to bind to the phosphate (NADP) or hydroxyl group (NAD) on the 2' ribose position. This is depicted in a  
25           Chou Fasman analysis of the secondary structure of horse alcohol dehydrogenase as a model NADP binding protein. The analysis of the structural characteristics using the Chou Fasman algorithm indicate that this structural motif is conserved in the rat FAS ER and KR domains, (Witkowski, A., 1991, Eur. J. Biochem., 198, 571-579). The structural  
30           predictions of the amino acid sequence of the TPKS ER and KR, as well as the 6MSAS KR, show variations of the model. All predicted structures show a  $\beta$  sheet leading into a turn region, even when amino acid homologies are not strong. It has been suggested that deviations from the structural model may reflect differences in substrate



- 39 -

specificity (Ma, Q., supra). It is possible that these structural variations are important in the programming of the PKS, resulting in different levels of reduction of the beta-keto group during successive cycles of the biosynthesis of the triol precursor. Consistent throughout the alignments are the presence of basic amino acids at position 20 to 23 amino acids from the "glycine rich" regions identified by the homology searches. The structural similarities and the presence of these basic amino acids suggest that these regions do indeed represent the keto and enoyl reductases of the TPKS protein.

#### EXAMPLE 25

##### Identification of the Acyl Carrier Protein

The last active site identified by alignment of the rat FAS with the TPKS is the acyl carrier protein (ACP) active site serine which binds the 4'-phosphopantetheine prosthetic group. While only 6 out of 30 amino acids surrounding the active site serine are conserved over TPKS, rat FAS and 6-MSAS, a higher degree of homology (13 of 30 amino acids) is observed between TPKS and either rat FAS or 6-MSAS.

#### EXAMPLE 26

##### Identification of the Methyl Transferase

One activity identified within the reading frame of the TPKS protein which is not present in rat FAS is the methyl transferase responsible for transfer of the methyl group from S-adenosylmethionine (SAM) to the polyketide chain at position 6. A comparison of both eucaryotic and procaryotic methyl transferases responsible for the methylation of RNA, DNA, and protein substrates has identified a sequence motif thought to be part of the SAM-binding domain (Ingrosso, D. et al., 1989, J. Biol. Chem., 264, 20131-20139; Wu, G. et al., 1992, J. Gen. Micro., 138, 2101-2112). The binding motif and its alignment with the proposed methyl transferase of the TPKS are shown in the figures.

- 40 -

The absence of a methyl group in compactin suggests that the methyl transferase domain may be absent or altered in the compactin PKS.

5

### EXAMPLE 27

#### A. Transformation of Monascus ruber

Cultures of M. ruber strains M4681 AND M82121 are grown, spheroplasted and transformed essentially according to the procedures described above. Petri dishes are incubated at 28°C and 65% humidity for 7-10 days before transformed colonies are picked.

#### B. Fermentation of Monascus

The transformed cultures are grown aerobically in a medium containing 7% glycerol, 3% glucose, 3% meat extract, 0.8% peptone, 0.2% NaNO<sub>3</sub>, and 0.1% MgSO<sub>4</sub>•7H<sub>2</sub>O at 25 degrees C for 10 days (Kimura et al., 1990. "Biosyn. of Monacolins, Conversion of Monacolin J. To Monacolin K (Mevinolin)", J. of Antibiotics, Vol. XLIII No. 12, 1621-1622). M. ruber M82121 is grown aerobically at 25°C for 11 days in a medium containing 11% glycerol, 1% glucose, 5% soy bean powder, 0.8% peptone, 0.1% NaNO<sub>3</sub>, 0.05% Zn(NO<sub>3</sub>)<sub>2</sub>, and 0.5% olive oil (pH 6.5) (Endo, et al., "Dihydromonacolin L and Monacolin X, New Metabolites Those Inhibit Cholesterol Biosynthesis", J. Antibiot., Vol. XXXVIII No. 3, 321-327). The culture broth is extracted with a solvent such as methanol or dichloromethane, concentrated and analyzed by methods such as HPLC. By comparison with an untransformed host or a M. ruber culture containing pL09 without the TPKS genes, the TPKS100 containing host or a derivative thereof produces increased levels of lovastatin, triol, monacolin, dihydromonacolin L or monacolin X.

- 41 -

### EXAMPLE 28

#### A. Transformation of Paecilomyces viridis

5 P. viridis strain L-63 is grown, spheroplasted and transformed essentially according to the procedures described above. Cells are transformed with pTPKS100 or a derivative thereof. An example of such a derivative is one in which the DNA encoding the methyl transferase activity of the TPKS protein is altered such that an  
10 active methyl transferase is not produced. Petri dishes are incubated at 28°C and 65% humidity for 7-10 days before transformed colonies are picked.

#### B. Fermentation of Paecilomyces

15 P. viridis L-63 is grown aerobically in a medium containing 7% glycerol, 3% glucose, 3% meat extract, 0.8% peptone, 0.2% NaNO<sub>3</sub>, and 0.1% MgSO<sub>4</sub>·7H<sub>2</sub>O at 25°C for 4 to 10 days (Kimura et al., supra). The culture broth is extracted with a solvent such as methanol or dichloromethane and concentrated by evaporation if  
20 necessary. By comparison with an untransformed host or a P. viridis culture containing pLOA without the TPKS genes, the transformed host can be shown to ferment increased levels of ML-236A and compactin.

### EXAMPLE 29

#### 25 A. Transformation of Penicillium citrinum

A suitable culture of P. citrinum (e.g., Nara, et al., 1993. "Development of a transformation system for the filamentous, ML-236B (compactin) - producing fungus Penicillium citrinum". Curr. Genet., 23, 28-32) is transformed with pTPKS100 or an appropriate  
30 derivative thereof using conventional methods.

#### B. Fermentation of P. citrinum

The transformed culture is maintained on yeast-malt extract agar slant (4 g/l dextrose, 10 g/l malt extract, 4 g/l yeast extract, agar

- 42 -

20 g/l, pH 7 prior to sterilization). The slant is washed and used to inoculate to flasks containing KF seed medium (10 g/l  $\text{CaCl}_2$ , 5 g/l corn steep liquor, 40 g/l tomato paste, 10 g/l oatmeal, 10 g/l cerelose, 10 ml trace element per liter, pH 6.8; trace elements consist of 1 g  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ , 1 g  $\text{MnSO}_4 \cdot 4\text{H}_2\text{O}$ , 25 mg  $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ , 100 mg  $\text{CaCl}_2$ , 56 mg  $\text{H}_3\text{BO}_3$ , 19 mg  $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24} \cdot \text{H}_2\text{O}$ , 200 mg  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$  in liter of  $\text{dH}_2\text{O}$ ). The KF seed flasks are incubated for about 3 days at about 28°C and 220 rpm. Approximately 1.5 ml is used to inoculate 40 ml of LM production medium per 250 ml flask. LM medium contains 20 g/l dextrose, 20 ml/l glycerol, 10 g/l arginine pH, 20 g/l malt extract, 8 mg/l  $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$  and 0.25% polyglycol P2000, pH 7.0. After 5 to 10 days at 25°C on a shaker, the broth is collected, extracted and concentrated. The transformed culture produces more compactin and dihydrocompactin than does the untransformed parent culture.

### EXAMPLE 30

#### Cloning of TPKS cDNA into a Mammalian Expression Vector

TPKS cDNA expression cassettes are ligated at appropriate restriction endonuclease sites to the following vectors containing strong, universal mammalian promoters:

Cassettes containing the TPKS cDNA in the positive orientation with respect to the promoter are ligated into appropriate restriction sites 3' of the promoter and identified by restriction site mapping and/or sequencing. These cDNA expression vectors are introduced into various host cells by standard methods including but not limited to electroporation, or chemical procedures (cationic liposomes, DEAE dextran, calcium phosphate). Transfected cells and cell culture supernatants can be harvested and analyzed for TPKS expression as described below.

Vectors used for mammalian transient expression may be used to establish stable cell lines expressing TPKS.

- 43 -

### EXAMPLE 31

#### Cloning of TPKS cDNA into a Baculovirus Expression Vector for Expression in Insect Cells

5 Baculovirus vectors, which are derived from the genome of the AcNPV virus, are designed to provide high level expression of cDNA in the Sf9 line of insect cells. Recombinant baculoviruses expressing TPKS cDNA are produced essentially by standard methods (InVitrogen Maxbac Manual). The TPKS cDNA constructs are ligated  
10 into the polyhedrin gene in a variety of baculovirus transfer vectors including but not limited to pAC360 and the BlueBac vector (InVitrogen). Recombinant baculoviruses are generated by homologous recombination following co-transfection of the baculovirus transfer vector and linearized AcNPV genomic DNA [Kitts, P.A., Nuc. Acid. Res., 18, 5667 (1990)] into Sf9 cells. Following plaque purification, TPKS expression is measured by the assays described above.

15 Authentic, enzymatically-active TPKS is found in the cytoplasm of infected cells. Active TPKS is extracted from infected cells under native conditions by hypotonic or detergent lysis.  
20

### EXAMPLE 32

#### Cloning of TPKS cDNA into a yeast expression vector

25 Recombinant TPKS is produced in the yeast S. cerevisiae following the insertion of the optimal TPKS cDNA cistron into expression vectors designed to direct the intracellular or extracellular expression of heterologous proteins. In the case of intracellular expression, vectors such as EmBLyex4 or the like are ligated to the TPKS cistron [Rinas, U. et al., Biotechnology, 8, 543-545 (1990);  
30 Horowitz B. et al., J. Biol. Chem., 265, 4189-4192 (1989)]. For extracellular expression, the TPKS cistron is ligated into yeast expression vectors which fuse a secretion signal (a yeast or mammalian peptide) to the NH<sub>2</sub> terminus of the TPKS protein [Jacobson, M. A.,

- 44 -

Gene, 85, 511-516 (1989); Riett L. and Bellon N., Biochem., 28, 2941-2949 (1989)].

### EXAMPLE 33

#### Use of TPKS for in vitro production of HMG-CoA inhibitors

Recombinant proteins, including complex proteins, can be overexpressed in a heterologous cells (e.g., Roberts et al., 1993, "Heterologous expression in *E. coli* of an intact multienzyme component of the erythromycin-producing polyketide synthase". Eur J. Biochem., 214, 305-311). If the recombinant protein is produced in an inclusion body, renaturation of the desired protein is carried out prior to enzymatic assay (Roberts, 1993).

A suitable host cell is transformed with a vector encoding the TPKS gene. The transformed host cell is grown under conditions that permit the expression of TPKS. The expressed TPKS is isolated and partially purified. The recovered active TPKS enzyme can be added to a reaction mixture containing acetyl-CoA or other charged acyl compounds, appropriate cofactors, and buffer. Incubation of the system can result in the formation of HMG-CoA reductase inhibitors.

### EXAMPLE 34

#### Cloning of other PKS genes using TPKS gene

The cross hybridization of the DNA representing portions of the TPKS gene to genomic DNA isolated from other organisms such as M. ruber or P. citrinum, makes it possible to clone the homologous genes from the parent organisms. To do this, a genomic library of M. ruber or P. citrinum was constructed from genomic DNA according to conventional methods. Using, for example, an EMBL vector, an EMBL genomic library was prepared, plated and screened by hybridization with a <sup>32</sup>P-labeled DNA probe consisting of the PstI fragment from the TPKS gene. The PstI fragment contains the keto synthase sequence of the gene. Positive plaques were selected and subjected to additional

- 45 -

screening until a purified cross-reacting plaque was selected. The DNA contained in the positive clone is further characterized by physical methods such as restriction mapping, Southern hybridization and DNA sequencing. The function of the defined gene is characterized by  
5 cloning the gene in an appropriate transformation vector and transforming a lovastatin non-producing strain with the vector. In the case of M. ruber, the cross-reacting PKS would be expected to restore production of Monacolin K (lovastatin) while introduction of a functional P. citrinum PKS would result in production of compactin.  
10

### EXAMPLE 35

#### Homology of A. terreus TPKS to other strains

15 A large segment of the 5' end of the A. terreus TPKS gene containing the keto synthase region was used to look for cross-hybridization of this region to other strains, including M. ruber, P. citrinum and P. brevicompactum. The homology was examined by Southern analyses with two probes. The Southern showed cross-reaction to all three strains.  
20

The first probe was the PstI fragment, an 800 bps probe which spans the KAS active site. This probe contains intron I 5' of the active site cysteine in addition to the entire KAS region. This probe was used to detect homology in all three strains. A. terreus displayed the profile of cross-reacting bands expected from the restriction map. M. ruber, another lovastatin-producing organism, and P. citrinum, a compactin-producing organism, showed different but strong hybridizations to the probe.  
25

The second probe was a synthetic oligonucleotide probe having the following sequence:  
30 5'GATACGGCATGCAGCTCGTCGTTGGTTGCCGTTTCATCTGGCT  
GCA3' (SEQ ID NO:3). Although the hybridization signal to this probe was weaker than the hybridization to the first probe, the results confirm the observations made with the PstI fragment.

- 46 -

When a 3' end cDNA probe was used, cross reaction to all three strains was observed. Single cross-reacting bands in many of the digests indicate that only one gene is being detected in the genomic DNA of each strain. These data suggest that M. ruber and P. citrinum contain a gene with substantial homology to the TPKS gene of A. terreus.

### EXAMPLE 36

#### Use of mutagenized TPKS

The DNA encoding TPKS is mutagenized using standard methods to produce an altered TPKS gene. Host cells are transformed with the altered TPKS to produce altered triol polyketides or altered polyketides with therapeutic use. The altered TPKS protein may be isolated and purified

20

25

30



- 47 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: VINCI, VICTOR A.  
CONDER, MICHAEL J.  
MCADA, PHYLLIS C.  
REEVES, CHRISTOPHER D.  
DAVIS, CHARLES R.  
HENDRICKSON, LEE E.  
RAMBOSEK, JOHN
- (ii) TITLE OF INVENTION: DNA ENCODING TRIOL POLYKETIDE SYNTHASE
- (iii) NUMBER OF SEQUENCES: 3
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: CHRISTINE E. CARTY
  - (B) STREET: P.O. BOX 2000; 126 E. LINCOLN AVENUE
  - (C) CITY: RAHWAY
  - (D) STATE: NJ
  - (E) COUNTRY: USA
  - (F) ZIP: 07065
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: US
  - (B) FILING DATE: 01-NOV-1993
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: CARTY, CHRISTINE E.
  - (B) REGISTRATION NUMBER: 36,099
  - (C) REFERENCE/DOCKET NUMBER: 19076
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 908-594-6734
  - (B) TELEFAX: 908-594-4720

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 11561 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

- 48 -

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: TPKS cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CTGCAGTCAA CGGATCACTT ACCATTGCTG TCGCCAAAAA TATCCGTGAT AATCCCGCTG	60
GCTTCATTGG CAAGAGGCTT GACGTACTTG GGAGCTTGGG TCTGGAAC TGTTTCATAACC	120
ACCTTGGTGA TGAGATGTGC ATCCCTCGTG ACTTCCTTGA ATCCATCGAA TCCGGGAAGA	180
TGAGAGTGAA AGTCCGTGAT AGAGCACGAA GATCAGTAAG TCAGGTCCCTC ACAGCGGAAG	240
CAGTTGCAAA GAACGGTGGA CTCCTTACCG TGCCCAAGAA CTTGTACATA CAGAGCTCTT	300
TCATCTTGCG AAATCATCG GCCATAGAGG AGGGAAGAAT GGTGCAGTAC CCAGAGTCGA	360
CTATGAACCG AATGGGCTTA TCATTTTGCG AGAACCAGCT CTCAATCCAT GACGGTG CAT	420
TGCGATCAAA ATCCCGTTTG GCCCTCATGG TCGTCAGTTC CCACCATGTT TTCGGATTGA	480
ACACCGGCAG ATCAGATCTC CGGCCACTCG AGCACAGGTA AAGAAGAAGG CATAGTAGCC	540
CCGCACTGGT AGTGACCAAG GCGCAAACC ACGAGCCATG TTGCTGCGTG TCATTCCAAG	600
CCAGCGACAG AAGGTGGTGC GGCTGTGTGA GCGCGTCGAC AGTCATGGCT AGGAGACCAG	660
GTGTGGTTGA GGGATAAGAT ATCGAGAGTG ATGTGAGCAA AAGATCCGGG AAAGGTCGCG	720
AAGGAAAGGG CGTCTCTCTT ACCAAGAAAG TCTGTTCCCT ATCATGCAAT CACCGCTTGC	780
TGTACGGTGG TGATGATGCT GGGATGGTGG TGGGTCCCCA CCGAATAACG CCGGACAGCT	840
GTTGAAGCCG AATGACGCCG GCAGGCCAAA AGAACCCTAC CTTCACTTAC TCAATCGGCG	900
CTTCCCCTCC TATCACCAA TCGGATGTAA ATGGACGGGC CTTAATAGCG ACCGGCCGGG	960
CCGGGAATCC CCAAACGTAG ATAGATAGGC ATAGACCCGA AATCTTTGGC CCGGCATACA	1020
TGAGCACAGG AAGTTTCACG CGACGGCGCC TTTCCTGCCT CAGCTTCAAT CCAAGCTCAC	1080
GAGTTCTGTC GCCTCTATCA GTCGTGCAAT TGTCCCTACTG CAAACAGCAT GGCTCAATCT	1140
ATGTATCCTA ATGAGCCTAT TGTCGTGGTC GGCAGTGTT GTGCTTCCC TGGTGACGCC	1200
AACACACCCT CCAAGCTCTG GGAGCTACTC CAGCATCCTC GCGATGTGCA GAGTCGAATC	1260
CCCAAAGAAC GATTTGACGT CGACACATTT TATCACCCGG ACGGGAAGCA CCACGGGCGA	1320
ACAAATGCAC CCTACGCCTA TGTTCTCCAA GACGATCTGG GCGCCTTCGA TCGGCCTTC	1380
TTCAATATCC AGGCTGGAGA GGCCGAGAGT ATGGACCCCC AGCACCGGCT GTTGCTGGAG	1440

- 49 -

ACGGTGTACG AGGCCGTAAC GAATGCTGGA ATGCGTATCC AGGATCTGCA GGGAACTTCG	1500
ACTGCTGTTT ACGTCGGGGT GATGACGCAC GACTATGAGA CTGTCTCAAC CCGCGACCTG	1560
GAGAGCATCC CCACCTACTC GGCACACGGT GTCGCGGTCA GTGTTGCGTC CAACCGCATC	1620
TCGTATTTTT TTGACTGGCA TGGACCAAGT GTAAGTCACC CAATATCGTG TAGCAGTCTA	1680
ATCATGCTCT AACGGACCGG GATGGTTGAA AGATGACGAT CGATACGGCA TGCAGCTCGT	1740
CGTTGGTTGC CGTTCATCTG GCGGTGCAAC AGCTACGGAC GGGTCAAAGC TCCATGGCAA	1800
TTGCTGCGGG TCGAATCTG ATTCTGGGGC CCATGACATT CGTCCTTGAA AGCAAATTGA	1860
GCATGCTATC CCCCTCGGGT CGATCCCGCA TGTGGGACGC CGGAGCTGAC GGCTATGCCA	1920
GAGGCGTGAG TGTTTCTTGA GCTCGTAGAT GACAGTTCCC ATCGCTGACC GTGATCAGGA	1980
AGCTGTTTGC TCTGTAGTGT TGAAGACATT GAGTCAAGCC TTGCGCGATG GGGACACGAT	2040
TGAATGTGTC ATCCGAGAAA CTGGGGTGAA TCAAGATGGC CGAACGACCG GAATTACGAT	2100
GCCGAACCAT AGTGCTCAGG AGGCACTCAT CAAGGCTACC TACGCCCAGG CTGGCCTTGA	2160
CATCACCAAG GCCGAGGACA GGTGCCAATT CTTGAGGCT CATGGTCAGC AAAGAGAACC	2220
TGTTCTGTTG GCGCCCTGCA GCTGACATTC GTATGATAGG GACTGGTACT CCGGCCGGAG	2280
ATCCCCAGGA GGCAGAGGCC ATTGCAACAG CCTTCTTCGG CCACGAGCAG GTAGCACGCA	2340
GCGACGGA AAA CGAGAGGGCC CCTCTGTTTCG TGGGCAGTGC GAAACTGTT GTCGGGCACA	2400
CCGAGGGCAC GGCCGGTCTG GCTGGTCTCA TGAAGGCGTC GTTCGCTGTC CGCCATGGGG	2460
TAATCCCCC CAACCTGCTG TTCGACAAAA TCAGCCCGCG AGTCGCCCCA TTCTATAAAA	2520
ACCTGAGGAT TCCGACAGAA GCTACCCAAT GGCCAGCTCT CCCACCCGGA CAACCGCGCC	2580
GCGCCAGTGT CAACTCCTTT GGTAAAGCGAG GATTGCCCGG AGGAACCCTC ACAAGTACTC	2640
GAATTAATGC TAACTGAACC GCGCCGATGG ACAGGATTCG GCGGCACGAA TGCGCATGCC	2700
ATTATTGAGG AATACATGGA GCCAGAGCAA AACCAGCTGC GAGTCTCGAA TAATGAGGAC	2760
TGCCCACCCA TGACCGGTGT CCTGAGTTTA CCCTTAGTCC TCTCGGCGAA GTCCAGCGC	2820
TCCTTAAAGA TAATGATGGA GGAGATGCTG CAATTCCTTC AGTCTCACC CGAGATACAC	2880
TTGCACGACC TCACCTGGTC CTTACTGCGC AAGCGGTCAG TTCTACCCTT CCGCCGGGCT	2940
ATTGTCGGCC ATAGTCATGA AACCATCCGC CGGGCTTTGG AGGATGCCAT CGAGGATGGT	3000
ATTGTGTCGA GCGACTTCAC TACGGAGGTC AGAGGCCAGC CATCGGTGTT GGGAAATCTTC	3060
ACCGGGCAGG GGGCGCAGTG GCCGGGGATG TTAAAGAATC TGATAGAGGC ATCGCCATAT	3120

- 50 -

GTGCGGAACA TAGTGAGGGA GCTGGACGAC TCCCTGCAGA GCTTGCCGGA AAAATACCGG	3180
CCCTCGTGGA CGCTACTGGA CCAGTTCATG CTAGAAGGAG AGGCCTCCAA CGTCCAATAT	3240
GCTACTTTCT CCCAGCCATT ATGCTGCGCG GTGCAAATTG TCCTGGTCCG TCTCCTTGAA	3300
GCCGCGAGAA TACGATTAC GGCTGTTGTT GGACATAGCT CCGGCGAAAT TGCTTGCGCC	3360
TTTGCTGCCG GGCTCATCAG TGCCTCGTTG GCGATTCGGA TTGCTTACTT ACGTGGAGTC	3420
GTCTCGGCAG GGGGCGCCAG AGGCACACCG GGAGCCATGT TGGCCGCCGG GATGTCCTTT	3480
GAGGAAGCAC AAGAGATCTG CGAGTTGGAT GCCTTTGAGG GCCGCATCTG CGTGGCTGCC	3540
AGCAATTCCC CAGACAGTGT AACTTTCTCT GCGACGCGA ACGCAATTGA TCACCTGAAG	3600
GGCATGTTGG AGGATGAGTC CACTTTTGCG AGACTGCTCA AGGTCGATAC AGCGTACCAC	3660
TCGCATCATA TGCTTCCATG TGCAGACCCA TATATGCAAG CCCTAGAAGA GTGTGGTTGT	3720
GCTGTTGCCG ATGCAGGTTT CCCAGCCGGA AGTGTACCCT GGTATTCGTC CGTGGACGCC	3780
GAGAACAGGC AAATGGCAGC AAGAGACGTG ACCGCCAAGT ACTGGAAAGA TAACTTAGTA	3840
TCTCCGGTGC TATTCTCCCA CGCAGTGCAG CGGGCAGTCG TCACGCACAA GCGCTGGAT	3900
ATCGGGATTG AAGTGGGCTG TCACCCAGCT CTCAAGAGCC CATGCGTCGC CACCATCAAG	3960
GATGTCCTAT CTGGGGTTGA CCTGGCGTAT ACAGGTTGCT TGGAGCGAGG AAAGAATGAT	4020
CTCGATTGAT TCTCTCGAGC ACTGGCATAT CTCTGGGAAA GGTTTGGTGC CTCCAGTTTC	4080
GATGCGGACG AGTTCATGCG TGCAGTCGCG CCTGATCGGC CCTGTATGAG TGTGTCGAAG	4140
CTCCTACCGG CCTATCCATG GGACCGCTCT CGTCGCTACT GGGTGGAAATC CCGAGCAACT	4200
CGCCACCATC TTCGAGGGCC CAAGCCCCAT CTTCTATTAG GAAAGCTCTC CGAATACAGC	4260
ACTCCGCTAA GCTTCCAGTG GCTGAATTTT GTGCGCCAC GAGACATTGA ATGGCTTGAT	4320
GGACATGCAT TGCAAGGCCA GACTGTCTTC CCTGCGGCCG GCTATATCGT CATGGCAATG	4380
GAAGCAGCCT TAATGATTGC TGGCACCAC GCAAAGCAGG TCAAGTTACT GGAGATCTTG	4440
GATATGAGCA TTGACAAGGC GGTGATATTT GACGACGAAG ACAGCTTGGT TGAGCTCAAC	4500
CTGACAGCTG ACGTGTCTCG CAACGCCGGC GAAGCAGGTT CAATGACCAT AAGCTTCAAG	4560
ATCGATTCTT GTCTATCGAA GGAGGGTAAC CTATCCCTAT CAGCCAAGGG CCAACTGGCC	4620
CTAACGATAG AAGATGTCAA TCCCAGGACG ACTTCCGCTA GCGACCAGCA CCATCTTCCC	4680
CCGCCAGAAG AGGAACATCC TCATATGAAC CGTGTCAACA TCAATGCTTT CTACCACGAG	4740
CTGGGGTTGA TGGGGTACAA CTACAGTAAG GACTTCCGGC GTCTCCATAA CATGCAACGA	4800

- 51 -

GCAGATCTTC GAGCCAGCGG CACCTTAGAC TTCATTCTTC TGATGGACGA GGGTAATGGC	4860
TGTCCTCTCC TGCTGCATCC TGCATCATTG GACGTCGCCT TCCAGACTGT CATCGGCGCA	4920
TACTCCTCCC CAGGTGATCG GCGTCTACGC TGTCTGTATG TACCCACTCA CGTTGATCGC	4980
ATCACACTTG TCCCATCCCT TTGCCTGGCA ACGGCTGAGT CCGGATGCGA GAAGGTTGCC	5040
TTCAATACTA TCAATACGTA CGACAAGGGA GACTACTTGA GCGGTGACAT TGTGGTGTTC	5100
GACGCGGAGC AGACCACCCT GTTCCAGGTT GAAAATATTA CTTTAAAGCC CTTTTACCC	5160
CCGGATGCTT CAACTGACCA TCGCATGTTT GCGCGATGGA GCTGGGGTCC GTTGACTCCG	5220
GACTCGCTGC TGGATAACCC GGAGTATTGG GCCACCGCGC AGGACAAGGA GGCGATTCTT	5280
ATTATCGAAC GCATCGTCTA CTTCTATATC CGATCGTTCC TCAGTCAGCT TACGCTGGAG	5340
GAGCGCCAGC AGGCAGCCTT CCATTTGCAG AAGCAGATCG AGTGGCTCGA ACAAGTCCTG	5400
GCCAGCGCCA AGGAGGGTCG TCACCTATGG TACGACCCCG GGTGGGAGAA TGATACTGAG	5460
GCCCAGATTG AGCACCTTTG TACTGCTAAC TCCTACCACC CTCATGTTTCG CCTGGTTTCAG	5520
CGAGTCGGCC AACACCTGCT CCCCACCGTA CGATCGAACG GCAACCCATT CGACCTTCTG	5580
GACCACGATG GGCTCCTGAC GGAGTTCTAT ACCAACACAC TCAGCTTCGG ACCCGCACTA	5640
CACTACGCCC GGAATTGGT GCGCGAGATC GCCCATCGCT ATCAGTCAAT GGATATTCTG	5700
GAGATTGGAG CAGGGACCGG CCGCGCTACC AAGTACGTGT TGGCCACGCC CCAGCTGGGG	5760
TTCAACAGCT ACACATACAC CGATATCTCC ACCGGATTCT TCGAGCAAGC GCGGGAGCAA	5820
TTTGCCCCCT TCGAGGACCG GATGGTGTTC GAACCCCTCG ATATCCGCCG CAGTCCCGCC	5880
GAGCAGGGCT TCGAGCCGCA TGCCTATGAT CTGATCATTG CCTCCAATGT GCTACATGCG	5940
ACACCCGACC TAGAGAAAAC CATGGCTCAC GCCCGCTCTC TGCTCAAGCC TGGAGGCCAG	6000
ATGGTTATTG TGGAGATTAC CCACAAAGAA CACACACGGC TCGGGTTTAT CTTTGGTCTG	6060
TTGCGCGACT GGTGGGCTGG GGTGGATGAT GGTGCTGCA CTGAGCCGTT TGTCTCGTTC	6120
GACCGCTGGG ATGCGATCCT AAAGCGTGTG GGGTTTTCCG GTGTGGACAG TCGCACCACG	6180
GATCGGGACG CAAATCTATT CCCGACCTCT GTGTTTAGTA CCCATGCAAT TGACGCCACC	6240
GTGGAGTACT TAGACGCGCC GCTTGCCAGC AGCGGCACCG TCAAGGACTC TTACCCTCCC	6300
TTGGTGGTGG TAGGAGGGCA GACCCCCCAA TCTCAGCGTC TCCTGAACGA TATAAAAGCG	6360
ATCATGCCTC CTCGTCCGCT CCAGACATAC AAGCGCCTCG TGGATTGCT AGACGCGGAG	6420
GAGCTGCCGA TGAAGTCCAC GTTGTTCATG CTCACGGAGC TGGACGAGGA ATTATTGCC	6480

- 52 -

GGGCTCACTG	AAGAGACCTT	CGAGGCAACC	AAGCTGCTGC	TCACGTACGC	CAGCAATACG	6540
GTCTGGCTGA	CAGAAAATGC	CTGGGTCCAA	CATCCTCACC	AGGCGAGCAC	GATCGGCATG	6600
CTACGCTCCA	TCCGCCGGGA	GCATCCTGAC	TTGGGAGTTC	ATGTTCTGGA	CGTCGACGCG	6660
GTTGAAACCT	TCGATGCAAC	CTTCCTGGTT	GAACAGGTGC	TTCGGCTTGA	GGAGCATACG	6720
GATGAGCTGG	CCAGTTCAAC	TACATGGACT	CAAGAACCCG	AGGTCTCCTG	GTGTAAAGGC	6780
CGCCCGTGGA	TTCTCTGTCT	GAAGCGCGAT	CTGGCTCGCA	ATAACCGAAT	GAACTCCTCG	6840
CGCCGTCCCA	TATACGAGAT	GATCGATTCT	TCGCGGGCTC	CCGTGGCATT	ACAGACGGCT	6900
CGGGATTTCAT	CATCCTACTT	CTTGAGGTCC	GCTGAAACCT	GGTTTGTGCC	TGAGAGTGTT	6960
CAGCAGATGG	AAACAAAGAC	GATCTATGTC	CACTTTAGCT	GTCCCATGTC	GCTTAGGGTC	7020
GGACAGCTCG	GGTTTTTCTA	TCTTGTGCAG	GGTCACGTCC	AGGAGGGCAA	TCGCGAAGTG	7080
CCCGTCGTGG	CCTTAGCAGA	GCGTAACGCA	TCCATTGTGC	ACGTTCTGTC	CGATTATATA	7140
TATACTGAGG	CAGATAACAA	TCTGTCTGAG	GGTGGTGGCA	GCCTTATGGT	AACCGTCTCT	7200
GCCGCGGCGG	TGTTGGCGGA	GACGGTGATC	AGTACCGCCA	AGTGCCTGGG	GGTAACTGAC	7260
TCAATCCTCG	TTCTGAATCC	CCCCAGCATA	TGTGGGCAGA	TGTTGCTCCA	TGCTGGTGAA	7320
GAGATCGGTC	TTCAAGTTCA	TCTGGCCACC	ACTTCTGGCA	ACAGGAGTTC	GGTTTCTGCT	7380
GGAGACGCCA	AGTCTTGGCT	AACATTGCAT	GCTCGCGACA	CGGACTGGCA	CCTGCGACGG	7440
GTACTGCCCC	GGGGTGTCCA	GGCTTTAGTC	GACTTATCAG	CCGACCAGAG	CTGTGAAGGT	7500
TTGACTCAGA	GGATGATGAA	AGTTCTGATG	CCTGGCTGTG	CCCATTACCG	TGCGGCAGAC	7560
CTGTTACACAG	ACACCGTTTC	CACTGAATTG	CATAGCGGAT	CGCGGCATCA	AGCTTCACTG	7620
CCCGCCGCAT	ATTGGGAGCA	TGTGGTATCC	TTAGCCCGCC	AGGGACTTCC	TAGTGTGAGC	7680
GAGGGGTGGG	AGGTGATGCC	GTGCACTCAA	TTTGCAGCGC	ATGCCGACAA	GACGCGCCCC	7740
GATCTCTCGA	CAGTTATTTT	CTGGCCCCGG	GAGTCGGACG	AGGCTACGCT	TCCTACCAGG	7800
GTTGCTCCCA	TTGACGCTGA	GACCCTCTTT	GCGGCCGACA	AAACATATCT	CCTGGTCCGA	7860
CTGACTGGAG	ATCTTGACG	ATCACTAGGT	CGTTGGATGG	TCCAGCATGG	GGCCTGCCAC	7920
ATTGTACTTA	CGAGCAGAAA	TCCGCAGGTG	AACCCCAAGT	GGCTGGCGCA	TGTTGAAGAA	7980
CTGGGTGGTC	GAGTCACTGT	TCTTTCCATG	TAAGAGGAGT	CCTTCCTTCT	GCAATTCTCT	8040
CTTATGATCC	CGACTAACGC	AGCTGGCTTC	AGGGACGTGA	CAAGCCAAAA	CTCAGTGGAA	8100
GCTGGCCTGG	CTAAACTCAA	GGATCTGCAT	CTGCCACCAG	TGGGGGTAT	TGCCTTTGGC	8160

- 53 -

CCTCTGGTTC	TGCAGGATGT	GATGCTAAAT	AATATGGAAC	TGCCAATGAT	GGAGATGGTG	8220
CTCAACCCCA	AGGTCTGAAGG	CGTCCGCATC	CTGCACGAGA	AGTTCTCCGA	TCCGACCACT	8280
AGCAACCCTC	TCGACTTCTT	CGTGATGTTT	TCCTCGATTG	TGGCCGTCAT	GGGCAACCCG	8340
GGTCAGGCTA	ACTACAGTGC	GGCTAACTGC	TACCTTCAAG	CGCTGGCGCA	GCAGCGAGTT	8400
GCATCCGGAT	TAGCAGTACG	TTTTCACTCC	ATCCTTTGCT	AAACACTCCT	ATGGGCCTTT	8460
ACTAAACCGG	GCAGGCGTCC	ACCATCGACA	TCGGTGCCGT	GTACGGCGTT	GGGTTCTGCA	8520
CTCGGGCGGA	GCTGGAGGAG	GACTTTAATG	CAATTCCGGT	CATGTTGCGT	TCGGTTGAGG	8580
AACATGAACT	GCATACACTG	TTTGCTGAGG	CAGTGGTGGC	CGGTCGACGA	GCCGTGCACC	8640
AGCAAGAGCA	GCAGCGGAAG	TTCGCGACAG	TGCTCGACAT	GGCTGATCTG	GAACGACAA	8700
CCGGAATTCC	GGCCCTGGAT	CCAGCCCTCA	AAGATCGGAT	CACCTTCTTC	GACGACCCCC	8760
GCATAGGCAA	CTTAAAAATT	CCGGAGTACC	GAGGGGCCAA	AGCAGGCGAA	GGGGCAGCCG	8820
GCTCCAAGGG	CTCGGTCAAA	GAACAGCTCT	TGCAGGCGAC	GAACCTGGAC	CAGGTCCGTC	8880
AGATCGTCAT	CGGTAAGTTG	AGCGAATCCG	GGGAATATTC	TCCCCCTCCT	CACTCAGCGG	8940
ACTGGAGATT	AACCGCTTCT	TTTCCTTTGG	CAGATGGACT	CTCCGCGAAG	CTGCAGGTGA	9000
CCCTGCAGAT	CCCCGATGGG	GAAAGCGTGC	ATCCCACCAT	CCCAC'TAATC	GATCAGGGGG	9060
TGGACTCTCT	GGGCGCGGTC	ACCGTGGGAA	CCTGGTTCTC	CAAGCAGCTG	TACCTTGATT	9120
TGCCACTCCT	GAAAGTGCTT	GGGGGTGCTT	CGATCACC GA	TCTCGCTAAT	GAGGCTGCTG	9180
CGCGATTGCC	ACCTAGCTCC	ATTCCCCTCG	TCGCAGCCAC	CGACGGGGGT	GCAGAGAGCA	9240
CTGACAATAC	TTCCGAGAAT	GAAGTTTCGG	GACGCGAGGA	TACTGACCTT	AGTGCCGCCG	9300
CCACCATCAC	TGAGCCCTCG	TCTGCCGACG	AAGACGATAC	GGAGCCGGGC	GACGAGGACG	9360
TCCCGCGTTC	CCACCATCCA	CTGTCTCTCG	GGCAAGAATA	CTCCTGGAGA	ATCCAGCAGG	9420
GAGCCGAAGA	CCCCACCGTC	TTTAACAACA	CCATTGGTAT	GTTTATGAAG	GGCTCTATTG	9480
ACCTTAAACG	GCTGTACAAG	GCGTTGAGAG	CGGTCTTGCG	CCGCCACGAG	ATCTTCCGCA	9540
CGGGGTTTGC	CAACGTGGAT	GAGAACGGGA	TGGCCCAGCT	GGTGT'TTGGT	CAAACCAAAA	9600
ACAAAGTCCA	GACCATCCAA	GTGTCTGACC	GAGCCGGCGC	CGAAGAGGGC	TACCGACAAC	9660
TGGTGCAGAC	ACGGTATAAC	CCTGCCGCAG	GAGACACCTT	GCGGCTGGTG	GACTTCTTCT	9720
GGGGCCAGGA	CGACCATCTG	CTGGTTGTGG	CTTACCACCG	ACTCGTCGGG	GATGGATCTA	9780
CTACAGAGAA	CATCTTCGTC	GAAGCGGGCC	AGCTCTACGA	CGGCACGTCT	CTAAGTCCAC	9840

- 54 -

ATGTCCCTCA	GTTTGCGGAC	CTGGCGGCAC	GGCAACGCGC	AATGCTCGAG	GATGGGAGAA	9900
TGGAGGAGGA	TCTCGCGTAC	TGGAAGAAAA	TGCATTACCG	ACCGTCCTCA	ATTCCAGTGC	9960
TCCCACTGAT	GCGGCCCCCTG	GTAGGTAACA	GTAGCAGGTC	CGATACTCCA	AATTTCCAGC	10020
ACTGTGGACC	CTGGCAGCAG	CACGAAGCCG	TGGCGCGACT	TGATCCGATG	GTGGCCTTCC	10080
GCATCAAGGA	GCGCAGTCGC	AAGCACAAGG	CGACGCCGAT	GCAGTTCTAT	CTGGCGGCGT	10140
ATCAGGTGCT	GTTGGCGCGC	CTCACCAGCA	GCACCGATCT	CACCGTGGGC	CTCGCCGACA	10200
CCAACCGTGC	GACTGTGCGAC	GAGATGGCGG	CCATGGGGTT	CTTCGCCAAC	CTCCTTCCCC	10260
TGCGCTTCCG	GGATTTCCGC	CCCCATATAA	CGTTTGCGCA	GCACCTTATC	GCCACCCGTG	10320
ACCTGGTGCG	TGAGGCCTTG	CAGCACGCCC	GCGTGCCCTA	CGGCGTCCTC	CTCGATCAAC	10380
TGGGGCTGGA	GGTCCCGGTC	CCGACCAGCA	ATCAACCTGC	GCCTTTGTTC	CAGGCCGTCT	10440
TCGATTACAA	GCAGGGCCAG	GCGGAAAGTG	GAACGATTGG	GGGTGCCAAG	ATAACCGAGG	10500
TGATTGCCAC	GCGCGAGCGC	ACCCCTTACG	ATGTCGTGCT	GGAGATGTCG	GATGATCCCA	10560
CCAAGGATCC	GCTGCTCAGG	GCCAAGTTAC	AGAGTTCCCG	CTACGAGGCT	CACCACCCTC	10620
AAGCCTTCTT	GGAGAGCTAC	ATGTCCCTTC	TCTCTATGTT	CTCGATGAAT	CCCGCCCTGA	10680
AGCTGGCATG	ATGGCGCAA	CATAGAACAT	GATAGCGCAG	CAGGGACGAT	GATAGATAGAG	10740
CTTTGCTTCT	GCGGGTGGAT	CTATAATATA	GTATATATAA	ATATGGTGAG	CCGAACGAAG	10800
AGGGGGGAAT	GCCACAATTA	TTTACTGTTT	TGCGCCGTAC	ACGAGGAGAA	GACGTCCAGA	10860
ACAACATAAA	TATATCACTC	TAGTGAGACA	CCATATATTC	GGAGAGACTA	TAAAAATATA	10920
CATCTACTCC	AATGTCTGGG	CCGTCACACA	CAGCTTACGA	AAACGATTAA	TGACCTCCAA	10980
CACGTCGCGC	GGTCGATTGG	GAAACTGATG	CTGCCCAGCA	AACTCCAATA	CCTGCGCCTC	11040
TCGGGGGGAG	AAATGGCGCG	CCACCAGCAT	CTTCGATCCT	GCGAGCGCAA	AATCATCGCG	11100
ACCCTGCAGA	TGTAATGTCG	GTATCCGAAT	GACCAGTTCC	TCCTGCCACT	CGGTATCTTT	11160
GCTGTGCTTG	TCGTGTCAT	GGTTCCTCAT	CATTGCTTCC	TCATATACTG	GCTTGCCCTG	11220
TCTTGATACC	AGGGACAGAT	CAACAGCGCA	ACACTCATCC	GGGGCAACCA	GGGCAGGTGA	11280
CCCATCTGCT	GCTGCCAGAG	GAGCAAGGTC	GTCACCAGGG	CACCTTCGGA	GAAACCGATA	11340
GCACCCACGA	TAGGGATGTG	GGGGTGTTGA	GTCTGCCAGT	CGACAATGGT	GCGGCGGATG	11400
GGGTGCTGGA	CGGCGGCGAG	GCGTTCGCTC	ACGGAGGGTC	CATTATGATT	GTTGTGCGCTG	11460
CTGCTTTCAA	ACCAGGAGTA	ATATGGCCCT	AGGTCGGCGA	AGACGGGGAG	AATCCCAGGC	11520



- 55 -

CCTGCAGAGG AAGGGAACGG AGCTGTCACG TAGACGAATT C

11561

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3038 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: TPKS Protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Ala	Gln	Ser	Met	Tyr	Pro	Asn	Glu	Pro	Ile	Val	Val	Val	Gly	Ser	1	5	10	15
Gly	Cys	Arg	Phe	Pro	Gly	Asp	Ala	Asn	Thr	Pro	Ser	Lys	Leu	Trp	Glu	20	25	30	
Leu	Leu	Gln	His	Pro	Arg	Asp	Val	Gln	Ser	Arg	Ile	Pro	Lys	Glu	Arg	35	40	45	
Phe	Asp	Val	Asp	Thr	Phe	Tyr	His	Pro	Asp	Gly	Lys	His	His	Gly	Arg	50	55	60	
Thr	Asn	Ala	Pro	Tyr	Ala	Tyr	Val	Leu	Gln	Asp	Asp	Leu	Gly	Ala	Phe	65	70	75	80
Asp	Ala	Ala	Phe	Phe	Asn	Ile	Gln	Ala	Gly	Glu	Ala	Glu	Ser	Met	Asp	85	90	95	
Pro	Gln	His	Arg	Leu	Leu	Leu	Glu	Thr	Val	Tyr	Glu	Ala	Val	Thr	Asn	100	105	110	
Ala	Gly	Met	Arg	Ile	Gln	Asp	Leu	Gln	Gly	Thr	Ser	Thr	Ala	Val	Tyr	115	120	125	
Val	Gly	Val	Met	Thr	His	Asp	Tyr	Glu	Thr	Val	Ser	Thr	Arg	Asp	Leu	130	135	140	
Glu	Ser	Ile	Pro	Thr	Tyr	Ser	Ala	Thr	Gly	Val	Ala	Val	Ser	Val	Ala	145	150	155	160
Ser	Asn	Arg	Ile	Ser	Tyr	Phe	Phe	Asp	Trp	His	Gly	Pro	Ser	Met	Thr	165	170	175	
Ile	Asp	Thr	Ala	Cys	Ser	Ser	Ser	Leu	Val	Ala	Val	His	Leu	Ala	Val	180	185	190	

- 56 -

Gln Gln Leu Arg Thr Gly Gln Ser Ser Met Ala Ile Ala Ala Gly Ala  
 195 200 205  
 Asn Leu Ile Leu Gly Pro Met Thr Phe Val Leu Glu Ser Lys Leu Ser  
 210 215 220  
 Met Leu Ser Pro Ser Gly Arg Ser Arg Met Trp Asp Ala Gly Ala Asp  
 225 230 235 240  
 Gly Tyr Ala Arg Gly Glu Ala Val Cys Ser Val Val Leu Lys Thr Leu  
 245 250 255  
 Ser Gln Ala Leu Arg Asp Gly Asp Thr Ile Glu Cys Val Ile Arg Glu  
 260 265 270  
 Thr Gly Val Asn Gln Asp Gly Arg Thr Thr Gly Ile Thr Met Pro Asn  
 275 280 285  
 His Ser Ala Gln Glu Ala Leu Ile Lys Ala Thr Tyr Ala Gln Ala Gly  
 290 295 300  
 Leu Asp Ile Thr Lys Ala Glu Asp Arg Cys Gln Phe Phe Glu Ala His  
 305 310 315 320  
 Gly Thr Gly Thr Pro Ala Gly Asp Pro Gln Glu Ala Glu Ala Ile Ala  
 325 330 335  
 Thr Ala Phe Phe Gly His Glu Gln Val Ala Arg Ser Asp Gly Asn Glu  
 340 345 350  
 Arg Ala Pro Leu Phe Val Gly Ser Ala Lys Thr Val Val Gly His Thr  
 355 360 365  
 Glu Gly Thr Ala Gly Leu Ala Gly Leu Met Lys Ala Ser Phe Ala Val  
 370 375 380  
 Arg His Gly Val Ile Pro Pro Asn Leu Leu Phe Asp Lys Ile Ser Pro  
 385 390 395 400  
 Arg Val Ala Pro Phe Tyr Lys Asn Leu Arg Ile Pro Thr Glu Ala Thr  
 405 410 415  
 Gln Trp Pro Ala Leu Pro Pro Gly Gln Pro Arg Arg Ala Ser Val Asn  
 420 425 430  
 Ser Phe Gly Phe Gly Gly Thr Asn Ala His Ala Ile Ile Glu Glu Tyr  
 435 440 445  
 Met Glu Pro Glu Gln Asn Gln Leu Arg Val Ser Asn Asn Glu Asp Cys  
 450 455 460  
 Pro Pro Met Thr Gly Val Leu Ser Leu Pro Leu Val Leu Ser Ala Lys  
 465 470 475 480  
 Ser Gln Arg Ser Leu Lys Ile Met Met Glu Glu Met Leu Gln Phe Leu  
 485 490 495

- 57 -

Gln Ser His Pro Glu Ile His Leu His Asp Leu Thr Trp Ser Leu Leu  
 500 505 510  
 Arg Lys Arg Ser Val Leu Pro Phe Arg Arg Ala Ile Val Gly His Ser  
 515 520 525  
 His Glu Thr Ile Arg Arg Ala Leu Glu Asp Ala Ile Glu Asp Gly Ile  
 530 535 540  
 Val Ser Ser Asp Phe Thr Thr Glu Val Arg Gly Gln Pro Ser Val Leu  
 545 550 555 560  
 Gly Ile Phe Thr Gly Gln Gly Ala Gln Trp Pro Gly Met Leu Lys Asn  
 565 570 575  
 Leu Ile Glu Ala Ser Pro Tyr Val Arg Asn Ile Val Arg Glu Leu Asp  
 580 585 590  
 Asp Ser Leu Gln Ser Leu Pro Glu Lys Tyr Arg Pro Ser Trp Thr Leu  
 595 600 605  
 Leu Asp Gln Phe Met Leu Glu Gly Glu Ala Ser Asn Val Gln Tyr Ala  
 610 615 620  
 Thr Phe Ser Gln Pro Leu Cys Cys Ala Val Gln Ile Val Leu Val Arg  
 625 630 635 640  
 Leu Leu Glu Ala Ala Arg Ile Arg Phe Thr Ala Val Val Gly His Ser  
 645 650 655  
 Ser Gly Glu Ile Ala Cys Ala Phe Ala Ala Gly Leu Ile Ser Ala Ser  
 660 665 670  
 Leu Ala Ile Arg Ile Ala Tyr Leu Arg Gly Val Val Ser Ala Gly Gly  
 675 680 685  
 Ala Arg Gly Thr Pro Gly Ala Met Leu Ala Ala Gly Met Ser Phe Glu  
 690 695 700  
 Glu Ala Gln Glu Ile Cys Glu Leu Asp Ala Phe Glu Gly Arg Ile Cys  
 705 710 715 720  
 Val Ala Ala Ser Asn Ser Pro Asp Ser Val Thr Phe Ser Gly Asp Ala  
 725 730 735  
 Asn Ala Ile Asp His Leu Lys Gly Met Leu Glu Asp Glu Ser Thr Phe  
 740 745 750  
 Ala Arg Leu Leu Lys Val Asp Thr Ala Tyr His Ser His His Met Leu  
 755 760 765  
 Pro Cys Ala Asp Pro Tyr Met Gln Ala Leu Glu Glu Cys Gly Cys Ala  
 770 775 780

- 58 -

Val Ala Asp Ala Gly Ser Pro Ala Gly Ser Val Pro Trp Tyr Ser Ser  
 785 790 795 800  
 Val Asp Ala Glu Asn Arg Gln Met Ala Ala Arg Asp Val Thr Ala Lys  
 805 810 815  
 Tyr Trp Lys Asp Asn Leu Val Ser Pro Val Leu Phe Ser His Ala Val  
 820 825 830  
 Gln Arg Ala Val Val Thr His Lys Ala Leu Asp Ile Gly Ile Glu Val  
 835 840 845  
 Gly Cys His Pro Ala Leu Lys Ser Pro Cys Val Ala Thr Ile Lys Asp  
 850 855 860  
 Val Leu Ser Gly Val Asp Leu Ala Tyr Thr Gly Cys Leu Glu Arg Gly  
 865 870 875 880  
 Lys Asn Asp Leu Asp Ser Phe Ser Arg Ala Leu Ala Tyr Leu Trp Glu  
 885 890 895  
 Arg Phe Gly Ala Ser Ser Phe Asp Ala Asp Glu Phe Met Arg Ala Val  
 900 905 910  
 Ala Pro Asp Arg Pro Cys Met Ser Val Ser Lys Leu Leu Pro Ala Tyr  
 915 920 925  
 Pro Trp Asp Arg Ser Arg Arg Tyr Trp Val Glu Ser Arg Ala Thr Arg  
 930 935 940  
 His His Leu Arg Gly Pro Lys Pro His Leu Leu Leu Gly Lys Leu Ser  
 945 950 955 960  
 Glu Tyr Ser Thr Pro Leu Ser Phe Gln Trp Leu Asn Phe Val Arg Pro  
 965 970 975  
 Arg Asp Ile Glu Trp Leu Asp Gly His Ala Leu Gln Gly Gln Thr Val  
 980 985 990  
 Phe Pro Ala Ala Gly Tyr Ile Val Met Ala Met Glu Ala Ala Leu Met  
 995 1000 1005  
 Ile Ala Gly Thr His Ala Lys Gln Val Lys Leu Leu Glu Ile Leu Asp  
 1010 1015 1020  
 Met Ser Ile Asp Lys Ala Val Ile Phe Asp Asp Glu Asp Ser Leu Val  
 1025 1030 1035 1040  
 Glu Leu Asn Leu Thr Ala Asp Val Ser Arg Asn Ala Gly Glu Ala Gly  
 1045 1050 1055  
 Ser Met Thr Ile Ser Phe Lys Ile Asp Ser Cys Leu Ser Lys Glu Gly  
 1060 1065 1070  
 Asn L u Ser L u Ser Ala Lys Gly Gln Leu Ala Leu Thr Ile Glu Asp  
 1075 1080 1085

- 59 -

Val Asn Pro Arg Thr Thr Ser Ala Ser Asp Gln His His Leu Pro Pro  
 1090 1095 1100  
 Pro Glu Glu Glu His Pro His Met Asn Arg Val Asn Ile Asn Ala Phe  
 1105 1110 1115 1120  
 Tyr His Glu Leu Gly Leu Met Gly Tyr Asn Tyr Ser Lys Asp Phe Arg  
 1125 1130 1135  
 Arg Leu His Asn Met Gln Arg Ala Asp Leu Arg Ala Ser Gly Thr Leu  
 1140 1145 1150  
 Asp Phe Ile Pro Leu Met Asp Glu Gly Asn Gly Cys Pro Leu Leu Leu  
 1155 1160 1165  
 His Pro Ala Ser Leu Asp Val Ala Phe Gln Thr Val Ile Gly Ala Tyr  
 1170 1175 1180  
 Ser Ser Pro Gly Asp Arg Arg Leu Arg Cys Leu Tyr Val Pro Thr His  
 1185 1190 1195 1200  
 Val Asp Arg Ile Thr Leu Val Pro Ser Leu Cys Leu Ala Thr Ala Glu  
 1205 1210 1215  
 Ser Gly Cys Glu Lys Val Ala Phe Asn Thr Ile Asn Thr Tyr Asp Lys  
 1220 1225 1230  
 Gly Asp Tyr Leu Ser Gly Asp Ile Val Val Phe Asp Ala Glu Gln Thr  
 1235 1240 1245  
 Thr Leu Phe Gln Val Glu Asn Ile Thr Phe Lys Pro Phe Ser Pro Pro  
 1250 1255 1260  
 Asp Ala Ser Thr Asp His Ala Met Phe Ala Arg Trp Ser Trp Gly Pro  
 1265 1270 1275 1280  
 Leu Thr Pro Asp Ser Leu Leu Asp Asn Pro Glu Tyr Trp Ala Thr Ala  
 1285 1290 1295  
 Gln Asp Lys Glu Ala Ile Pro Ile Ile Glu Arg Ile Val Tyr Phe Tyr  
 1300 1305 1310  
 Ile Arg Ser Phe Leu Ser Gln Leu Thr Leu Glu Glu Arg Gln Gln Ala  
 1315 1320 1325  
 Ala Phe His Leu Gln Lys Gln Ile Glu Trp Leu Glu Gln Val Leu Ala  
 1330 1335 1340  
 Ser Ala Lys Glu Gly Arg His Leu Trp Tyr Asp Pro Gly Trp Glu Asn  
 1345 1350 1355 1360  
 Asp Thr Glu Ala Gln Ile Glu His Leu Cys Thr Ala Asn Ser Tyr His  
 1365 1370 1375

- 60 -

Pro His Val Arg Leu Val Gln Arg Val Gly Gln His Leu Leu Pro Thr  
 1380 1385 1390  
 Val Arg Ser Asn Gly Asn Pro Phe Asp Leu Leu Asp His Asp Gly Leu  
 1395 1400 1405  
 Leu Thr Glu Phe Tyr Thr Asn Thr Leu Ser Phe Gly Pro Ala Leu His  
 1410 1415 1420  
 Tyr Ala Arg Glu Leu Val Ala Gln Ile Ala His Arg Tyr Gln Ser Met  
 1425 1430 1435 1440  
 Asp Ile Leu Glu Ile Gly Ala Gly Thr Gly Gly Ala Thr Lys Tyr Val  
 1445 1450 1455  
 Leu Ala Thr Pro Gln Leu Gly Phe Asn Ser Tyr Thr Tyr Thr Asp Ile  
 1460 1465 1470  
 Ser Thr Gly Phe Phe Glu Gln Ala Arg Glu Gln Phe Ala Pro Phe Glu  
 1475 1480 1485  
 Asp Arg Met Val Phe Glu Pro Leu Asp Ile Arg Arg Ser Pro Ala Glu  
 1490 1495 1500  
 Gln Gly Phe Glu Pro His Ala Tyr Asp Leu Ile Ile Ala Ser Asn Val  
 1505 1510 1515 1520  
 Leu His Ala Thr Pro Asp Leu Glu Lys Thr Met Ala His Ala Arg Ser  
 1525 1530 1535  
 Leu Leu Lys Pro Gly Gly Gln Met Val Ile Leu Glu Ile Thr His Lys  
 1540 1545 1550  
 Glu His Thr Arg Leu Gly Phe Ile Phe Gly Leu Phe Ala Asp Trp Trp  
 1555 1560 1565  
 Ala Gly Val Asp Asp Gly Arg Cys Thr Glu Pro Phe Val Ser Phe Asp  
 1570 1575 1580  
 Arg Trp Asp Ala Ile Leu Lys Arg Val Gly Phe Ser Gly Val Asp Ser  
 1585 1590 1595 1600  
 Arg Thr Thr Asp Arg Asp Ala Asn Leu Phe Pro Thr Ser Val Phe Ser  
 1605 1610 1615  
 Thr His Ala Ile Asp Ala Thr Val Glu Tyr Leu Asp Ala Pro Leu Ala  
 1620 1625 1630  
 Ser Ser Gly Thr Val Lys Asp Ser Tyr Pro Pro Leu Val Val Val Gly  
 1635 1640 1645  
 Gly Gln Thr Pro Gln Ser Gln Arg Leu Leu Asn Asp Ile Lys Ala Ile  
 1650 1655 1660  
 Met Pro Pro Arg Pro Leu Gln Thr Tyr Lys Arg Leu Val Asp Leu Leu  
 1665 1670 1675 1680

- 61 -

Asp Ala Glu Glu Leu Pro Met Lys Ser Thr Phe Val Met Leu Thr Glu  
 1685 1690 1695  
 Leu Asp Glu Glu Leu Phe Ala Gly Leu Thr Glu Glu Thr Phe Glu Ala  
 1700 1705 1710  
 Thr Lys Leu Leu Leu Thr Tyr Ala Ser Asn Thr Val Trp Leu Thr Glu  
 1715 1720 1725  
 Asn Ala Trp Val Gln His Pro His Gln Ala Ser Thr Ile Gly Met Leu  
 1730 1735 1740  
 Arg Ser Ile Arg Arg Glu His Pro Asp Leu Gly Val His Val Leu Asp  
 1745 1750 1755 1760  
 Val Asp Ala Val Glu Thr Phe Asp Ala Thr Phe Leu Val Glu Gln Val  
 1765 1770 1775  
 Leu Arg Leu Glu Glu His Thr Asp Glu Leu Ala Ser Ser Thr Thr Trp  
 1780 1785 1790  
 Thr Gln Glu Pro Glu Val Ser Trp Cys Lys Gly Arg Pro Trp Ile Pro  
 1795 1800 1805  
 Arg Leu Lys Arg Asp Leu Ala Arg Asn Asn Arg Met Asn Ser Ser Arg  
 1810 1815 1820  
 Arg Pro Ile Tyr Glu Met Ile Asp Ser Ser Arg Ala Pro Val Ala Leu  
 1825 1830 1835 1840  
 Gln Thr Ala Arg Asp Ser Ser Ser Tyr Phe Leu Glu Ser Ala Glu Thr  
 1845 1850 1855  
 Trp Phe Val Pro Glu Ser Val Gln Gln Met Glu Thr Lys Thr Ile Tyr  
 1860 1865 1870  
 Val His Phe Ser Cys Pro His Ala Leu Arg Val Gly Gln Leu Gly Phe  
 1875 1880 1885  
 Phe Tyr Leu Val Gln Gly His Val Gln Glu Gly Asn Arg Glu Val Pro  
 1890 1895 1900  
 Val Val Ala Leu Ala Glu Arg Asn Ala Ser Ile Val His Val Arg Pro  
 1905 1910 1915 1920  
 Asp Tyr Ile Tyr Thr Glu Ala Asp Asn Asn Leu Ser Glu Gly Gly Gly  
 1925 1930 1935  
 Ser Leu Met Val Thr Val Leu Ala Ala Ala Val Leu Ala Glu Thr Val  
 1940 1945 1950  
 Ile Ser Thr Ala Lys Cys Leu Gly Val Thr Asp Ser Ile Leu Val Leu  
 1955 1960 1965

- 62 -

Asn Pro Pro Ser Ile Cys Gly Gln Met Leu Leu His Ala Gly Glu Glu  
 1970 1975 1980

Ile Gly Leu Gln Val His Leu Ala Thr Thr Ser Gly Asn Arg Ser Ser  
 1985 1990 1995 2000

Val Ser Ala Gly Asp Ala Lys Ser Trp Leu Thr Leu His Ala Arg Asp  
 2005 2010 2015

Thr Asp Trp His Leu Arg Arg Val Leu Pro Arg Gly Val Gln Ala Leu  
 2020 2025 2030

Val Asp Leu Ser Ala Asp Gln Ser Cys Glu Gly Leu Thr Gln Arg Met  
 2035 2040 2045

Met Lys Val Leu Met Pro Gly Cys Ala His Tyr Arg Ala Ala Asp Leu  
 2050 2055 2060

Phe Thr Asp Thr Val Ser Thr Glu Leu His Ser Gly Ser Arg His Gln  
 2065 2070 2075 2080

Ala Ser Leu Pro Ala Ala Tyr Trp Glu His Val Val Ser Leu Ala Arg  
 2085 2090 2095

Gln Gly Leu Pro Ser Val Ser Glu Gly Trp Glu Val Met Pro Cys Thr  
 2100 2105 2110

Gln Phe Ala Ala His Ala Asp Lys Thr Arg Pro Asp Leu Ser Thr Val  
 2115 2120 2125

Ile Ser Trp Pro Arg Glu Ser Asp Glu Ala Thr Leu Pro Thr Arg Val  
 2130 2135 2140

Arg Ser Ile Asp Ala Glu Thr Leu Phe Ala Ala Asp Lys Thr Tyr Leu  
 2145 2150 2155 2160

Leu Val Gly Leu Thr Gly Asp Leu Gly Arg Ser Leu Gly Arg Trp Met  
 2165 2170 2175

Val Gln His Gly Ala Cys His Ile Val Leu Thr Ser Arg Asn Pro Gln  
 2180 2185 2190

Val Asn Pro Lys Trp Leu Ala His Val Glu Glu Leu Gly Gly Arg Val  
 2195 2200 2205

Thr Val Leu Ser Met Asp Val Thr Ser Gln Asn Ser Val Glu Ala Gly  
 2210 2215 2220

Leu Ala Lys Leu Lys Asp Leu His Leu Pro Pro Val Gly Gly Ile Ala  
 2225 2230 2235 2240

Phe Gly Pro Leu Val Leu Gln Asp Val Met Leu Asn Asn Met Glu Leu  
 2245 2250 2255

Pro Met Met Glu M t Val Leu Asn Pro Lys Val Glu Gly Val Arg Ile  
 2260 2265 2270



- 63 -

Leu His Glu Lys Phe Ser Asp Pro Thr Ser Ser Asn Pro Leu Asp Phe  
 2275 2280 2285  
 Phe Val Met Phe Ser Ser Ile Val Ala Val Met Gly Asn Pro Gly Gln  
 2290 2295 2300  
 Ala Asn Tyr Ser Ala Ala Asn Cys Tyr Leu Gln Ala Leu Ala Gln Gln  
 2305 2310 2315 2320  
 Arg Val Ala Ser Gly Leu Ala Ala Ser Thr Ile Asp Ile Gly Ala Val  
 2325 2330 2335  
 Tyr Gly Val Gly Phe Val Thr Arg Ala Glu Leu Glu Glu Asp Phe Asn  
 2340 2345 2350  
 Ala Ile Arg Phe Met Phe Asp Ser Val Glu Glu His Glu Leu His Thr  
 2355 2360 2365  
 Leu Phe Ala Glu Ala Val Val Ala Gly Arg Arg Ala Val His Gln Gln  
 2370 2375 2380  
 Glu Gln Gln Arg Lys Phe Ala Thr Val Leu Asp Met Ala Asp Leu Glu  
 2385 2390 2395 2400  
 Leu Thr Thr Gly Ile Pro Pro Leu Asp Pro Ala Leu Lys Asp Arg Ile  
 2405 2410 2415  
 Thr Phe Phe Asp Asp Pro Arg Ile Gly Asn Leu Lys Ile Pro Glu Tyr  
 2420 2425 2430  
 Arg Gly Ala Lys Ala Gly Glu Gly Ala Ala Gly Ser Lys Gly Ser Val  
 2435 2440 2445  
 Lys Glu Gln Leu Leu Gln Ala Thr Asn Leu Asp Gln Val Arg Gln Ile  
 2450 2455 2460  
 Val Ile Asp Gly Leu Ser Ala Lys Leu Gln Val Thr Leu Gln Ile Pro  
 2465 2470 2475 2480  
 Asp Gly Glu Ser Val His Pro Thr Ile Pro Leu Ile Asp Gln Gly Val  
 2485 2490 2495  
 Asp Ser Leu Gly Ala Val Thr Val Gly Thr Trp Phe Ser Lys Gln Leu  
 2500 2505 2510  
 Tyr Leu Asp Leu Pro Leu Leu Lys Val Leu Gly Gly Ala Ser Ile Thr  
 2515 2520 2525  
 Asp Leu Ala Asn Glu Ala Ala Ala Arg Leu Pro Pro Ser Ser Ile Pro  
 2530 2535 2540  
 Leu Val Ala Ala Thr Asp Gly Gly Ala Glu Ser Thr Asp Asn Thr Ser  
 2545 2550 2555 2560

- 64 -

Glu Asn Glu Val Ser Gly Arg Glu Asp Thr Asp Leu Ser Ala Ala Ala  
 2565 2570 2575  
 Thr Ile Thr Glu Pro Ser Ser Ala Asp Glu Asp Asp Thr Glu Pro Gly  
 2580 2585 2590  
 Asp Glu Asp Val Pro Arg Ser His His Pro Leu Ser Leu Gly Gln Glu  
 2595 2600 2605  
 Tyr Ser Trp Arg Ile Gln Gln Gly Ala Glu Asp Pro Thr Val Phe Asn  
 2610 2615 2620  
 Asn Thr Ile Gly Met Phe Met Lys Gly Ser Ile Asp Leu Lys Arg Leu  
 2625 2630 2635 2640  
 Tyr Lys Ala Leu Arg Ala Val Leu Arg Arg His Glu Ile Phe Arg Thr  
 2645 2650 2655  
 Gly Phe Ala Asn Val Asp Glu Asn Gly Met Ala Gln Leu Val Phe Gly  
 2660 2665 2670  
 Gln Thr Lys Asn Lys Val Gln Thr Ile Gln Val Ser Asp Arg Ala Gly  
 2675 2680 2685  
 Ala Glu Glu Gly Tyr Arg Gln Leu Val Gln Thr Arg Tyr Asn Pro Ala  
 2690 2695 2700  
 Ala Gly Asp Thr Leu Arg Leu Val Asp Phe Phe Trp Gly Gln Asp Asp  
 2705 2710 2715 2720  
 His Leu Leu Val Val Ala Tyr His Arg Leu Val Gly Asp Gly Ser Thr  
 2725 2730 2735  
 Thr Glu Asn Ile Phe Val Glu Ala Gly Gln Leu Tyr Asp Gly Thr Ser  
 2740 2745 2750  
 Leu Ser Pro His Val Pro Gln Phe Ala Asp Leu Ala Ala Arg Gln Arg  
 2755 2760 2765  
 Ala Met Leu Glu Asp Gly Arg Met Glu Glu Asp Leu Ala Tyr Trp Lys  
 2770 2775 2780  
 Lys Met His Tyr Arg Pro Ser Ser Ile Pro Val Leu Pro Leu Met Arg  
 2785 2790 2795 2800  
 Pro Leu Val Gly Asn Ser Ser Arg Ser Asp Thr Pro Asn Phe Gln His  
 2805 2810 2815  
 Cys Gly Pro Trp Gln Gln His Glu Ala Val Ala Arg Leu Asp Pro Met  
 2820 2825 2830  
 Val Ala Phe Arg Ile Lys Glu Arg Ser Arg Lys His Lys Ala Thr Pro  
 2835 2840 2845  
 Met Gln Phe Tyr L u Ala Ala Tyr Gln Val Leu Leu Ala Arg Leu Thr  
 2850 2855 2860

- 65 -

Asp Ser Thr Asp Leu Thr Val Gly Leu Ala Asp Thr Asn Arg Ala Thr  
 2865 2870 2875 2880  
 Val Asp Glu Met Ala Ala Met Gly Phe Phe Ala Asn Leu Leu Pro Leu  
 2885 2890 2895  
 Arg Phe Arg Asp Phe Arg Pro His Ile Thr Phe Gly Glu His Leu Ile  
 2900 2905 2910  
 Ala Thr Arg Asp Leu Val Arg Glu Ala Leu Gln His Ala Arg Val Pro  
 2915 2920 2925  
 Tyr Gly Val Leu Leu Asp Gln Leu Gly Leu Glu Val Pro Val Pro Thr  
 2930 2935 2940  
 Ser Asn Gln Pro Ala Pro Leu Phe Gln Ala Val Phe Asp Tyr Lys Gln  
 2945 2950 2955 2960  
 Gly Gln Ala Glu Ser Gly Thr Ile Gly Gly Ala Lys Ile Thr Glu Val  
 2965 2970 2975  
 Ile Ala Thr Arg Glu Arg Thr Pro Tyr Asp Val Val Leu Glu Met Ser  
 2980 2985 2990  
 Asp Asp Pro Thr Lys Asp Pro Leu Leu Thr Ala Lys Leu Gln Ser Ser  
 2995 3000 3005  
 Arg Tyr Glu Ala His His Pro Gln Ala Phe Leu Glu Ser Tyr Met Ser  
 3010 3015 3020  
 Leu Leu Ser Met Phe Ser Met Asn Pro Ala Leu Lys Leu Ala  
 3025 3030 3035

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: probe

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GATACGGCAT GCAGCTCGTC GTTGTTGCC GTTCATCTGG CTGCA

45

- 66 -

WHAT IS CLAIMED IS:

1. Purified DNA molecule encoding triol polyketide synthase.

2. The purified DNA molecule of Claim 1 wherein the DNA encodes triol polyketide synthase from a microorganism, the microorganism being selected from the group consisting of Aspergillus terreus, Monascus ruber, Penicillium citrinum, Penicillium brevicompactum, Hypomyces chrysospermus, Paecilomyces sp M2016, Eupenicillium sp. MM603, Trichoderma longibrachiatum M6735 and Trichoderma pseudokoningii M6828.

3. The purified DNA molecule of Claim 1 wherein the DNA encodes triol polyketide synthase from Aspergillus terreus.

4. The purified DNA molecule of Claim 1 having the sequence

20	CTGCAGTCAA CGGATCACTT ACCATTGCTG TCGCCAAAAA TATCCGTGAT	50
	AATCCCGCTG GCTTCATTGG CAAGAGGCTT GACGTACTTG GGAGCTTGGG	100
	TCTGGAAGTG GTTCATAACC ACCTTGGTGA TGAGATGTGC ATCCCTCGTG	150
	ACTTCCTTGA ATCCATCGAA TCCGGGAAGA TGAGAGTGAA AGTCCTGATG	200
25	AGAGCACGAA GATCAGTAAG TCAGGTCCTC ACAGCGGAAG CAGTTGCAAA	250
	GAACGGTGGA CTCCTTACCG TGCCCAAGAA CTTGTACATA CAGAGCTCTT	300
	TCATCTTGCG AAACATCATCG GCCATAGAGG AGGAAGAAT GGTGCAGTAC	350
	CCAGAGTCGA CTATGAACCG AATGGGCTTA TCATTTTGCG AGAACCAGCT	400
	CTCAATCCAT GACGGTGCAT TCGCATCAA ATCCCGTTTG GCCCTCATGG	450
30	TCGTCAAGTTC CCACCATGTT TTCGGATTGA ACACCGGCAG ATCAGATCTC	500
	CGGCCACTCG AGCACAGGTA AAGAAGAAGG CATAGTAGCC CCGCACTGGT	550
	AGTGACCAAG GGCAGCAACC ACGAGCCATG TTGCTGCGTG TCATTCCAAG	600
	CCAGCGACAG AAGGTGGTGC GGCTGTGTGA GCGCGTCGAC AGTCATGGCT	650
	AGGAGACCAG GTGTGGTTGA GGGATAAGAT ATCGAGAGTG ATGTGAGCAA	700
	AAGATCCGGG AAAGGTCGCG AAGGAAAGGG CGTCTCTCTT ACCAAGAAAG	750

- 67 -

	TCTGTTCCCT	ATCATGCAAT	CACCGCTTGC	TGTACGGTGG	TGATGATGCT	800
	GGGATGGTGG	TGGGTCCCCA	CCGAATAACG	CCGGACAGCT	GTTGAAGCCG	850
	AATGACGCCG	GCAGGCCAAA	AGAACCCTAC	CTTCACTTAC	TCAATCGGCG	900
	CTTCCCCTCC	TATCACCAAA	TCGGATGTAA	ATGGACGGGC	CTTAATAGCG	950
5	ACCGGCCGGG	CCGGGAATCC	CCAAACGTAG	ATAGATAGGC	ATAGACCCGA	1000
	AATCTTTGGC	CCGGCATACT	TGAGCACAGG	AAGTTTCACG	CGACGGCGCC	1050
	TTTCCTGCCT	CAGCTTCAAT	CCAAGCTCAC	GAGTTCTGTC	GCCTCTATCA	1100
	GTCGTGCAAT	TGTCCTACTG	CAAACAGCAT	GGCTCAATCT	ATGTATCCTA	1150
10	ATGAGCCTAT	TGTCGTGGTC	GGCAGTGGTT	GTCGCTTCCC	TGGTGACGCC	1200
	AACACACCCT	CCAAGCTCTG	GGAGCTACTC	CAGCATCCTC	GCGATGTGCA	1250
	GAGTCGAATC	CCCAAAGAAC	GATTTGACGT	CGACACATTT	TATCACCCGG	1300
	ACGGGAAGCA	CCACGGGCGA	ACAAATGCAC	CCTACGCCTA	TGTTCTCCAA	1350
	GACGATCTGG	GCGCCTTCGA	TGCGGCCTTC	TTCAATATCC	AGGCTGGAGA	1400
15	GGCCGAGAGT	ATGGACCCCC	AGCACCGGCT	GTTGCTGGAG	ACGGTGTACG	1450
	AGGCCGTAAC	GAATGCTGGA	ATGCGTATCC	AGGATCTGCA	GGAACCTTCG	1500
	ACTGCTGTTT	ACGTCGGGGT	GATGACGCAC	GACTATGAGA	CTGTCTCAAC	1550
	CCGCGACCTG	GAGAGCATCC	CCACCTACTC	GGCGACGGGT	GTCGCGGTCA	1600
	GTGTTGCGTC	CAACCGCATC	TCGTATTTTT	TTGACTGGCA	TGGACCAAGT	1650
20	GTAAGTCACC	CAATATCGTG	TAGCAGTCTA	ATCATGCTCT	AACGGACCCG	1700
	GATGGTTGAA	AGATGACGAT	CGATACGGCA	TGCAGCTCGT	CGTTGGTTGC	1750
	CGTTCATCTG	GCGGTGCAAC	AGCTACGGAC	GGGTCAAAGC	TCCATGGCAA	1800
	TTGCTGCGGG	TGCGAATCTG	ATTCTGGGGC	CCATGACATT	CGTCCTTGAA	1850
	AGCAAATTGA	GCATGCTATC	CCCCTCGGGT	CGATCCCGCA	TGTGGGACGC	1900
25	CGGAGCTGAC	GGCTATGCCA	GAGGCGTGAG	TGTTTCTTGA	GCTCGTAGAT	1950
	GACAGTTCCC	ATCGCTGACC	GTGATCAGGA	AGCTGTTTGC	TCTGTAGTGT	2000
	TGAAGACATT	GAGTCAAGCC	TTGCGCGATG	GGGACACGAT	TGAATGTGTC	2050
	ATCCGAGAAA	CTGGGGTGAA	TCAAGATGGC	CGAACGACCG	GAATTACGAT	2100
	GCCGAACCAT	AGTGCTCAGG	AGGCACTCAT	CAAGGCTACC	TACGCCCAGG	2150
30	CTGGCCCTGA	CATCACCAAG	GCCGAGGACA	GGTGCCAATT	CTTCGAGGCT	2200
	CATGGTCAGC	AAAGAGAACC	TGTTCTGTTG	GCGCCCTGCA	GCTGACATTC	2250
	GTATGATAGG	GACTGGTACT	CCGGCCGGAG	ATCCCCAGGA	GGCGGAGGCC	2300
	ATTGCAACAG	CTTCTTTCGG	CCACGAGCAG	GTAGCACGCA	GCGACGGAAA	2350
	CGAGAGGGCC	CCTCTGTTTCG	TGGGCAGTGC	GAAAACTGTT	GTCGGGCACA	2400
	CCGAGGGCAC	GGCCGGTCTG	GCTGGTCTCA	TGAAGGCGTC	GTTGCTGTCT	2450
	CGCCATGGGG	TAATCCCCCC	CAACCTGCTG	TTGACAAAAA	TCAGCCCGCG	2500

- 68 -

	AGTCGCCCCA	TTCTATAAAA	ACCTGAGGAT	TCCGACAGAA	GCTACCCAAT	2550
	GGCCAGCTCT	CCCACCCGGA	CAACCGCGCC	GCGCCAGTGT	CAACTCCTTT	2600
	GGTAAGCGAG	GATTGCCCCG	AGGAACCCCTC	ACAAGTACTC	GAATTAATGC	2650
	TAAGTGAACC	GCGCCGATGG	ACAGGATTTCG	GCGGCACGAA	TGCGCATGCC	2700
5	ATTATTGAGG	AATACATGGA	GCCAGAGCAA	AACCAGCTGC	GAGTCTCGAA	2750
	TAATGAGGAC	TGCCCACCCA	TGACCGGTGT	CCTGAGTTTA	CCCTTAGTCC	2800
	TCTCGGCGAA	GTCCCAGCGC	TCCTTAAAGA	TAATGATGGA	GGAGATGCTG	2850
	CAATTCCTTC	AGTCTCACCC	CGAGATACAC	TTGCACGACC	TCACCTGGTC	2900
	CTTACTGCGC	AAGCGGTCAG	TTCTACCCCTT	CCGCCGGGCT	ATTGTGCGGC	2950
10	ATAGTCATGA	AACCATCCGC	CGGGCTTTGG	AGGATGCCAT	CGAGGATGGT	3000
	ATTGTGTCGA	GCGACTTCAC	TACGGAGGTC	AGAGGCCAGC	CATCGGTGTT	3050
	GGGAATCTTC	ACCGGGCAGG	GGGCGCAGTG	GGCGGGGATG	TTAAAGAATC	3100
	TGATAGAGGC	ATCGCCATAT	GTGCGGAACA	TAGTGAGGGA	GCTGGACGAC	3150
	TCCCTGCAGA	GCTTGCCGGA	AAAATACCGG	CCCTCGTGGA	CGCTACTGGA	3200
15	CCAGTTCATG	CTAGAAGGAG	AGGCCTCCAA	CGTCCAATAT	GCTACTTTCT	3250
	CCCAGCCATT	ATGCTGCGCG	GTGCAAATTG	TCCTGGTCCG	TCTCCTTGAA	3300
	GCCGCGAGAA	TACGATTAC	GGCTGTTGTT	GGACATAGCT	CCGGCGAAAT	3350
	TGCTTGCGCC	TTTGCTGCCG	GGCTCATCAG	TGCCTCGTTG	GCGATTCCGA	3400
	TTGCTTACTT	ACGTGGAGTC	GTCTCGGCAG	GGGGCGCCAG	AGGCACACCG	3450
20	GGAGCCATGT	TGGCCGCGCG	GATGTCCTTT	GAGGAAGCAC	AAGAGATCTG	3500
	CGAGTTGGAT	GCCTTTGAGG	GCCGCATCTG	CGTGGCTGCC	AGCAATTCCC	3550
	CAGACAGTGT	AACTTTCTCT	GGCGACGCGA	ACGCAATTGA	TCACCTGAAG	3600
	GGCATGTTGG	AGGATGAGTC	CACTTTTCGG	AGACTGCTCA	AGGTCGATAC	3650
	AGCGTACCAC	TCGCATCATA	TGCTTCCATG	TGCAGACCCA	TATATGCAAG	3700
25	CCCTAGAAGA	GTGTGGTTGT	GCTGTTGCCG	ATGCAGGTTC	CCCAGCCGGA	3750
	AGTGTACCCT	GGTATTCGTC	CGTGGACGCC	GAGAACAGGC	AAATGGCAGC	3800
	AAGAGACGTG	ACCGCCAAGT	ACTGGAAAAGA	TAACCTAGTA	TCTCCGGTGC	3850
	TATTCCTCCCA	CGCAGTGCAG	CGGGCAGTCG	TCACGCACAA	GGCGCTGGAT	3900
	ATCGGGATTG	AAGTGGGCTG	TCACCCAGCT	CTCAAGAGCC	CATGCGTCGC	3950
30	CACCATCAAG	GATGTCCTAT	CTGGGGTTGA	CCTGGCGTAT	ACAGGTTGCT	4000
	TGGAGCGAGG	AAAGAATGAT	CTCGATTTCAT	TCTCTCGAGC	ACTGGCATAT	4050
	CTCTGGGAAA	GGTTTGTTGC	CTCCAGTTTC	GATGCGGACG	AGTTCATGCG	4100
	TGCAGTCGCG	CCTGATCGGC	CCTGTATGAG	TGTGTGGAAG	CTCCTACCGG	4150
	CCTATCCATG	GGACCGCTCT	CGTCGCTACT	GGGTGGAATC	CCGAGCAACT	4200
	CGCCACCATC	TTCGAGGGCC	CAAGCCCCAT	CTTCTATTAG	GAAAGCTCTC	4250

- 69 -

	CGAATACAGC	ACTCCGCTAA	GCTTCCAGTG	GCTGAATTTT	GTGCGCCAC	4300
	GAGACATTGA	ATGGCTTGAT	GGACATGCAT	TGCAAGGCCA	GAAGTCTTTC	4350
	CCTGCGGCCG	GCTATATCGT	CATGGCAATG	GAAGCAGCCT	TAATGATTGC	4400
	TGGCACCCAC	GCAAAGCAGG	TCAAGTTACT	GGAGATCTTG	GATATGAGCA	4450
5	TTGACAAGGC	GGTGATATTT	GACGACGAAG	ACAGCTTGGT	TGAGCTCAAC	4500
	CTGACAGCTG	ACGTGTCTCG	CAACGCCGGC	GAAGCAGGTT	CAATGACCAT	4550
	AAGCTTCAAG	ATCGATTCCCT	GTCTATCGAA	GGAGGGTAAC	CTATCCCTAT	4600
	CAGCCAAGGG	CCAAC TGGCC	CTAACGATAG	AAGATGTCAA	TCCCAGGACG	4650
	ACTTCCGCTA	GCGACCAGCA	CCATCTTCCC	CCGCCAGAAG	AGGAACATCC	4700
10	TCATATGAAC	CGTGTCACA	TCAATGCTTT	CTACCACGAG	CTGGGGTTGA	4750
	TGGGGTACAA	CTACAGTAAG	GACTTCCGGC	GTCTCCATAA	CATGCAACGA	4800
	GCAGATCTTC	GAGCCAGCGG	CACCTTAGAC	TTCATTCTTC	TGATGGACGA	4850
	GGGTAATGGC	TGTCCTCTCC	TGCTGCATCC	TGCATCATTG	GACGTCGCCT	4900
	TCCAGACTGT	CATCGGCGCA	TACTCCTCCC	CAGGTGATCG	GCGTCTACGC	4950
15	TGTCTGTATG	TACCCACTCA	CGTTGATCGC	ATCACACTTG	TCCCATCCCT	5000
	TTGCCTGGCA	ACGGCTGAGT	CCGGATGCGA	GAAGGTGCCC	TTCAATACTA	5050
	TCAATACGTA	CGACAAGGGA	GACTACTTGA	GCGGTGACAT	TGTGGTGTTT	5100
	GACGCGGAGC	AGACCACCCT	GTTCCAGGTT	GAAAATATTA	CTTTTAAGCC	5150
	CTTTTCACCC	CCGGATGCTT	CAACTGACCA	TGCGATGTTT	GCCCCGATGGA	5200
20	GCTGGGGTCC	GTTGACTCCG	GACTCGCTGC	TGGATAACCC	GGAGTATTGG	5250
	GCCACCGCGC	AGGACAAGGA	GGCGATTCCCT	ATTATCGAAC	GCATCGTCTA	5300
	CTTCTATATC	CGATCGTTCC	TCAGTCAGCT	TACGCTGGAG	GAGCGCCAGC	5350
	AGGCAGCCTT	CCATTTGCAG	AAGCAGATCG	AGTGGCTCGA	ACAAGTCCCTG	5400
	GCCAGCGCCA	AGGAGGGTCG	TCACCTATGG	TACGACCCCG	GGTGGGAGAA	5450
25	TGATACTGAG	GCCCAGATTG	AGCACCTTTG	TACTGCTAAC	TCCTACCACC	5500
	CTCATGTTCC	CCTGGTTTCAG	CGAGTCGGCC	AACACCTGCT	CCCCACCGTA	5550
	CGATCGAACG	GCAACCCATT	CGACCTTCTG	GACCACGATG	GGCTCCTGAC	5600
	GGAGTTCTAT	ACCAACACAC	TCAGCTTCGG	ACCCGCACTA	CACTACGCCC	5650
	GGGAATTGGT	GGCGCAGATC	GCCCATCGCT	ATCAGTCAAT	GGATATTCTG	5700
30	GAGATTGGAG	CAGGGACCGG	CGGCGCTACC	AAGTACGTGT	TGGCCACGCC	5750
	CCAGCTGGGG	TTCAACAGCT	ACACATACAC	CGATATCTCC	ACCGGATTCT	5800
	TCGAGCAAGC	GCGGGAGCAA	TTTGCCCCCT	TCGAGGACCG	GATGGTGTTT	5850
	GAACCCCTCG	ATATCCGCCG	CAGTCCCGCC	GAGCAGGGCT	TCGAGCCGCA	5900
	TGCCTATGAT	CTGATCATTG	CCTCCAATGT	GCTACATGCG	ACACCCGACC	5950
	TAGAGAAAAC	CATGGCTCAC	GCCCGCTCTC	TGCTCAAGCC	TGGAGGCCAG	6000

- 70 -

	ATGGTTATTC	TGGAGATTAC	CCACAAAGAA	CACACACGGC	TCGGGTTTAT	6050
	CTTTGGTCTG	TTCGCCGACT	GGTGGGCTGG	GGTGGATGAT	GGTCGCTGCA	6100
	CTGAGCCGTT	TGTCCTCGTC	GACCGCTGGG	ATGCGATCCT	AAAGCGTGTC	6150
	GGGTTTTCCG	GTGTGGACAG	TCGCACCACG	GATCGGGACG	CAAATCTATT	6200
5	CCCGACCTCT	GTGTTTAGTA	CCCATGCAAT	TGACGCCACC	GTGGAGTACT	6250
	TAGACGCGCC	GCTTGCCAGC	AGCGGCACCG	TCAAGGACTC	TTACCCTCCC	6300
	TTGGTGGTGG	TAGGAGGGCA	GACCCCCCAA	TCTCAGCGTC	TCCTGAACGA	6350
	TATAAAAGCG	ATCATGCCTC	CTCGTCCGCT	CCAGACATAC	AAGCGCCTCG	6400
	TGGATTTGCT	AGACGCGGAG	GAGCTGCCGA	TGAAGTCCAC	GTTTGTTCATG	6450
10	CTCACGGAGC	TGGACGAGGA	ATTATTGCGC	GGGCTCACTG	AAGAGACCTT	6500
	CGAGGCAACC	AAGCTGCTGC	TCACGTACGC	CAGCAATACG	GTCTGGCTGA	6550
	CAGAAAATGC	CTGGGTCCAA	CATCCTCACC	AGGCGAGCAC	GATCGGCATG	6600
	CTACGCTCCA	TCCGCCGGGA	GCATCCTGAC	TTGGGAGTTC	ATGTTCTGGA	6650
	CGTCGACGCG	GTTGAAACCT	TCGATGCAAC	CTTCCTGGTT	GAACAGGTGC	6700
15	TTCGGCTTGA	GGAGCATACG	GATGAGCTGG	CCAGTTCAAC	TACATGGACT	6750
	CAAGAACCCG	AGGTCTCCTG	GTGTAAAGGC	CGCCCGTGGA	TTCTCTCGTCT	6800
	GAAGCGCGAT	CTGGCTCGCA	ATAACCGAAT	GAACCTCTCG	CGCCGTCCCA	6850
	TATACGAGAT	GATCGATTGG	TCGCGGGCTC	CCGTGGCATT	ACAGACGGCT	6900
	CGGGATTTCAT	CATCCTACTT	CTTGGAGTCC	GCTGAAACCT	GGTTTGTGCC	6950
20	TGAGAGTGTT	CAGCAGATGG	AAACAAAGAC	GATCTATGTC	CACTTTAGCT	7000
	GTCCCCATGC	GCTTAGGGTC	GGACAGCTCG	GGTTTTTCTA	TCTTGTGCAG	7050
	GGTCACGTCC	AGGAGGGCAA	TCGCGAAGTG	CCCGTCGTGG	CCTTAGCAGA	7100
	GCGTAACGCA	TCCATTGTGC	ACGTTTCGTCC	CGATTATATA	TATACTGAGG	7150
	CAGATAACAA	TCTGTCTGAG	GGTGGTGGCA	GCCTTATGGT	AACCGTCCTC	7200
25	GCCGCGGCGG	TGTTGGCGGA	GACGGTGATC	AGTACCGCCA	AGTGCCCTGGG	7250
	GGTAACTGAC	TCAATCCTCG	TTCTGAATCC	CCCCAGCATA	TGTGGGCAGA	7300
	TGTTGCTCCA	TGCTGGTGAA	GAGATCGGTC	TTCAAGTTCA	TCTGGCCACC	7350
	ACTTCTGGCA	ACAGGAGTTC	GGTTTCTGCT	GGAGACGCCA	AGTCCTGGCT	7400
	AACATTGCAT	GCTCGCGACA	CGGACTGGCA	CCTGCGACGG	GTA CTGCCCC	7450
30	GGGGTGTTCA	GGCTTTAGTC	GACTTATCAG	CCGACCAGAG	CTGTGAAGGT	7500
	TTGACTCAGA	GGATGATGAA	AGTTCTGATG	CCTGGCTGTG	CCCATTACCG	7550
	TGCGGCAGAC	CTGTTACACG	ACACCGTTTC	CACTGAATTG	CATAGCGGAT	7600
	CGCGGCATCA	AGCTTCACTG	CCCGCCGCAT	ATTGGGAGCA	TGTGGTATCC	7650
	TTAGCCCGCC	AGGGACTTCC	TAGTGTCAGC	GAGGGGTGGG	AGGTGATGCC	7700
	GTGCACTCAA	TTTGCAGCGC	ATGCCGACAA	GACGCGCCCG	GATCTCTCGA	7750



- 71 -

	CAGTTATTTTC	CTGGCCCCGG	GAGTCGGACG	AGGCTACGCT	TCCTACCAGG	7800
	GTTTCGCTCCA	TTGACGCTGA	GACCCCTCTTT	GCGGCCGACA	AAACATATCT	7850
	CCTGGTCGGA	CTGACTGGAG	ATCTTGGACG	ATCACTAGGT	CGTTGGATGG	7900
5	TCCAGCATGG	GGCCTGCCAC	ATTGTACTTA	CGAGCAGAAA	TCCGCAGGTG	7950
	AACCCCAAGT	GGCTGGCGCA	TGTTGAAGAA	CTGGGTGGTC	GAGTCACTGT	8000
	TCTTTCCATG	TAAGAGGAGT	CCTTCCTTCT	GCAATTCCCTC	CTTATGATCC	8050
	CGACTAACGC	AGCTGGCTTC	AGGGACGTGA	CAAGCCAAAA	CTCAGTGGAA	8100
	GCTGGCCTGG	CTAAACTCAA	GGATCTGCAT	CTGCCACCAG	TGGGGGGTAT	8150
10	TGCCTTTGGC	CCTCTGGTTC	TGCAGGATGT	GATGCTAAAT	AATATGGAAC	8200
	TGCCAATGAT	GGAGATGGTG	CTCAACCCCA	AGGTCGAAGG	CGTCCGCATC	8250
	CTGCACGAGA	AGTTCTCCGA	TCCGACCAGT	AGCAACCCTC	TCGACTTCTT	8300
	CGTGATGTTT	TCCTCGATTG	TGGCCGTCAT	GGGCAACCCG	GGTCAGGCTA	8350
	ACTACAGTGC	GGCTAACTGC	TACCTTCAAG	CGCTGGCGCA	GCAGCGAGTT	8400
15	GCATCCGGAT	TAGCAGTACG	TTTTCACTCC	ATCCTTTGCT	AAACACTCCT	8450
	ATGGGCCTTT	ACTAAACCGG	GCAGGCGTCC	ACCATCGACA	TCGGTGCCGT	8500
	GTACGGCGTT	GGGTTCTCA	CTCGGGCGGA	GCTGGAGGAG	GACTTTAATG	8550
	CAATTCCGTT	CATGTTTCGAT	TCGGTTGAGG	AACATGAACT	GCATACACTG	8600
	TTTGCTGAGG	CAGTGGTGGC	CGGTCGACGA	GCCGTGCACC	AGCAAGAGCA	8650
20	GCAGCGGAAG	TTTCGCGACAG	TGCTCGACAT	GGCTGATCTG	GAAGTGACAA	8700
	CCGGAATTCC	GCCCCGAT	CCAGCCCTCA	AAGATCGGAT	CACCTTCTTC	8750
	GACGACCCCC	GCATAGGCAA	CTTAAAAATT	CCGGAGTACC	GAGGGGCCAA	8800
	AGCAGGCGAA	GGGGCAGCCG	GCTCCAAGGG	CTCGGTCAAA	GAACAGCTCT	8850
	TGCAGGCGAC	GAACCTGGAC	CAGGTCCGTC	AGATCGTCAT	CGGTAAGTTG	8900
25	AGCGAATCCG	GGGAATATTC	TCCCCCTCCT	CACTCAGCGG	ACTGGAGATT	8950
	AACCGCTTCT	TTTCCTTTGG	CAGATGGACT	CTCCGCGAAG	CTGCAGGTGA	9000
	CCCTGCAGAT	CCCCGATGGG	GAAAGCGTGC	ATCCCACCAT	CCCCTAATC	9050
	GATCAGGGGG	TGGACTCTCT	GGGCGCGGTC	ACCGTGGGAA	CCTGGTTCTC	9100
	CAAGCAGCTG	TACCTTGATT	TGCCACTCCT	GAAAGTGCTT	GGGGGTGCTT	9150
30	CGATCACC GA	TCTCGCTAAT	GAGGCTGCTG	CGCGATTGCC	ACCTAGCTCC	9200
	ATTCCCCCTCG	TCGCAGCCAC	CGACGGGGGT	GCAGAGAGCA	CTGACAATAC	9250
	TTCCGAGAAT	GAAGTTTCGG	GACGCGAGGA	TACTGACCTT	AGTGCCGCCG	9300
	CCACCATCAC	TGAGCCCTCG	TCTGCCGACG	AAGACGATAC	GGAGCCGGGC	9350
	GACGAGGACG	TCCCGCGTTC	CCACCATCCA	CTGTCTCTCG	GGCAAGAATA	9400
	CTCCTGGAGA	ATCCAGCAGG	GAGCCGAAGA	CCCCACCGTC	TTTAACAACA	9450
	CCATTGGTAT	GTTTCATGAAG	GGCTCTATTG	ACCTTAAACG	GCTGTACAAG	9500

- 72 -

	GCCTTGAGAG	CGGTCTTGCG	CCGCCACGAG	ATCTTCCGCA	CGGGGTTTGC	9550
	CAACGTGGAT	GAGAACGGGA	TGGCCCAGCT	GGTGTTTGGT	CAAACCAAAA	9600
	ACAAAGTCCA	GACCATCCAA	GTGTCTGACC	GAGCCGGCGC	CGAAGAGGGC	9650
	TACCGACAAC	TGGTGCAGAC	ACGGTATAAC	CCTGCCGCAG	GAGACACCTT	9700
5	GCGGCTGGTG	GACTTCTTCT	GGGGCCAGGA	CGACCATCTG	CTGGTTGTGG	9750
	CTTACCACCG	ACTCGTCGGG	GATGGATCTA	CTACAGAGAA	CATCTTCGTC	9800
	GAAGCGGGCC	AGCTCTACGA	CGGCACGTCG	CTAAGTCCAC	ATGTCCCTCA	9850
	GTTTGCGGAC	CTGGCGGCAC	GGCAACGCGC	AATGCTCGAG	GATGGGAGAA	9900
	TGGAGGAGGA	TCTCGCGTAC	TGGAAGAAAA	TGCATTACCG	ACCGTCCCTCA	9950
10	ATTCCAGTGC	TCCCACTGAT	GCGGCCCCCTG	GTAGGTAACA	GTAGCAGGTC	10000
	CGATACTCCA	AATTTCCAGC	ACTGTGGACC	CTGGCAGCAG	CACGAAGCCG	10050
	TGGCGCGACT	TGATCCGATG	GTGGCCTTCC	GCATCAAGGA	GCGCAGTCGC	10100
	AAGCACAAGG	CGACGCCGAT	GCAGTTCTAT	CTGGCGGCGT	ATCAGGTGCT	10150
	GTTGGCGCGC	CTCACCAGCA	GCACCGATCT	CACCGTGGGC	CTCGCCGACA	10200
15	CCAACCGTGC	GACTGTGCGAC	GAGATGGCGG	CCATGGGGTT	CTTCGCCAAC	10250
	CTCCTTCCCC	TGCGCTTCCG	GGATTTCCGC	CCCCATATAA	CGTTTGCGCA	10300
	GCACCTTATC	GCCACCCGTG	ACCTGGTGCG	TGAGGCCTTG	CAGCACGCCC	10350
	GCGTGCCCTA	CGGCGTCCTC	CTCGATCAAC	TGGGGCTGGA	GGTCCC GGTC	10400
	CCGACCAGCA	ATCAACCTGC	GCCTTTGTTC	CAGGCCGTCT	TCGATTACAA	10450
20	GCAGGGCCAG	GCGGAAAAGTG	GAACGATTGG	GGGTGCCAAG	ATAACCGAGG	10500
	TGATTGCCAC	GCGCGAGCGC	ACCCCTTACG	ATGTCGTGCT	GGAGATGTGG	10550
	GATGATCCCA	CCAAGGATCC	GCTGCTCACG	GCCAAGTTAC	AGAGTTCCCG	10600
	CTACGAGGCT	CACCACCCTC	AAGCCTTCTT	GGAGAGCTAC	ATGTCCCTTC	10650
	TCTCTATGTT	CTCGATGAAT	CCCGCCCTGA	AGCTGGCATG	ATGGCGCAA	10700
25	CATAGAACAT	GATAGCGCAG	CAGGGACGAT	GATAGATAGAG	CTTTGCTTCT	10750
	GCGGGTGGAT	CTATAATATA	GTATATATAA	ATATGGTGAG	CCGAACGAAG	10800
	AGGGGGGAAT	GCCACAATTA	TTTACTGTTT	TGCGCCGTAC	ACGAGGAGAA	10850
	GACGTCCAGA	ACAACATAAA	TATATCACTC	TAGTGAGACA	CCATATATTC	10900
	GGAGAGACTA	TAAAAATATA	CATCTACTCC	AATGTCTGGG	CCGTACACAA	10950
30	CAGCTTACGA	AAACGATTAA	TGACCTCCAA	CACGTCGCGC	GGTCGATTGG	11000
	GAAACTGATG	CTGCCCAGCA	AACTCCAATA	CCTGCGCCTC	TCGGGGGGAG	11050
	AAATGGCGCG	CCACCAGCAT	CTTCGATCCT	GCGAGCGCAA	AATCATCGCG	11100
	ACCCTGCAGA	TGTAATGTGG	GTATCCGAAT	GACCAGTTCC	TCCTGCCACT	11150
	CGGTATCTTT	GCTGTGCTTG	TCGTGCTCAT	GGTTCTTCAT	CATTCGTTCC	11200
	TCATATACTG	GCTTGCCCTCG	TCTTGATACC	AGGGACAGAT	CAACAGCGCA	11250

- 73 -

5  
 10  
 15  
 20  
 25  
 30

ACACTCATCC	GGGGCAACCA	GGGCAGGTGA	CCCATCTGCT	GCTGCCAGAG	11300
GAGCAAGGTC	GTCACCAGGG	CACCTTCGGA	GAAACCGATA	GCACCCACGA	11350
TAGGGATGTG	GGGGTGTTGA	GTCTGCCAGT	CGACAATGGT	GCGGCGGATG	11400
GGGTCGTGGA	CGGCGGCGAG	GCGTTCGCTC	ACGGAGGGTC	CATTATGATT	11450
5 GTTGTCGCTG	CTGCTTTCAA	ACCAGGAGTA	ATATGGCCCT	AGGTCGGCGA	11500
AGACGGGGAG	AATCCCAGGC	CCTGCAGAGG	AAGGGAACGG	AGCTGTCACG	11550
TAGACGAATT	C (SEQ ID NO:1)				11561

5. The purified DNA molecule of Claim 1 having the sequence shown in Figure 1.

6. An expression vector for the expression of cloned genes in a host cell, the expression vector containing the DNA molecule of Claim 1.

7. The expression vector of Claim 6 wherein the host cell is a fungal cell.

8. The expression vector of Claim 6 which is designated pTPKS100 (ATCC 69416).

9. The expression vector of Claim 6, wherein the DNA molecule has the sequence of Figure 1.

10. A host cell containing the purified DNA molecule of Claim 1.

11. Purified triol polyketide synthase encoded by the DNA of Claim 1.

12. The triol polyketide synthase of Claim 11 having an amino acid sequence of

MAQSMYPNEP	IVVVGSGCRF	PGDANTPSKL	WELLQHPRDV	QSRIPKERFD	50
VDTFYHPDGK	HHGRTNAPYA	YVLQDDLGA	DAAFFNIQAG	EAESMDPQHR	100

- 74 -

	L L L E T V Y E A V	T N A G M R I Q D L	Q G T S T A V Y V G	V M T H D Y E T V S	T R D L E S I P T Y	150
	S A T G V A V S V A	S N R I S Y F F D W	H G P S M T I D T A	C S S S L V A V H L	A V Q Q L R T G Q S	200
	S M A I A A G A N L	I L G P M T F V L E	S K L S M L S P S G	R S R M W D A G A D	G Y A R G E A V C S	250
	V V L K T L S Q A L	R D G D T I E C V I	R E T G V N Q D G R	T T G I T M P N H S	A Q E A L I K A T Y	300
5	A Q A G L D I T K A	E D R C Q F F E A H	G T G T P A G D P Q	E A E A I A T A F F	G H E Q V A R S D G	350
	N E R A P L F V G S	A K T V V G H T E G	T A G L A G L M K A	S F A V R H G V I P	P N L L F D K I S P	400
	R V A P F Y K N L R	I P T E A T Q W P A	L P P G Q P R R A S	V N S F G F G G T N	A H A I I E E Y M E	450
	P E Q N Q L R V S N	N E D C P P M T G V	L S L P L V L S A K	S Q R S L K I M M E	E M L Q F L Q S H P	500
	E I H L H D L T W S	L L R K R S V L P F	R R A I V G H S H E	T I R R A L E D A I	E D G I V S S D F T	550
10	T E V R G Q P S V L	G I F T G Q G A Q W	P G M L K N L I E A	S P Y V R N I V R E	L D D S L Q S L P E	600
	K Y R P S W T L L D	Q F M L E G E A S N	V Q Y A T F S Q P L	C C A V Q I V L V R	L L E A A R I R F T	650
	A V V G H S S G E I	A C A F A A G L I S	A S L A I R I A Y L	R G V V S A G G A R	G T P G A M L A A G	700
	M S F E E A Q E I C	E L D A F E G R I C	V A A S N S P D S V	T F S G D A N A I D	H L K G M L E D E S	750
	T F A R L L K V D T	A Y H S H H M L P C	A D P Y M Q A L E E	C G C A V A D A G S	P A G S V P W Y S S	800
15	V D A E N R Q M A A	R D V T A K Y W K D	N L V S P V L F S H	A V Q R A V V T H K	A L D I G I E V G C	850
	H P A L K S P C V A	T I K D V L S G V D	L A Y T G C L E R G	K N D L D S F S R A	L A Y L W E R F G A	900
	S S F D A D E F M R	A V A P D R P C M S	V S K L L P A Y P W	D R S R R Y W V E S	R A T R H H L R G P	950
	K P H L L L G K L S	E Y S T P L S F Q W	L N F V R P R D I E	W L D G H A L Q G Q	T V F P A A G Y I V	1000
	M A M E A A L M I A	G T H A K Q V K L L	E I L D M S I D K A	V I F D D E D S L V	E L N L T A D V S R	1050
20	N A G E A G S M T I	S F K I D S C L S K	E G N L S L S A K G	Q L A L T I E D V N	P R T T S A S D Q H	1100
	H L P P P E E E H P	H M N R V N I N A F	Y H E L G L M G Y N	Y S K D F R R L H N	M Q R A D L R A S G	1150
	T L D F I P L M D E	G N G C P L L L H P	A S L D V A F Q T V	I G A Y S S P G D R	R L R C L Y V P T H	1200
	V D R I T L V P S L	C L A T A E S G C E	K V A F N T I N T Y	D K G D Y L S G D I	V V F D A E Q T T L	1250
	F Q V E N I T F K P	F S P P D A S T D H	A M F A R W S W G P	L T P D S L L D N P	E Y W A T A Q D K E	1300
25	A I P I I E R I V Y	F Y I R S F L S Q L	T L E E R Q Q A A F	H L Q K Q I E W L E	Q V L A S A K E G R	1350
	H L W Y D P G W E N	D T E A Q I E H L C	T A N S Y H P H V R	L V Q R V G Q H L L	P T V R S N G N P F	1400
	D L L D H D G L L T	E F Y T N T L S F G	P A L H Y A R E L V	A Q I A H R Y Q S M	D I L E I G A G T G	1450
	G A T K Y V L A T P	Q L G F N S Y T Y T	D I S T G F F E Q A	R E Q F A P F E D R	M V F E P L D I R R	1500
	S P A E Q G F E P H	A Y D L I I A S N V	L H A T P D L E K T	M A H A R S L L K P	G G Q M V I L E I T	1550
30	H K E H T R L G F I	F G L F A D W W A G	V D D G R C T E P F	V S F D R W D A I L	K R V G F S G V D S	1600
	R T T D R D A N L F	P T S V F S T H A I	D A T V E Y L D A P	L A S S G T V K D S	Y P P L V V V G G Q	1650
	T P Q S Q R L L N D	I K A I M P P R P L	Q T Y K R L V D L L	D A E E L P M K S T	F V M L T E L D E E	1700
	L F A G L T E E T F	E A T K L L L T Y A	S N T V W L T E N A	W V Q H P H Q A S T	I G M L R S I R R E	1750
	H P D L G V H V L D	V D A V E T F D A T	F L V E Q V L R L E	E H T D E L A S S T	T W T Q E P E V S W	1800
	C K G R P W I P R L	K R D L A R N N R M	N S S R R P I Y E M	I D S S R A P V A L	Q T A R D S S S Y F	1850

- 75 -

	LESAETWFVP	ESVQQMETKT	IYVHFSCPHA	LRVGQLGFFY	LVQGHVQEGN	1900
	REVPVVALAE	RNASIVHVRP	DYIYTEADNN	LSEGGGSLMV	TVLAAAVLAE	1950
	TVISTAKCLG	VTDSILVLNP	PSICGQMLLH	AGEEIGLQVH	LATTSGNRSS	2000
	VSAGDAKSWL	TLHARDTDWH	LRRVLPRGVQ	ALVDLSADQS	CEGLTQRMK	2050
5	VLMPGCAHYR	AADLFTDTVS	TELHSGSRHQ	ASLPAAYWEH	VVSLARQGLP	2100
	SVSEGWEVMP	CTQFAAHADK	TRPDLSTVIS	WPRESDEATL	PTRVRSIDAE	2150
	TLFAADKTYL	LVGLTGD LGR	SLGRWMVQHG	ACHIVLTSRN	PQVNPKWLAH	2200
	VEELGGRVTV	LSMDVTSQNS	VEAGLAKLKD	LHLPPVGGIA	FGPLVLQDVM	2250
	LNNMELPMME	MVLNPKVEGV	RILHEKFSDP	TSSNPLDFFV	MFSSIVAVMG	2300
10	NPGQANYSAA	NCYLQALAAQ	RVASGLAAST	IDIGAVYGVG	FVTRAELEED	2350
	FNAIRFMFDS	VEEH LHTLF	AEAVVAGRRA	VHQEQQRKF	ATVLD MADLE	2400
	LTTGIPPLDP	ALKDRITFFD	DPRIGNLKIP	EYRGAKAGEG	AAGSKGSVKE	2450
	QLLQATNL DQ	VRQIVIDGLS	AKLQVTLQIP	DGESVHPTIP	LIDQGVDSL G	2500
	AVTVGTWFSK	QLYLDLPLLK	VLGGASITDL	ANEAARLPP	SSIPLVAATD	2550
15	GGAESTDN TS	ENEVSGREDT	DLSAAATITE	PSSADEDDTE	PGDEDVPRSH	2600
	HPLSLGQEYS	WRIQQAEDP	TVFNNTIGMF	MKGSIDLKRL	YKALRAVLRR	2650
	HEIFRTGFAN	VDENGMAQLV	FGQTKNKVQT	IQVSDRAGAE	EGYRQLVQTR	2700
	YNPAAGDTLR	LVDFFWGQDD	HLLVVAYHRL	VGDGSTTENI	FVEAGQLYDG	2750
	TSLSPHVPQF	ADLAARQRAM	LEDGRMEEDL	AYWKKMHYRP	SSIPVLPLMR	2800
20	PLVGNSSRSD	TPNFQHC GPW	QQHEAVARLD	PMVAFRIKER	SRKHKATPMQ	2850
	FYLAAYQVLL	ARLTDSTDLT	VGLADTN RAT	VDEMAAMGFF	ANLLPLRFRD	2900
	FRPHITFGEH	LIATRD LVRE	ALQHARVPYG	VLLDQLGLEV	PVPTSNQPAP	2950
	LFQAVFDYKQ	GQAESGTIGG	AKITEVIATR	ERTPYDVVLE	MSDDPTKDPL	3000
25	LTAKLQSSRY	EAHHPQAFLE	SYMSLLSMFS	MNPALKLA	(SEQ ID NO:2)	3038

13. The triol polyketide synthase of Claim 11 having the amino acid sequence of Figure 2.

30 14. An antibody which is immunologically reactive with the triol polyketide synthase of Claim 10.

15. A process for producing HMG-CoA reductase inhibitors, comprising:

- (a) transforming a cell with the DNA molecule of Claim 1;

- 76 -

- (b) cultivating the transformed cell under conditions that permit the expression of the DNA molecule; and
- (c) recovering the HMG-CoA reductase inhibitor.

5

16. The process of Claim 16 wherein the HMG-CoA reductase inhibitors are selected from the group consisting of lovastatin, simvastatin, pravastatin, triol and compactin.

10

17. The process of Claim 16 wherein the culture is selected from the group consisting of Aspergillus terreus, Monascus ruber, Penicillium citrinum, Penicillium brevicompactum, Hypomyces chrysospermus, Paecilomyces sp. M2016, Eupenicillium sp. MM603, Trichoderma longibrachiatum M6735 and Trichoderma pseudokoningii M6828.

15

18. A method of isolating DNA encoding polyketide synthase, comprising:

20

- (a) hybridizing the DNA of Claim 1 to a sample, the sample containing DNA encoding polyketide synthase, to form a complex; and
- (b) purifying the complex.

25

19. The method of Claim 19 wherein the sample is derived from a microorganism, the microorganism being selected from the group consisting of Aspergillus terreus, Monascus ruber, Penicillium citrinum, Penicillium brevicompactum, Hypomyces chrysospermus, Paecilomyces sp. M2016, Eupenicillium sp. MM603, Trichoderma longibrachiatum M6735 and Trichoderma pseudokoningii M6828.

30

20. Purified nucleic acid encoding functional triol polyketide synthase which is capable of hybridizing with nucleic acid encoding triol polyketide synthase under low stringency conditions

- 77 -

comprising incubating or washing with about 0.15 M sodium chloride and about 0.015 M sodium citrate at about 20°- 55°C or its equivalent.

5

10

15

20

25

30

1/30

CTGCAGTCAA CGGATCACTT ACCATTGCTG TCGCCAAAAA TATCCGTGAT AATCCCGCTG 60  
GCTTCATTGG CAAGAGGCTT GACGTACTTG GGAGCTTGGG TCTGGAACTG GTTCATAAACC 120  
ACCTTGGTGA TGAGATGTGC ATCCCTCGTG ACTTCCTTGA ATCCATCGAA TCCGGGAAGA 180  
TGAGAGTGAA AGTCCTGATG AGAGCACGAA GATCAGTAAG TCAGGTCCTC ACAGCGGAAG 240  
CAGTTGCAAA GAACGGTGGA CTCCTTACCG TGCCCAAGAA CTTGTACATA CAGAGCTCTT 300  
TCATCTTCCG AAATCATCG GCCATAGAGG AGGGAAGAAT GGTGCAGTAC CCAGAGTCGA 360  
CTATGAACCG AATGGGCTTA TCATTTTGCG AGAACCAGCT CTCAATCCAT GACGGTGCA 420  
TCGCATCAA ATCCCGTTTG GCCCTCATGG TCGTCAGTTC CCACCATGTT TTCGGATTGA 480  
ACACCGGCAG ATCAGATCTC CGGCCACTCG AGCACAGGTA AAGAAGAAGG CATAGTAGCC 540  
CCGCACTGGT AGTGACCAAG GCGCAAAACC ACGAGCCATG TTGCTGCGTG TCATTCCAAG 600  
CCAGCGACAG AAGGTGGTGC GGCTGTGTGA GCGGTCGAC AGTCATGGCT AGGAGACCAG 660  
GTGTGGTTGA GGGATAAGAT ATCGAGAGTG ATGTGAGCAA AAGATCCGGG AAAGGTCGCG 720

FIG. 1A

SUBSTITUTE SHEET (RULE 26)



2/30

AAGGAAAGGG CGTCTCTCTT ACCAAGAAAG TCTGTCCCT ATCATGCAAT CACCGCTTGC 780  
TGTAACGGTGG TGATGATGCT GGGATGGTGG TGGGTCCCCA CCGAATAACG CCGGACAGCT 840  
GTTGAAGCCG AATGACGCCG GCAGGCCAAA AGAACCCTAC CTTCACTTAC TCAATCGGCG 900  
CTTCCCCCTCC TATCACCAA TCGGATGTAA ATGGACGGG CTTAATAGCG ACCGGCCGGG 960  
CCGGGAATCC CCAAACGTAG ATAGATAGG ATAGACCCGA AATCTTTGGC CCGGCATACA 1020  
TGAGCACAGG AAGTTTCAG CGACGGCGCC TTTCCTGCCT CAGCTTCAAT CCAAGCTCAC 1080  
GAGTCTGTC GCCTCTATCA GTCGTGCAAT TGTCCTACTG CAAACAGCAT GGCTCAATCT 1140  
ATGTATCCTA ATGAGCCTAT TGTCGTGGTC GGCAGTGTT GTCGCTTCCC TGGTGACGCC 1200  
AACACACCCT CCAAGCTCTG GGAGCTACTC CAGCATCCTC GCGATGTGCA GAGTCGAATC 1260  
CCCAAAGAAC GATTGACGT CGACACATTT TATCACCCCG ACGGGAAGCA CCACGGGCGA 1320  
ACAAATGCAC CCTACGCCCTA TGTTCTCAA GACGATCTGG GCGCCTTCGA TCGGCCCTC 1380  
TTCAATATCC AGGCTGGAGA GGCCGAGAGT ATGGACCCCC AGCACCGGCT GTTGCTGGAG 1440

FIG. 1B

SUBSTITUTE SHEET (RULE 26)

3/30

ACGGTGTAAG	AGGCCGTAAC	GAATGCTGGA	ATCGGTATCC	AGGATCTGCA	GGGAACCTCG	1500
ACTGCTGTTT	ACGTCGGGGT	GATGACGCAC	GACTATGAGA	CTGTCTCAAC	CCGCGACCTG	1560
GAGAGCATCC	CCACCTACTC	GGCGACGGGT	GTCGCGGTCA	GTGTTGCGTC	CAACCGCATC	1620
TCGTATTTTT	TTGACTGGCA	TGGACCAAGT	GTAAGTCACC	CAATATCGTG	TAGCAGTCTA	1680
ATCATGCTCT	AACGGACCGG	GATGGTTGAA	AGATGACGAT	CGATACGGCA	TGCAGCTCGT	1740
CGTTGGTTGC	CGTTCATCTG	GCGGTGCAAC	AGCTACGGAC	GGGTCAAAGC	TCCATGGCAA	1800
TTGCTGCGGG	TCCGAATCTG	ATTCTGGGGC	CCATGACATT	CGTCCTTGAA	AGCAAATTGA	1860
GCATGCTATC	CCCCTCGGGT	CGATCCCAGC	TGTGGGACGC	CGGAGCTGAC	GGCTATGCCA	1920
GAGGCGTGAG	TGTTTCTTGA	GCTCGTAGAT	GACAGTTCCC	ATCGCTGACC	GTGATCAGGA	1980
AGCTGTTTGC	TCTGTAGTGT	TGAAGACATT	GAGTCAAGCC	TTGCGCGGATG	GGGACACGAT	2040

FIG. 1C

SUBSTITUTE SHEET (RULE 26)

4/30

TGAATGTGTC ATCCGAGAAA CTGGGGTGAA TCAAGATGGC CGAACGACCG GAATTACGAT 2100  
GCCGAACCAT AGTGCTCAGG AGGCACTCAT CAAGGCTACC TACGCCCAGG CTGGCCTTGA 2160  
CATCACCAAG GCCGAGGACA GGTGCCAATT CTTGAGGCT CATGGTCAGC AAAGAGAACC 2220  
TGTTCTGTTG GCGCCCTGCA GCTGACATTC GTATGATAGG GACTGGTACT CCGGCCCGAG 2280  
ATCCCCAGGA GCGGAGGCC ATTGCAACAG CCTTCTTCGG CCACGAGCAG GTAGCACGCA 2340  
GCGACGGAAA CGAGAGGGCC CCTCTGTTGG TGGGCAGTGC GAAAACTGTT GTCGGGCACA 2400  
CCGAGGGCAC GCGCGGTCTG GCTGGTCTCA TGAAGGCGTC GTTCGCTGTC CGCCATGGGG 2460  
TAATCCCCC CAACCTGCTG TTCGACAAAA TCAGCCCGCG AGTCGCCCCA TTCTATAAAA 2520  
ACCTGAGGAT TCCGACAGAA GCTACCCAAT GGCCAGCTCT CCCACCCGGA CAACCGCGCC 2580  
GCGCCAGTGT CAACTCCTTT GGTAGCGAG GATTGCCCGG AGGAACCCCTC ACAAGTACTC 2640

FIG.1D

SUBSTITUTE SHEET (RULE 26)

GAATTAATGC TAACTGAACC GCGCCGATGG ACAGGATTGG GCGGCACGAA TCGCATGCC 2700  
ATTATTGAGG AATACATGGA GCCAGAGCAA AACCAGCTGC GAGTCTCGAA TAATGAGGAC 2760  
TGCCCCACCCA TGACCGGTGT CCTGAGTTTA CCCTTAGTCC TCTCGGCGAA GTCCCAGCGC 2820  
TCCTTAAAGA TAATGATGGA GGAGATGCTG CAATTCCTTC AGTCTCACCC CGAGATACAC 2880  
TTGCACGACC TCACCTGGTC CTTACTGCGC AAGCGGTCAG TTCTACCCCTT CCGCCGGGCT 2940  
ATTGTCGGCC ATAGTCATGA AACCATCCGC CGGGCTTTGG AGGATGCCAT CGAGGATGGT 3000  
ATTGTGTCGA GCGACTTCAC TACGGAGGTC AGAGGCCAGC CATCGGTGTT GGAATCTTC 3060  
ACCGGGCAGG GGGCGCAGTG GCCGGGGATG TTAAAGAATC TGATAGAGGC ATCGCCATAT 3120

5/30

FIG.1E

SUBSTITUTE SHEET (RULE 26)

GTGCGGAACA TAGTGAGGGA GCTGGACGAC TCCCTGCAGA GCTTGCCGGA AAAATACCGG 3180  
CCCTCGTGGA CGCTACTGGA CCAGTTCATG CTAGAAGGAG AGGCTCCAA CGTCCAATAT 3240  
GCTACTTTCT CCCAGCCATT ATGCTGCCG GTGCAAAATG TCCTGGTCCG TCTCCTTGAA 3300  
GCCGCGAGAA TACGATTAC GGCTGTTGTT GGACATAGCT CCGCGGAAAT TGCTTGCGCC 3360  
TTTGCTGCCG GGCTCATCAG TGCCTCGTTG GCGATTGGA TTGCTTACTT ACGTGGAGTC 3420  
GTCTCGGCAG GGGCGGCCAG AGGCACACCG GGAGCCATGT TGGCCGCCGG GATGTCCTTT 3480  
GAGGAAGCAC AAGAGATCTG CGAGTTGGAT GCCTTTGAGG GCCGCATCTG CGTGGCTGCC 3540  
AGCAATTCCC CAGACAGTGT AACTTTCTCT GCGACGCGA ACGCAATTGA TCACCTGAAG 3600  
GGCATGTTGG AGGATGAGTC CACTTTTGCG AGACTGCTCA AGTCGATAC AGCGTACCAC 3660

6/30

FIG.1F

SUBSTITUTE SHEET (RULE 26)

7/30

TCGCATCATA TGCTTCCATG TGCAGACCCA TATATGCAAG CCTAGAAGA GTGTGGTTGT	3720
GCTGTTGCCG ATGCAGGTTT CCCAGCCGGA AGTGTAACCT GGTATTCTGTC CGTGGACGCC	3780
GAGAACAGGC AAATGGCAGC AAGAGACGTG ACCGCCAAGT ACTGGAAGA TAACTTAGTA	3840
TCTCCGGTGC TATTCTCCCA CGCAGTGCAG CCGGCAGTCG TCACGCACAA GGCGCTGGAT	3900
ATCGGGATTG AAGTGGGCTG TCACCCAGCT CTCAGAGCC CATGCGTCGC CACCATCAAG	3960
GATGTCCTAT CTGGGGTTGA CCTGGCGTAT ACAGGTTGCT TGGAGCGAGG AAAGAATGAT	4020
CTCGATTGAT TCTCTCGAGC ACTGGCATAT CTCTGGGAAA GGTTTGGTGC CTCCAGTTTC	4080
GATGCGGACG AGTTGATGCG TGCAGTCGCG CCTGATCGGC CCTGTATGAG TGTGTCGAAG	4140
CTCCTACCGG CCTATCCATG GGACCGCTCT CGTCGCTACT GGGTGGAATC CCGAGCAACT	4200

FIG.1G

SUBSTITUTE SHEET (RULE 26)

CGCCACCATC TTCGAGGGCC CAAGCCCCAT CTTCATTAG GAAAGCTCTC CGAATACAGC 4260  
ACTCCGCTAA GCTTCCAGTG GCTGAATTTT GTGCGCCAC GAGACATTGA ATGGCTTGAT 4320  
GGACATGCAT TGCAAGGCCA GACTGTCTTC CCTGCGGCCG GCTATATCGT CATGGCAATG 4380  
GAAGCAGCCT TAATGATTC TGCACCCAC GCAAGCAGG TCAAGTTACT GGAGATCTTG 4440  
GATATGAGCA TTGACAAGGC GGTGATATTT GACGACGAAG ACAGCTTGGT TGAGCTCAAC 4500  
CTGACAGCTG ACGTGTCTCG CAACGCCGC GAAGCAGGT CAATGACCAT AAGCTTCAAG 4560  
ATCGATTCTT GTCTATCGAA GGAGGGTAAC CTATCCCTAT CAGCCAAGG CCAACTGGCC 4620  
CTAACGATAG AAGATGTCAA TCCCAGGACG ACTTCCGCTA GCGACCAGCA CCATCTTCCC 4680  
CCGCCAGAAG AGGAACATCC TCATATGAAC CGTGTCAACA TCAATGCTTT CTACCACGAG 4740  
CTGGGGTTGA TGGGGTACAA CTACAGTAAG GACTTCCGGC GTCTCCATAA CATGCAACGA 4800

8/30

FIG.1H

SUBSTITUTE SHEET (RULE 26)

9/30

GCAGATCTTC GAGCCAGCGG CACCTTAGAC TTCATTCCCTC TGATGGACGA GGGTAATGCC 4860  
TGTCCTCTCC TGCTGCATCC TGCATCATTG GACGTCGCCT TCCAGACTGT CATCGGCGCA 4920  
TACTCCTCCC CAGGTGATCG GCGTCTACGC TGCTGTATG TACCCACTCA CGTTGATCGC 4980  
ATCACACTTG TCCCATCCCT TTGCCCTGGCA ACGGCTGAGT CCGGATGCCA GAAGGTGCCC 5040  
TTCAATACTA TCAATACGTA CGACAAGGA GACTACTGA GCGGTGACAT TGTGGTGTTC 5100  
GACGCGGAGC AGACCACCCT GTTCCAGGTT GAAATATTA CTTTAAAGCC CTTTTCACCC 5160  
CCGGATGCTT CAACTGACCA TCGGATGTTT GCCCGATGGA GCTGGGGTCC GTTGAATCCG 5220  
GACTCGCTGC TGGATAACCC GGAGTATTGG GCCACCGCGC AGGACAAGGA GCGGATTCCT 5280

FIG. 11

SUBSTITUTE SHEET (RULE 26)



10/30

ATTATCGAAC GCATCGTCTA CTTCTATATC CGATCGTTCC TCAGTCAGCT TACGCTGGAG 5340  
GAGCGCCAGC AGGCAGCCTT CCATTGCGAG AAGCAGATCG AGTGGCTCGA ACAAGTCCTG 5400  
GCCAGCGCCA AGGAGGGTCG TCACCTATGG TACGACCCCG GGTGGGAGAA TGATACTGAG 5460  
GCCCAGATTG AGCACCTTTG TACTGCTAAC TCCTACCACC CTCATGTTTCG CCTGGTTTCAG 5520  
CGAGTCGGCC AACACCTGCT CCCACCGTA CGATCGAAGC GCAACCCATT CGACCTTCIG 5580  
GACCACGATG GGCTCCTGAC GGAGTTCTAT ACCAACACAC TCAGCTTCGG ACCCGCACTA 5640  
CACTACGCCC GGAATTGGT GCGGCAGATC GCCCATCGCT ATCAGTCAAT GGATATTCTG 5700  
GAGATTGGAG CAGGGACCGG CGGCGCTACC AAGTACGTGT TGGCCACGCC CCAGCTGGGG 5760  
TTCAACAGCT ACACATACAC CGATATCTCC ACCGGATTCT TCGAGCAAGC GCGGGAGCAA 5820  
TTTGCCCCCT TCGAGGACCG GATGGTGTTT GAACCCCTCG ATATCCGCCG CAGTCCCGCC 5880

FIG.1J

SUBSTITUTE SHEET (RULE 26)

5940 GAGCAGGGCT TCGAGCCGCA TGCCTATGAT CTGATCATTG CCTCCAATGT GCTACATGCG  
6000 ACACCCGACC TAGAGAAAC CATGGCTCAC GCCCGCTCTC TGCTCAAGCC TGGAGGCCAG  
6060 ATGGTTATTC TGGAGATTAC CCACAAGAA CACACACGGC TCGGGTTTAT CTTTGGTCTG  
6120 TTCGCCGACT GGTGGGCTGG GGTGGATGAT GGTCGCTGCA CTGAGCCGTT TGTCTCGTTC  
6180 GACCGCTGGG ATCCGATCCT AAAGCGTGC GGGTTTCCG GTGTGGACAG TCGCACCCAG  
11/30  
6240 GATCGGGACG CAAATCTATT CCCGACCTCT GTGTTTAGTA CCCATGCAAT TGACGCCACC  
6300 GTGGAGTACT TAGACCGGCC GCTTGCCAGC AGCGGCACCG TCAAGGACTC TTACCCCTCCC  
6360 TTGGTGGTGG TAGGAGGCA GACCCCCCAA TCTCAGCGTC TCCTGAACGA TATAAAGCG  
6420 ATCATGCCCT CTCGTCCGCT CCAGACATAC AAGCCCTCG TGGATTGCT AGACGGGAG  
6480 GAGCTGCCGA TGAAGTCCAC GTTGTCTATG CTCACGGAGC TGGACGAGGA ATTATTGCCC

FIG. 1K

SUBSTITUTE SHEET (RULE 26)

GGGCTCACTG AAGAGACCTT CGAGGCAACC AAGCTGCTGC TCACGTACGC CAGCAATACG 6540  
GTCTGGCTGA CAGAAAATGC CTGGGTCCAA CATCCTCACC AGGCGAGCAC GATCGGCATG 6600  
CTACGCTCCA TCCGCCGGGA GCATCCTGAC TTGGGAGTTC ATGTTCTGGA CGTCGACGG 6660  
GTGAAACCT TCGATGCAAC CTTCTGGT GAACAGGTGC TTCGGCTTGA GGAGCATACG 6720  
GATGAGCTGG CCAGTTCAAC TACATGGACT CAAGAACCCG AGGTCTCCTG GTGTAAGGC 6780  
CGCCCGTGGA TTCTCTGTCT GAAGCGGAT CTGGCTCGCA ATAACCGAAT GAACTCCTCG 6840  
CGCCGTCCCA TATACGAGAT GATCGATTG TCGCGGGCTC CCGTGGCATT ACAGACGGCT 6900  
CGGGATTCAAT CATCCTACTT CTTGGAGTCC GCTGAAACCT GGTTTGTGCC TGAGAGTGTT 6960  
CAGCAGATGG AAACAAGAC GATCTATGTC CACTTAGCT GTCCCCATGC GCTTAGGGTC 7020

12/30

FIG. 1L

SUBSTITUTE SHEET (RULE 26)

13/30

GGACAGCTCG GGTTTTCTA TCTTGTCAG GGTACGTCC AGGAGGCAA TCGCGAAGTG 7080  
CCCGTCGTGG CCTFAGCAGA GCGTAACGCA TCCATTGTGC ACGTTCGTCC CGATTATATA 7140  
TATACTGAGG CAGATAACAA TCTGTCTGAG GGTGGTGGA GCCTATGGT AACCGTCCTC 7200  
GCCGCGGCGG TGTGGCGGA GACGGTGATC AGTACCGCCA AGTGCCCTGGG GGTAACCTGAC 7260  
TCAATCCTCG TTCTGAATCC CCCAGCATA TGTGGGCAGA TGTGCTCCA TGCTGGTGAA 7320  
GAGATCGGTC TTCAAGTTCA TCTGGCCACC ACTTCTGGCA ACAGGAGTTC GGTTCCTGCT 7380  
GGAGACGCCA AGTCCTGGCT AACATTGCAT GCTCGCGACA CGGACTGGCA CCTGCCACGG 7440  
GTACTGCCCC GGGGTGTCCA GGCTTTAGTC GACTTATCAG CCGACCAGAG CTGTGAAGGT 7500  
TTGACTCAGA GGATGATGAA AGTTCGTATG CCTGGCTGTG CCCATTACCG TCGGCAGAC 7560

FIG. 1M

SUBSTITUTE SHEET (RULE 26)

14/30

CTGTTTCACAG ACACCGTTTC CACTGAATTG CATAGCGGAT CGCGGCATCA AGCTTCACTG	7620
CCCGCCGCAT ATTGGGAGCA TGTGGTATCC TTAGCCCGCC AGGACTTCC TAGTGTACAG	7680
GAGGGGTGGG AGGTGATGCC GTGCACTCAA TTTGCAGCGC ATGCCGACAA GACGCGCCCG	7740
GATCTCTCGA CAGTTATTTC CTGGCCCCGG GAGTCGGACG AGGCTACGCT TCCTACCAGG	7800
GTTCGCTCCA TTGACGCTGA GACCCTCTTT GCGGCCGACA AAACATATCT CCTGGTCGGA	7860
CTGACTGGAG ATCTTGGACG ATCACTAGGT CGTTGGATGG TCCAGCATGG GGCCTGCCAC	7920
ATTGTACTTA CGAGCAGAAA TCCGCAGGTG AACCCCAAGT GGCTGGCGCA TGTTGAAGAA	7980
CTGGGTGGTC GAGTCACTGT TCTTTCCATG TAAGAGGAGT CCTTCCTTCT GCAATTCCCTC	8040
CTTATGATCC CGACTAACGC AGCTGGCTTC AGGACGTGA CAAGCCAAAA CTCAGTGGAA	8100
GCTGGCCCTGG CTAAACTCAA GGATCTGCAT CTGCCACCAG TGGGGGTAT TGCCTTTGGC	8160

FIG. 1N

SUBSTITUTE SHEET (RULE 26)

15/30

CCTCTGGTTC TGCAGGATGT GATGCTAAAT AATATGAAC TGCCAATGAT GGAGATGGTG 8220  
CTCAACCCCA AGGTCGAAGG CGTCCGCATC CTGCACGAGA AGTTCTCCGA TCCGACCAGT 8280  
AGCAACCCCTC TCGACTTCTT CGTGATGTTT TCCTCGATTG TGGCCGTCAT GGGCAACCCG 8340  
GGTCAGGCTA ACTACAGTGC GGCTAACTGC TACCTTCAAG CGCTGGCGCA GCAGCGAGTT 8400  
GCATCCGGAT TAGCAGTACG TTTTCACTCC ATCCTTTGCT AAACACTCCT ATGGGCCCTT 8460  
ACTAAACCGG GCAGGCGTCC ACCATCGACA TCGGTGCCGT GTACGGCGTT GGGTTCGTCA 8520  
CTCGGGCGGA GCTGGAGGAG GACTTTAATG CAATTCGGTT CATGTTGAT TCGGTTGAGG 8580  
AACATGAACT GCATACACTG TTTGCTGAGG CAGTGGTGGC CGGTCGACGA GCCGTGCACC 8640  
AGCAAGAGCA GCAGCGAAG TTCCGACAG TGCTCGACAT GGCTGATCTG GAACTGACAA 8700

FIG. 10

SUBSTITUTE SHEET (RULE 26)

CCGGAATTCC GCCCTGGAT CCAGCCCTCA AAGATCGGAT CACCTTCTTC GACGACCCCC 8760  
GCATAGGCAA CTTAAAAATT CCGGAGTACC GAGGGGCCAA AGCAGGCGAA GGGGCAGCCG 8820  
GCTCCAAGG CTCGGTCAA GAACAGCTCT TGCAGGCGAC GAACCTGGAC CAGGTCCGTC 8880  
AGATCGTCAT CGGTAAGTG AGCGAATCCG GGGAATATTC TCCCCTTCCT CACTCAGCCG 8940  
ACTGGAGATT AACCGCTTCT TTTCCCTTGG CAGATGGACT CTCCGCCAAG CTGCAGGTGA 9000  
CCCTGCAGAT CCCCAGTGG GAAAGCGTGC ATCCCACCAT CCCACTAATC GATCAGGGGG 9060  
TGGACTCTCT GGGCGCGTC ACCGTGGAA CCTGGTTCTC CAAGCAGCTG TACCTTGATT 9120  
TGCCACTCCT GAAAGTGCTT GGGGGTGCTT CGATCACCGA TCTCGCTAAT GAGGCTGCTG 9180  
CGCGATTGCC ACCTAGCTCC ATTCCCCTCG TCGCAGCCAC CGACGGGGGT GCAGAGAGCA 9240  
CTGACAATAC TTCCGAGAAT GAAGTTTCGG GACCGAGGA TACTGACCTT AGTGCCGCCG 9300

16/30

FIG. 1P

SUBSTITUTE SHEET (RULE 26)

CCACCATCAC TGAGCCCTCG TCTGCCGACG AAGACGATAC GGAGCCGGGC GACGAGGACG 9360  
TCCCGCGTTC CCACCATCCA CTGTCTCTCG GGCAAGAATA CTCCTGGAGA ATCCAGCAGG 9420  
GAGCCGAAGA CCCACCGTC TTTAACAACA CCATTGGTAT GTTCATGAAG GGCTCTATTG 9480  
ACCTTAAACG GCTGTACAAG GCGTTGAGAG CCGTCTTCCG CCGCCACGAG ATCTTCCGCA 9540  
CGGGGTTTGC CAACGTGGAT GAGAACGGGA TGGCCCAGCT GGTGTTTGGT CAAACCAAAA 9600  
ACAAAGTCCA GACCATCCAA GTGTCTGACC GAGCCGGCGC CGAAGAGGGC TACCGACAAC 9660  
TGGTGCAGAC ACGGTATAAC CCTGCCGCAG GAGACACCTT GCGGCTGGTG GACTTCTTCT 9720  
GGGGCCAGGA CGACCATCTG CTGGTTGTGG CTTACCACCG ACTCGTCGGG GATGGATCTA 9780  
CTACAGAGAA CATCTTCGTC GAAGCGGGCC AGCTCTACGA CGGCACGTCG CTAAGTCCAC 9840

17/30

FIG. 1Q

SUBSTITUTE SHEET (RULE 26)



ATGTCCCTCA GTTTGCGGAC CTGGCGGCAC GGCAACGCCG AATGCTCGAG GATGGGAGAA 9900  
TGGAGGAGGA TCTCGCGTAC TGGAGAGAAA TGCATTACCG ACCGTCCCTCA ATTCCAGTGC 9960  
TCCCACTGAT GCGGCCCCCTG GTAGGTAACA GTAGCAGGTC CGATACTCCA AATTTCAGC 10020  
ACTGTGGACC CTGGCAGCAG CACGAAGCCG TGGCGCGACT TGATCCGATG GTGGCCTTCC 10080  
GCATCAAGGA GCGCAGTCGC AAGCACAAGG CGACGCCGAT GCAGTTCAT CTGGCGGCGT 10140  
ATCAGGTGCT GTTGGCGGC CTCACCGACA GCACCGATCT CACCGTGGC CTCGCCGACA 10200  
CCAACCGTGC GACTGTGCGAC GAGATGGCGG CCATGGGGTT CTCGCCAAC CTCCTTCCCC 10260  
TGGCCTTCCG GGATTTCGCG CCCCATATAA CGTTTGGCGA GCACCTTATC GCCACCCGTG 10320  
ACCTGGTGCG TGAGGCCTTG CAGCAGCCC GCGTGCCCTA CGCGTCCTC CTCGATCAAC 10380

18/30

FIG. 1R

SUBSTITUTE SHEET (RULE 26)

19/30

TGGGGCTGGA	GGTCCCGGTC	CCGACCAGCA	ATCAACCTGC	GCCTTTGTTC	CAGGCCGTCT	10440
TCGATTACAA	GCAGGGCCAG	GCGGAAAGTG	GAACGATTGG	GGGTGCCAAG	ATAACCGAGG	10500
TGATTGCCAC	GCGCGAGCGC	ACCCCTTACG	ATGTCGTGCT	GGAGATGTGG	GATGATCCCA	10560
CCAAGGATCC	GCTGCTCAGG	GCCAAGTTAC	AGAGTTCCCG	CTACGAGGCT	CACCACCCCTC	10620
AAGCCTTCTT	GGAGAGCTAC	ATGTCCCTTC	TCTCTATGTT	CTCGATGAAT	CCCGCCCTGA	10680
AGCTGGCATG	<u>ATGGCGCAA</u>	CATAGAACAT	GATAGCGCAG	CAGGACGAT	GTAGATAGAG	10740
CTTTGCTTCT	GCGGGTGGAT	CTATAATATA	GTATATATA	ATATGGTGAG	CCGAACGAAG	10800
AGGGGGGAAT	GCCACAATTA	TTTACTGTTT	TGCGCCGTAC	ACGAGGAGAA	GACGTCCAGA	10860
ACAACATAAA	TATATCACTC	TAGTGAGACA	CCATATATTC	GGAGAGACTA	TAAAAATATA	10920
CATCTACTCC	AATGTCTGGG	CCGTCACACA	CAGCTTACGA	AAACGATTAA	TGACCTCCAA	10980

FIG.1S

SUBSTITUTE SHEET (RULE 26)

20/30

CACGTCGGCG	GGTCGATTGG	GAAACTGATG	CTGCCCAGCA	AACTCCAATA	CCTGCGCCTC	11040
TCGGGGGGAG	AAATGGCGCG	CCACCAGCAT	CTTCGATCCT	GCGAGCGCAA	AATCATCGCG	11100
ACCCCTGCAGA	TGTAATGTCTG	GTATCCGAAT	GACCAGTTCC	TCCTGCCACT	CGGTATCTTT	11160
GCTGTCTGTTG	TCGTCTGTCAT	GGTTCTTTCAT	CATTCGTTCC	TCATATACTG	GCTTGCCTCG	11220
TCTTGATACC	AGGGACAGAT	CAACAGCGCA	ACACTCATCC	GGGCAACCA	GGCAGGTGA	11280
CCCATCTGCT	GCTGCCAGAG	GAGCAAGGTC	GTCACCAGGG	CACCTTCGGA	GAAACCGATA	11340
GCACCCACGA	TAGGGATGTG	GGGGTGTGA	GTCTGCCAGT	CGACAATGGT	GCGCGCGATG	11400
GGGTCGTGGA	CGGCGGCGAG	GCGTTCGCTC	ACGAGGGTC	CATTATGATT	GTTGTCTGCTG	11460
CTGCTTTTCAA	ACCAGGAGTA	ATATGGCCCT	AGGTCGGCGA	AGACGGGGAG	AATCCCAGGC	11520
CCTGCAGAGG	AAGGGAACGG	AGCTGTCACG	TAGACGAATT	C		11561

FIG. 17

SUBSTITUTE SHEET (RULE 26)

21 / 30

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
MAQSMYPNEP	IVVVGSGCRF	PGDANTPSKL	WELLQHPRDV	QSRIPKERFD	50
VDTFYHPDGK	HHGRTNAPYA	YVLQDDLGA	DAAFFNIQAG	EAESMDPQHR	100
LLLETVYEAV	TNAGMRIQDL	QGTSTAVYVG	VMIHDIETVS	TRDLESIPTY	150
SATGVAVSVA	SNRISYFFDW	HGPSMTTDTA	CSSSLVAVHL	AVQQLRTGQS	200
SMAIAAGANL	ILGPMTFVLE	SKLSMLSPSG	RSRMWDAGAD	GYARGEAVCS	250
VVLKTLSQL	RDGDTTECVI	RETGVNQDGR	<u>TIGTIMPKHS</u>	AQEALIKATY	300
AQAGLDITKA	EDRCQFFEAH	GTGTPAGDPQ	EAEAIATAFF	GHEQVAPGGG	350
NERAPLFVGS	AKTVVGHTEG	TAGLAGLMKA	SFAVRHGVIP	PNLLFIKISP	400
RVAPFYKNLR	IPTEATQWPA	LPPGQPRRAS	VNSFGFGGIN	AHAIIIEEYME	450
PEQNQLRVSN	NEDCPPMTGV	LSLPLVLSAK	SQRSLKIMME	EMLQFLQSHP	500
EIHLHDETWS	LLRKRSVLPF	RRAIVGHSHE	TEAAALEDAI	EDGIVSSDIT	550
TEVRGQPSVL	GIFTGQGAQW	PGMLKNLIEA	SPVYRNIVRE	LDDSLQSLPE	600
KYRPSWTLLD	QFMLEGEASN	VQYATFSQPL	CCAVQIVLVR	LLEAARIRFT	650
AVVGHSSGEI	ACAFAAGLIS	ASLAIRIAYL	RGVVSAGGAR	GTPGAMLAAG	700
MSFEEAQEIC	ELDAFEGRIC	VAASNPSDSV	TFSGDANAID	HLKGMLEDES	750
TFARLLKVD	AYHSHHMLPC	ADPYMQALEE	CGCAVADAGS	PAGSVPWYSS	800
VDAENRQMAA	RDVTAKYWKD	NLVSPVLFSH	AVQRAVVIHK	ALDIGIEVGC	850
HPALKSPCVA	TIKDVLSGVD	LAYTGCLERG	KNDLDSFSRA	LAYLWERFGA	900
SSFDADEFMR	AVAPDRPQMS	VSKLLPAYPW	DRSRRYWVES	RATRHHLPGP	950

FIG.2A

SUBSTITUTE SHEET (RULE 26)

22/30

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
KPHLLLGKLS	EYSTPLSFQW	LNFRVRPDIE	WLDGHALQGQ	TVFPAAGYTV	1000
MAMEAALMIA	GTHAKQVKLL	ETLDMSIDKA	VIFDDEDSL	ELNLTADVSR	1050
NAGEAGSMTI	SFKIDSCLSK	EGNLSLSAKG	QLALTIEDVN	PRTTSASDQH	1100
HLPPPEEEHP	HMNRVNINAF	YHELGLMGYN	YSKDFRRLHN	MQRADLRASG	1150
TLDFIPLMDE	GNGCPLLLHP	ASLDVAFQTV	IGAYSSPGDR	RLRCLYVPTH	1200
VDRITLVPSL	CLATAESGCE	KVAFNTTNTY	DKGDYLSGDI	VVFDAEQTTL	1250
FQVENTTFKP	FSPPDASTDH	AMFARWSWGP	LTPDSLLDNP	EYWATAQDKE	1300
APIIIERIVY	FYIRSFLSQL	TLEERQQAAF	HLQKQIEWLE	QVLASAKEGR	1350
HLWYDPGWEN	DTEAQIEHLC	TANSYHPHVR	LVQRVGQHLL	PTVRSNGNPF	1400
DLLDHDGLLT	EFYTNLSFG	PALHYARELV	AQIAHRYQSM	<u>DILEIGAGTG</u>	1450
<u>GATKYVLATP</u>	QLGFNSYTYT	DISTGFFEQA	REQFAPFEDR	MVFEPLDIRR	1500
SPAEQGFEPH	AYDLIIASWV	LHATPDLEKT	MAHARSLLKP	GGQMVILETT	1550
HKEHTRLGFI	FGLFADWWAG	VDDGRCTEPF	VSFDRWDAIL	KRVGFSGVDS	1600
<u>RTIDRDANLF</u>	<u>PISVFSTHAI</u>	DATVEYLDAP	LASSGTVKDS	YPPLVVGGQ	1650
TPQSQRLND	IKAIMPPRPL	QTYKRLVDLL	DAEELPMKST	FVMLTELDEE	1700
LFAGLTEETF	EATKLLITYA	SNTVWLTEA	WVQHPHQAST	IGMLRSIRRE	1750
HPDLGVHVD	VDAVETFDAT	FLVEQVLRLE	EHTDELASST	TWTQEPEVSW	1800
CKGRPWIPL	MRDLARNNRM	NSSRRPIYEM	IDSSRAPVAL	QTARDSSSYF	1850
LESAETWFVP	ESVQQMETKT	IYVHFSCPHA	LRVQLGFFY	LVQGHVQEGN	1900
REVPVVALAE	RNASIVHVRP	DYTYTEADNN	<u>LSEGGGSLMV</u>	TVLAAAVLAE	1950

FIG.2B

SUBSTITUTE SHEET (RULE 26)

23/30

10	20	30	40	50	
1234567890	1234567890	1234567890	1234567890	1234567890	
TVISTAMCLG	VIDSILVLNP	PSICGQMLLH	AGEEIGLQVH	LATTSGNRSS	2000
VSAGDAKSAL	TLHARDTDWH	LRRVLPRGVQ	ALVDLSADQS	CEGLTQRMKK	2050
VIMPGCAHYR	AADLFTDTVS	TELHSGSRHQ	ASLPAAYWEH	VVSLARQGLP	2100
SVSEGWEVMP	CTQFAAHADK	TRPDLSTVIS	WPRESDEATL	PTRVRSIDAE	2150
TLFAADKTYL	LVGLTGD <del>LGR</del>	SLGRWWVQHG	ACHIVLTSRN	PQVNPKWLAH	2200
VEELGGRVTV	LSMDVTSQNS	VEAGLAKLKD	LHLPPVGGIA	FGPLVLQQVM	2250
LNNMELPMME	MVLNPKVEGV	RILHEKFSDP	TSSNPLDFFV	MFSSIVAVMG	2300
NPGQANYSAA	NCYLQALAAQ	RVASGLAAS	IDIGAVYGVG	FVTRAELEED	2350
FNAIRFMFDS	VEEHELHTLF	AEAVVAGRRA	VHQEQQRKF	ATVLDMADLE	2400
LTTGIPPLDP	ALKDRITFFD	DPRIGNLKIP	EYRGAKAGEG	AAGSKGSVKE	2450
QLLQATNLDQ	VRQIVIDGLS	AKLQVTLQIP	DGESVHPTIP	LIDQGVDSLG	2500
AVTVGTWFSK	QLYLDLPLLK	<u>VLGGASITDL</u>	<u>ANEAARLPP</u>	SSIPLVAATD	2550
GGAESTDN	TS ENEVSGREDT	DLSAAATTE	PSSADEDDTE	PGDEDVPRSH	2600
HPLSLGQEYS	WRIQQGAEDP	TVFNNTIGMF	MKGSIDLKRL	YKALRAVLRR	2650
HEIFRTGFAN	VDENGMAQLV	FGQTKNKVQT	IQVSDRAGAE	EGYRQLVQTR	2700
YNPAAGDTLR	LVDDFWGQDD	HLLVVAYHRL	VGDGSTTENI	FVEAGQLYDG	2750
TSLSPHVPQF	ADLAARQRAM	LEDGRMEEDL	AYWKMHYRP	SSIPVLPLMR	2800
PLVGNSSRSD	TRNFQHC	GPW QQHEAVARLD	RMVAFRIKER	SRKHKATPMQ	2850
FYLAAYQVLL	ARLTDSTDLT	VGLADINRAT	VDEMAAMGFF	ANLLPLRFRD	2900
FRPHITFGEH	LIATRDLVRE	ALQHARVPYG	VLLDQLGLEV	PVPTSNQPAP	2950
LFQAVFDYKQ	GQAESGTIGG	AKITEVIATR	ERTPYDVVLE	MSDDPTKDPL	3000
LTAKLQSSRY	EAHHPQAFLE	SYMSLLSMFS	MNPALKLA		3038

SUBSTITUTE SHEET (RULE 26)

FIG.2C

24/30




ASPERGILLUS TERREUS DNA:


FIG.3

SUBSTITUTE SHEET (RULE 26)

TRIOL PKS PROTEIN MAP



RAT FAS PROTEIN MAP



PEPTIDE = SEQUENCE ALIGNMENT BETWEEN PEPTIDES AND FINAL TPKS SEQUENCE

KAS = KETO ACYL SYNTHASE

AT/KT = ACETYL/KALONNYL TRANSFERASE

DH = DEHYDRATASE

ER = ENOYL REDUCTASE

KR = KETO REDUCTASE

ACP = ACYL CARRIER PROTEIN

MeT = METHYL TRANSFERASE

FIG.4



26/30

## KETO ACYLSYNTHASE ALIGNMENT

FAS\_RATF (130-229) YSMGCGRAM MANRLSFFFD FKGPSIALDT ACSSLLALQ NAYQAIRSGE  
 TRIOL PKS (150-249) YSATGVAVSV ASNRISYFFD WHGPSMTIDT ACSSSLVAHV LAVQQLRTGQ  
 MSAS\_PENPA (173-272) WMGIGTAYCG VPNRISYHLN LMGPSIAVDA ACASSLVAIH HGVQAIRLGE  
 Consensus ....G..... .NR.S..... .GPS....D. AC.SSL.A... ..Q..R.G.

## ACETYL/MALONYL TRANSFERASE ALIGNMENT

MSAS\_PENPA (621-671) SDRVQILTYV MQIGLSALLQ SNGITPQAVI GHSVGEIAAS WAGALSPAE  
 FAS\_RATF (553-603) F--V-SL-TA IQIALIDLLT SMGLKPDGII GHSLGEVACG YADGCLSQRE  
 TRIOL PKS (626-676) F--SQPLCCA VQIVLVRLLE AARIRFTAW GHSSGEIACA FAAGLISASL  
 Consensus .....L.... .QI.L..LL. ....GHS.GE.A... ..G..S....

## DEHYDRATASE ALIGNMENT

MSAS\_PENPA (943-982) YTTRLDNDTK PFCGSHPLHG TEIVPAAGLI NTFKLGIGGQ  
 FAS\_RATF (863-902) NIDASSESD HYLVDHCIDG RVLFPGTGYL YLVWK-TLAR S  
 TRIOL PKS (970-1010) WLNFRVRPDI EWLGDHALQG QTVFPAAGYI WMAMEALMI A  
 Consensus .....H....G ....P..G... ..

FIG.5

SUBSTITUTE SHEET (RULE 26)

27/30

## ENOYL REDUCTASE ALIGNMENT

TRIOL PKS (1903-1950) VPVVALAERN ASIVHVRPDY IYTEADNNLS EGGSLMVTV LAAAVLAE  
 FAS\_RATF (1642-1691) VPWYTTAY SLVVRGRIGH GETVLHSGS GGVGAATSI ALSIGCRVFT  
 SU4 ER VPIAYTTAHY ALHDLAQLRA GQSVLIHAA GGVGMAVAL ARRAG-LAEV

Consensus VP..... .G.G.....

## KETO REDUCTASE ALIGNMENT

TRIOL PKS (2141-2196) PTRVRSIDAE TLFAADKTYL LVCLTGLGR SLGRWVQHG ACHIVLTSRN  
 MSAS\_PENPA (1398-1451) LP-ASEG-PR LLPREGTYL ITGGLGVGL EVADFLVEKG ARRLLSRR  
 FAS\_RATF (1864-1921) PTLISAI-SK TFCPEKSYI ITGGLGGFGL ELARWLVLRG AQRVLTSRS

Consensus .....Y..G.G.G..G.....V.GA....L.SR.

## ACYL CARRIER PROTEIN ALIGNMENT

TRIOL PKS (2461-2548) VRQIVIDGLS AKLQVTLQIP DGESVHTIP LIDQGVDSL AVTVGTWFSK  
 FAS\_RATF (2114-2201) GDGEAQRDLV KAVAHILGIR DLIGINLDS LADLGDSL GVEVRQILER  
 MSAS\_PENPA (1697-1758) -KAYLDEKIR GCVAKVLQMT A-EDVDSKAA LADLGVD SVM TVTLRRQLQ-

Consensus .....L....L.D.G.DS...V.....

FIG.6

28/30




FIG.7

SUBSTITUTE SHEET (RULE 26)

29/30

Potential SAM Binding Region in Methyl Transferase	
Consensus	$\Delta\Delta$ D/E $\Delta$ GXGXG $\Delta$ XXX $\Delta\Delta\Delta$ $\wedge$ /P
TPKS (1444)	I L E I GAGTGG A TKY V L P

 $\Delta$  = hydrophobic A.A.

X = any A.A.

 $\wedge$  = charged A.A.

FIG. 8

SUBSTITUTE SHEET (RULE 26)

30/30




FIG. 9

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/12423

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C12N 1/15, 15/54, 15/80

US CL : 435/254.11, 320.1; 536/23.2, 23.74, 24.32

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/254.11, 320.1; 536/23.2, 23.74, 24.32

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, BIOSIS, CA, INPADOC, JICST-E search terms: polyketide synthase, DNA, nucleic acid, RNA

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	EP, A1, 0,556,699 (DAHIYA) 25 August 1993, page 4, lines 15-50, and page 6, Table 1.	10, 20 ----- 1-9,18,19
Y	EUROPEAN JOURNAL OF BIOCHEMISTRY, Volume 192, issued September 1990, Beck et al, "The multifunctional 6-methylsalicylic acid synthase gene of <i>Penicillium patulum</i> ", pages 487-498, see entire document.	1-10, 18-20
Y	EUROPEAN JOURNAL OF BIOCHEMISTRY, Volume 204, issued February 1992, Bevitt et al, "6-Deoxyerythronolide-B synthase 2 from <i>Saccharopolyspora erythraea</i> ", pages 39-49, see entire document.	1-10,18-20

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 DECEMBER 1994

Date of mailing of the international search report

09 FEB 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

STEPHEN WALSH

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/12423

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MOLECULAR & GENERAL GENETICS, Volume 235, Number 2-3, issued November 1992, Mayorga et al, "The developmentally regulated <i>Aspergillus nidulans</i> wA gene encodes a polypeptide homologous to polyketide and fatty acid synthases", pages 205-212, see entire document.	1-10,18-20
Y	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, Volume 107, issued 1985, Moore et al, "Biosynthesis of the Hypocholesterolemic Agent Mevinolin by <i>Aspergillus terreus</i> . Determination of the Origin of Carbon, Hydrogen, and Oxygen Atoms by 13-C NMR and Mass Spectrometry", pages 3694-3701, see paragraph bridging pages 3694-3695.	1-10,18-20

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*

